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GENERAL INTRODUCTION 
 
1. 1. The avian respiratory system 
 
1.1.1. Anatomy and physiology 
The principal function of the respiratory system in birds is exchanging oxygen 
(O2) and carbon dioxide (CO2) between atmosphere and blood, but also temperature 
regulation and phonation. In complete contrast to the tidally ventilated mammalian 
respiratory system, where fresh inhaled air is mixed with residual stale air in the 
respiratory airways, the avian lung is a flow-through system (Reese et al., 2006). The 
respiratory tract begins at the nares, consists of passages between conchae in the head 
and subsequently leads inhaled gas to the larynx. The trachea extends from the 
larynx, and branches into two extrapulmonary primary bronchi. From each primary 
bronchus, four groups of secondary bronchi (medioventral, mediodorsal, lateroventral 
and laterodorsal) arise and from the secondary bronchi multiple parabronchi (Fedde, 
1998). In birds, the body cavity is not divided by a diaphragm and ventilation is 
achieved through a unique way of air transport which requires the action of the air 
sacs. As a consequence, the avian lung is rigid, fixed at the thoracic walls and 
comprises a highly complex structure. Air sacs occupy every available space in the 
body coelom not occupied by other viscera and most birds have nine air sacs: paired 
cervical air sacs, an unpaired clavicular air sac that is connected to each lung, paired 
cranial thoracic air sacs, paired caudal thoracic air sacs, and paired abdominal air 
sacs. The cervical, clavicular, and cranial thoracic air sacs arise from the 
medioventral secondary bronchi, and they are often called the cranial air sacs. The 
caudal thoracic and abdominal air sacs (the caudal air sacs) arise from the 
lateroventral and mediodorsal secondary bronchi and from the continuation of the 
intrapulmonary primary bronchus. The air sacs are auxiliary structures that pump air 
through the respiratory tract, but do not contribute to the gas exchange with the blood 
(Fedde, 1998; Reese et al., 2006). The O2 and CO2 exchange only occurs in the lungs. 
During inspiration, active contraction of some muscles of the body wall causes an 
increase in the volume of the air sacs which results in pressure in the air sacs less than 
that in the atmosphere and gas moves through the lungs into the air sacs. The inspired 
air completely bypasses the cranially lying openings of the medioventral secondary 
bronchi, a process which is called inspiratory aerodynamic valving (Reese et al., 
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2006). In contrast, during the inspiratory phase as well as the expiratory phase, air 
flows in the mediodorsal and lateroventral secondary bronchi. About one half of the 
inspired volume passes through the paleopulmonic parabronchi and in this way in the 
cranial air sacs, and the remainder passes through the much smaller neopulmonic 
parabronchial network to the caudal air sacs, and through the direct connection from 
the intrapulmonary primary bronchus to the abdominal air sacs. During expiration, 
reduction in coelomic volume (decrease in the volume of the air sacs) increases the 
pressure in the air sacs and air moves out of the air sacs. Some of the air from the 
caudal air sacs again traverses the neopulmonic parabronchi and most of the air enters 
the paleopulmonic parabronchi, travelling in the same direction as during inspiration. 
Air from the cranial air sacs flows through the medioventral secondary bronchi to exit 
the lung without contacting any parabronchial gas exchanging surfaces. Thus 
exchange of O2 and CO2 between air and blood occurs both during inspiration and 
expiration in birds and nearly all of the air that was inhaled, has passed over 
paleopulmonic parabronchial gas exchanging surfaces during some part of the 
respiratory cycle. The walls of the parabronchi are perforated by numerous openings 
that lead to the respiratory atria. Funnel-shaped infundibulae arise from the atria and 
open into the air capillaries. The inhaled air flows through the parabronchial lumen 
and then into the exchange tissue through the atria, the infundibulae, and the network 
of air capillaries. The air capillaries are closely surrounded by a network of blood 
capillaries, which together constitute the most efficient gas exchanger unit among air-
breathing vertebrates (Reese et al., 2006). The blood-gas barrier in the avian lung is 
approximately 56-67% thinner than that of a mammal of the same body mass and the 
respiratory surface area is approximately 15% greater (Maina et al., 1989). While 
large surface area and thin tissue barrier enhance respiratory efficiency, these 
structural features predispose birds to pulmonary injury from environmental toxicants 
and invasion by pathogenic organisms (Reese et al., 2006). 
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Figure 1. Schematic representation of the right paleopulmonic lung and air sacs of a 
bird and the pathway of gas flow through the pulmonary system during inspiration 
and expiration. For purposes of clarity, the neopulmonic lung is not shown. A: 
Inspiration. B : Expiration.  
(Source: http://www.people.eku.edu/ritchisong/birdrespiration.html) 
 
1.1.2. Defense mechanisms 
The respiratory system harbours the most extensive and thinnest surface 
across which the body is exposed to the external environment. Due to this 
characteristic, a vast array of proteins and pathogens are challenging this system on a 
daily basis. To cope with these pathogens, birds have well-developed defense 
mechanisms.  
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1.1.2.1. Innate resistance 
The initial line of defense for the airway is the nasal and tracheal epithelium, 
which prevents pathogens from entering the body. Multiple mucous glands within the 
pseudostratified ciliated columnar epithelium produce mucus which forms a layer on 
top of the cilia of the epithelial surface. Particulate material that is caught in the 
mucus gets transported by the movement of the cilia in an oral direction, where it is 
swallowed and digested or excreted by coughing and sneezing (Koch, 1991; Sharma, 
2003). Furthermore, mucus contains antibacterial enzymes which impede the attempts 
of pathogens to colonize. 
For pathogens that do enter the body, the next line of defense is provided by 
other innate immune mechanisms, such as phagocytic cells that include heterophils 
and macrophages, and natural killer (NK) cells. Monocytes-macrophages, cells 
belonging to the mononuclear phagocytic system, are considered to be the first line of 
immunological defense. These cells originate from the bone marrow and 
subsequently enter the blood circulation. Upon migration to various tissues, 
monocytes mature and differentiate into tissue macrophages (Dietert et al., 1991; 
Qureshi et al., 2000). Macrophages then get involved in innate and acquired 
immunity (Qureshi et al., 2000). Since the respiratory surface is in proportion much 
larger than that of mammals and the tissue barrier is much thinner (Maina, 1989; 
Maina et al., 1989), one can expect that, as stated above, the avian respiratory tract is 
relatively more easily attacked by pathogens than the mammalian one (Nganpiep and 
Maina, 2002). One would hence assume that for a similar defense competence, more 
residing avian respiratory phagocytes (ARP = macrophages and polymorphonuclear 
leukocytes such as heterophils) would occur on the surface of avian lungs. 
Paradoxically, the normal, steady-state avian respiratory system has very low 
numbers of residing ARP in comparison to the mammalian system, and as a 
consequence birds must rely heavily on the influx of ARP into the site of infection for 
non-specific defense against bacteria and other pathogens (Ficken et al., 1986; 
Qureshi et al., 1994; Klika et al., 1996; Lorz and Lopez, 1997; Qureshi et al., 2000; 
Toth, 2000). Interestingly, ARPs were never found on the surface of the air capillaries 
(respiratory surface) which represent the functional equivalent to the mammalian 
alveoli but were regularly present on the surfaces of the atria and the infundibulae, 
structural units immediate to the air capillaries (Nganpiep and Maina, 2002; Reese et 
al., 2006). Thus, macrophages seem to be located at strategic check points were fresh 
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air is distributed into the gas exchange areas and where particles can be trapped and 
removed. The paucity and even lack of ARPs in birds has been used to explain a 
purported high susceptibility of poultry to respiratory diseases. Nganpiep and Maina 
(2002), however, showed that a composite defense armament has additionally 
developed in the avian respiratory system. A highly lytic upper airway epithelium 
endowed with lysosomes (apparently lacking in mammals), generally robust ARPs, 
and efficient translocation of subepithelial macrophages onto the respiratory surface, 
play a role in the protection of the respiratory system (Nganpiep and Maina, 2002). In 
the air sacs, being thin walled and lacking an elaborate ciliated epithelium, particle 
clearance is largely accomplished by phagocytic cells albeit significantly lower than 
in the lungs (Nganpiep and Maina, 2002; Reese et al., 2006). 
 
1.1.2.2. Adaptive immunity 
When pathogens cannot be withheld by physical barriers nor controlled by 
innate immune defense mechanisms, adaptive immunity (specific immune response) 
is required to specifically focus defense mechanisms on that particular antigen 
resulting not only in the elimination of the pathogen but also in protecting in case of a 
repeat encounter with the same pathogen (memory). Adaptive immunity is mediated 
by a variety of cells, of which T lymphocytes, B lymphocytes, and macrophages are 
the most important.  
In poultry, adaptive immunity, including the cell-mediated and humoral arm, 
is critically dependent on regulation by T lymphocytes (T cells), the coordinators of 
the immune response. Maturation of the T cells takes place in the thymus, a feature 
shared with mammalian species (Arstila et al., 1994). Before T cells can initiate and 
participate in an adaptive immune response to a pathogen, the antigen has to be 
presented by host cells in the context of their major histocompatibility complex 
(MHC) molecules, i.e., as an antigenic peptide bound to the MHC molecule. The 
MHC molecules come in two forms: the MHC class I is expressed by essentially all 
nucleated cells, whereas the MHC class II is expressed mainly by cells of the immune 
system, the so-called antigen presenting cells (APC) such as macrophages, dendritic 
cells and B lymphocytes (B cells). These APC also deliver other signals equally 
important to the T cell activation, the so-called second or costimulatory signals 
(Arstila et al., 1994). Activation of T cells results in proliferation of the activated T 
cells and their differentiation into subpopulations of diverse effector cells, helper T 
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cells (CD4+), suppressor T cells, and cytotoxic T cells (CD8+), or memory cells. 
Effector functions of T helper cells primarily involve production of cytokines (soluble 
molecules secreted to the extracellular space), and expression of membrane-bound 
cell-surface molecules, all affecting other cells of the immune system. The cytotoxic 
T cells, in contrast, are mostly killers that are specialized in the elimination of 
intracellular antigens. The latter include those that have entered cells via the 
endocytic pathway (exogenous antigens; e.g., phagocytosed bacteria) or were 
produced within the cell such as viral proteins and proteins resulting from neoplastic 
transformation of the cell (endogenous antigen) (Erf, 2004). Another lineage of T 
cells exists (γδ T cells), but their physiological significance remains largely a matter 
of speculation. 
Besides the T lymphocytes, other cells important to the cellular immune 
response include macrophages, dendritic cells, NK cells, and effector cells of 
antibody dependent cellular toxicity (Sharma, 1991). NK cells can also be regarded 
an effector cell of specific cell-mediated immunity as they greatly benefit from T 
helper mediated activity (Erf, 2004).  
Unlike mammals, birds have a special organ, the bursa of Fabricius, where the 
development of B lymphocytes (B cells) from their immature precursors takes place. 
For humoral immunity, B cells differentiate into plasma cells that secrete antigen-
specific antibodies. Antibodies can prevent disease caused by pathogens and provide 
protection, but they are primarily effective in preventing entry of pathogens through 
mucosal surfaces (e.g., secretory IgA) and in eliminating extracellular antigens 
(Koch, 1991). Most organisms stimulate both cell-mediated immunity and humoral 
immunity, although the type of immunity most critical for defense may vary with the 
organism (Vandaveer et al., 2001; Sharma, 2003; Erf, 2004). 
 
1.2. Respiratory disease in turkeys 
Respiratory disorders are one of the important diseases affecting turkeys and 
are continuing to cause high economic losses in many areas world-wide due to 
reduced growth, increased feed conversion rates, an increased mortality rate, high 
medication costs and a higher number of condemnations at slaughter (van Empel and 
Hafez, 1999). They may be induced by various viral and bacterial agents, either alone 
or in combination. Besides these infectious organisms, non-infectious factors, such as 
climatic conditions (e.g. inadequate ventilation, high ammonia levels, too high or too 
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low relative humidity) and management-related problems, may also contribute to the 
occurrence or the severity of respiratory problems in turkeys (van Empel and Hafez, 
1999).  
Different respiratory viruses such as influenza virus type A, paramyxovirus 
types 1, 2, 3 and 6, and avian metapneumovirus (APV), have been shown to be able 
to elicit respiratory problems (Van de Zande, 2001). Viral agents are mostly being 
attributed a triggering role, since the clinical signs following experimental inoculation 
with these viruses are less severe than those observed in the field. Viral infections 
generally cause rather acute respiratory problems from which birds usually can 
recover fairly easily. The problems, however, become more critical when bacterial 
pathogens are involved. Implicated bacteria include Escherichia coli, Pasteurella 
multocida, Bordetella avium, Ornithobacterium rhinotracheale, Mycoplasma 
gallisepticum, M. synoviae, M. iowae, M. meleagridis, M. imitans, Chlamydophila 
psittaci and Riemerella anatipestifer. With these bacterial agents, it is not always 
straightforward to reproduce clinical signs following experimental infection. This has 
led to a still contemporary discussion point whether the different bacterial agents are 
primary or rather secondary pathogens. 
In the present thesis, the experimental research focuses on four important 
turkey pathogens, i.e. APV, O. rhinotracheale, E. coli, and M. gallisepticum. Hence, 
the most important literature data on these agents will be discussed below.  
 
1.2.1. Avian metapneumovirus 
 
1.2.1.1. Etiology, epidemiology and pathogenesis 
APV (avian metapneumovirus, avian pneumovirus, turkey rhinotracheitis 
virus) is a member of the family Paramyxoviridae, subfamily Pneumovirinae and 
genus Metapneumovirus (Pringle, 1998; 1999). The disease was reported initially in 
turkeys and shortly thereafter in chickens in South Africa in the late 1970s (Buys et 
al., 1989a; Buys et al., 1989b). Later, the disease was reported in Europe, with the 
etiological agent being isolated in the United Kingdom, France and Germany (Giraud 
et al., 1986; Wilding, 1986; Hafez and Weiland, 1990). At present, the disease is a 
major problem in most turkey and chicken producing countries worldwide (Van de 
Zande, 2001). 
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The APV isolates that exist worldwide are currently classified into four 
subgroups, namely, subgroups A, B, C, and D, according to their antigenic and 
molecular variations. The U.S. strains of APV belong to subgroup C (which have 
been shown to be more related to human metapneumovirus than other APV 
subgroups), while the strains in other parts of the world, especially the European 
countries, belong to the other three subgroups (Govindarajan et al., 2006; Guionie et 
al., 2007). 
The two most important species susceptible to APV infection are turkeys and 
chickens, although pheasants, guinea fowl and ducks may also become infected. APV 
antibodies have occasionally been reported in ostriches and in sea gulls, but the virus 
has not been isolated from these species. Geese and pigeons appear to be refractory to 
APV. In both turkeys and chickens the primary site of replication appears to be the 
respiratory tract (mainly turbinates and trachea, but also lungs and air sacs), and 
ciliated epithelial cells are the target cells (Jones et al., 1988; Majó et al., 1995). 
Rapid transmission occurs horizontally, mainly by direct contact, although fomites 
are possibly involved. There is no published evidence that APV may be vertically 
transmitted, even though the virus can be detected in the reproductive tract of laying 
birds (Jones et al., 1988).  
 
1.2.1.2. Clinical findings and lesions 
A primary APV infection may result in severe respiratory disease in 
susceptible turkeys, though mild or even subclinical infections occur as well. All ages 
are predisposed to APV infections, but with a different clinical outcome. Young 
poults seem to be more susceptible than older ones and the severity of disease and 
mortality is higher (Alexander et al., 1986). APV outbreaks can be characterized by 
sneezing, depression, tracheal rales, swollen infraorbital sinuses and nasal and often 
frothy, ocular discharge, snicking, dyspnoea, and head shaking. The nasal discharge 
may become thicker and mucopurulent as a result of secondary bacterial infection. In 
laying birds, there may be a drop in egg production with an increased incidence of 
poor shell quality and peritonitis (Gough, 2003). The onset of signs is rapid and the 
infection may spread through a flock within 24h. The morbidity reaches 100% and 
mortality varies between 2 and 50%, with the highest percentage in young birds. 
Secondary infections and bad management conditions increase the mortality rate and 
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prolong the disease, and this is probably the reason why the disease in the field is 
much more severe than under experimental conditions (Cook, 2000; Gough, 2003). 
 
1.2.1.3. Diagnosis 
The clinical picture of an APV outbreak can be indicative, but laboratory 
diagnosis is necessary to confirm an APV infection. Virus can be isolated from 
suspensions of turbinates and trachea or from tracheal swabs using tracheal organ 
cultures (TOC) prepared from chick or turkey embryos (Cook et al., 1976), since 
subgroups A and B viruses cause ciliostasis, this in contrast to subgroup C. APV can 
also be isolated in chicken embryo yolk sac and different cell lines such as chicken 
embryo fibroblasts (CEF), monkey kidney cells (VERO) and chicken embryo liver 
(CEL). Virus isolation should be attempted at the very first sign of clinical disease, 
since the virus shedding takes place for a very short period (Cook and Cavanagh, 
2002). Detection of the virus can be done by direct and indirect immunofluorescence 
staining and PCR. Still diagnosis of APV is usually done serologically. The 
seroneutralization (SN) test, which can be performed in a variety of systems, 
including TOC, CEF, CEL or VERO cultures, is sometimes used. However, the 
ELISA is the most commonly used test since it shows similar sensitivity and is much 
less time consuming compared with the SN test (Grant et al., 1987; Hafez and 
Löhren, 1990; Cook and Cavanagh, 2002). 
 
1.2.1.4. Treatment and control 
For treatment and control, one can say that good management practices and 
good biosecurity are important in helping to prevent infection and minimize the 
effects. Although APV infections themselves cannot be treated, antimicrobials are 
used to control secondary bacterial infections (Hafez et al., 1990). Quality vaccines 
are available and APV infections can be prevented by vaccination (Cook, 2000). 
Today, several live-attenuated and inactivated vaccines, developed by different 
companies, have been licensed. 
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1.2.2. Ornithobacterium rhinotracheale 
 
1.2.2.1. Etiology, epidemiology and pathogenesis 
Already in 1991, a new respiratory disease was observed in broiler chickens in 
South Africa by J. Du Preez (van Beek et al., 1994), but O. rhinotracheale was 
actually first characterized in 1993 by Charlton et al. Within a relatively short period 
of time, a world-wide spread of O. rhinotracheale was seen. O. rhinotracheale is a 
Gram-negative, non-motile, pleomorphic, rod-shaped, non-sporulating bacterium of 
the rRNA superfamily V.  
O. rhinotracheale has been isolated throughout the world from numerous bird 
species, including turkey, chicken, (chukar) partridge, duck, goose, guinea fowl, gull, 
ostrich, pheasant, pigeon, quail, and rook (Hafez, 2002; Chin et al., 2003). 
Up to date, 18 serotypes (A through R) of O. rhinotracheale have been determined. 
Serotyping has revealed that the majority of chicken isolates are of serotype A (94%). 
Serotype A is also the most prevalent serotype among turkey isolates (57%). In 
turkeys, 97% of the strains isolated belong to the four major serotypes A, B, D, and E 
(van Empel, 1997; van Empel and Hafez, 1999). 
Although it has been proven that O. rhinotracheale is highly sensitive to 
different chemical disinfectants (Hafez, 2002; Hafez and Schulze, 2003), it seems 
difficult to eradicate it. O. rhinotracheale infection can affect every new restocking 
even in previously cleaned and disinfected houses, especially in areas with intensive 
poultry production as well as in multiple age farms. O. rhinotracheale appears to 
have become endemic (Hafez, 2002; Chin et al., 2003). O. rhinotracheale spreads 
horizontally by direct and indirect contact through aerosols or drinking water, and 
there is circumstantial evidence that vertical transmission occurs (van Empel, 1998; 
van Empel and Hafez, 1999; Chin et al., 2003). 
 
1.2.2.2. Clinical findings and lesions 
By now, it is clear that O. rhinotracheale can cause acute, highly contagious 
disease in poultry, but the severity of clinical signs, duration of the disease and 
mortality of confirmed O. rhinotracheale outbreaks have been found to be extremely 
variable (van Empel and Hafez, 1999; Chin et al., 2003). In many cases, young poults 
are affected between two and eight weeks of age (Chin et al., 2003). Initial symptoms 
are coughing, sneezing and nasal discharge followed, in some cases, by severe 
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respiratory distress, dyspnoea, prostration, and sinusitis. These symptoms are 
accompanied with a reduction in feed consumption and water intake. In turkey 
breeder flocks, there can also be a decrease in egg production and in the number of 
hatchable eggs (De Rosa et al., 1996; van Empel and Hafez, 1999; Chin et al., 2003). 
Normal mortality ranges between 1 and 15% during the acute phase (8 days post 
infection), but infections can be accompanied with mortality rates of up to 50% (Chin 
et al., 2003). The pathological lesions can include rhinitis, tracheitis, airsacculitis, 
oedema, uni- or bilateral consolidation of the lungs with fibrinopurulent exudates in 
the pleura (Hinz et al., 1994; van Empel et al., 1996; Sprenger et al., 1998). 
Pericarditis, peritonitis and enteritis can also be detected (van Empel and Hafez, 
1999). In some cases, swelling of the liver and spleen as well as degeneration of heart 
muscles have been observed. After infection of the respiratory tract, the bacterium 
can also disseminate to other sites of the body resulting in local pathology such as 
hepatitis, meningitis and joint-infections (Sprenger et al., 1998; van Empel and 
Hafez, 1999; Chin et al., 2003). 
 
1.2.2.3. Diagnosis  
It is difficult to make a presumptive diagnosis based on clinical signs and 
necropsy findings. O. rhinotracheale can usually be isolated from trachea, tracheal 
swabs, lungs and air sacs. The infraorbital sinus and nasal cavity are also suitable 
sites for culture, but O. rhinotracheale can be masked easily by the overgrowth of 
other bacterial species. Optimal growth of the organism is obtained by incubation on 
5% sheep blood agar for at least 48 h under micro-aerophilic conditions (5 to 10% 
CO2). A good selective medium is not yet available, but to suppress overgrowth by 
fast-growing bacteria (e.g. E. coli, Proteus sp., Pseudomonas sp.) in contaminated 
samples, gentamicin and polymyxin (both 5 µg/ml) can be added to the sheep blood 
agar (van Empel, 1997). As only about 90% of O. rhinotracheale strains are resistant 
to both these antimicrobials, sheep blood agar without these additives should always 
be included (van Empel and Hafez, 1999). Further identification can be done by the 
different biochemical properties of O. rhinotracheale as included in the API-20NE 
and API-ZYM systems (BioMèrieux, France) or fatty acid profile (Charlton et al., 
1993). Other tests for identification include rapid slide agglutination (RSA) test, agar 
gel precipitation (AGP) test, PCR assays (van Empel, 1998; Hung and Alvarado, 
2001) and immunohistochemical staining. 
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Serology is useful for flock monitoring or as an aid in the diagnosis of O. 
rhinotracheale infection, and can be carried out using slide agglutination test 
prepared from different serotypes, ELISA tests (commercially available), or DOT-
immunobinding assays (Hafez, 2002). 
 
1.2.2.4. Treatment and control 
In practice O. rhinotracheale infections are mostly dealt with using different 
antimicrobials such as amoxicillin, ampicillin, doxycycline, tetracycline, 
trimethoprim/sulphonamide, chlortetracycline, enrofloxacin and florfenicol. 
Treatment of O. rhinotracheale infections with antimicrobials is being compromised 
by the variable susceptibility of strains. O. rhinotracheale can acquire resistance 
against antimicrobials such as doxycycline, enrofloxacin, flumequine, lincomycin, 
trimethoprim, sulfachloropyridazine and tylosin (Devriese et al., 1995; Chin et al., 
2003). The sensitivity of O. rhinotracheale to antimicrobials is very inconsistent and 
appears to depend upon the source of the strain. In Germany, 90% of strains are 
resistant to enrofloxacin (Hafez, 1996), while those isolated in France and Belgium 
are almost always very sensitive to this antimicrobial (Devriese et al., 1995; Dudouyt 
et al., 1995; Roger and Léorat, 1997; Devriese et al., 2001). 
In the past, vaccines based on inactivated whole-cell formulations have been 
developed and shown to induce protective immunity in both chickens and turkeys 
(van Empel and Hafez, 1999; Schuijffel et al., 2006). For chickens, serotype A is the 
most important serotype, but for turkeys protection against more serotypes is needed. 
Both in experimental studies and in the field, it was found that cross-protection is not 
always induced by vaccination with bacterins in oil adjuvant (van Empel and Hafez, 
1999). Very recently, Schuijffel et al. (2005) used an alternative strategy in order to 
identify cross-protective vaccine targets: sera from live vaccinated and cross-
protected birds were used for immunoscreening of an O. rhinotracheale serotype G 
expression library. Based on further obtained results, it appears they identified a good 
candidate for the development of a cross-protective vaccine against O. rhinotracheale 
infections. Vaccination with live O. rhinotracheale has been investigated and shown 
to be feasible (van Empel and van den Bosch, 1998) although in practice it is not yet 
possible because, until now, all the investigated O. rhinotracheale strains have been 
pathogenic after viral priming. 
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1.2.3. Escherichia coli 
 
1.2.3.1. Etiology, epidemiology and pathogenesis 
E. coli is a Gram-negative, non-sporeforming, rod-shaped bacterium, of the 
family Enterobacteriaceae. Most strains are motile and have petrichous flagella 
(Barnes et al., 2003). 
Although E. coli is present in the normal microbiota of the intestinal tract, 
other host mucosal surfaces and in the bird’s environment, only a certain number of 
these strains possessing specific virulence attributes, designated as avian pathogenic 
E. coli (APEC), are able to cause disease (Dho-Moulin and Fairbrother, 1999; 
Vandekerchove, 2004). Since serotyping for the somatic antigen (O-serotyping) is 
still the most frequently used typing method for diagnostic purposes, the O-type is 
often used for APEC description. O1, O2 and O78 are reported as the main serotypes 
in different disease types by several authors (Barnes et al., 2003; Vandekerchove, 
2004). Many other serotypes have been found less frequently, and some pathogenic 
isolates do not belong to known serotypes or are untypeable (Barnes et al., 2003). 
Colibacillosis refers to any localized or systemic infection (e.g. septicemia, 
peritonitis, cellulitis, salpingitis, osteomyelitis, synovitis, omphalitis, airsacculitis, 
and coligranuloma) caused entirely or partly by APEC, and is the most frequently 
reported disease in surveys of poultry diseases or condemnations at slaughter, hence 
responsible for severe economic losses (Dho-Moulin and Fairbrother, 1999; Barnes et 
al., 2003). Most, if not all avian species, are susceptible, although clinical disease is 
reported most often in chickens, turkeys and ducks. Susceptibility and severity of 
infection are greatest in young birds (Barnes et al., 2003; Rodriguez-Siek et al., 
2005). 
Horizontal infection with E. coli usually occurs through contact with other 
birds, or through faeces, contaminated water and feed. Natural respiratory tract 
infection of poultry by APEC is thought to occur via the inhalation of faeces-
contaminated dust (Dho-Moulin and Fairbrother, 1999). Carlson and Whenham 
(1968) have demonstrated that the risk of colibacillosis increases with the level of 
environmental contamination. Dust in poultry houses may contain 105-106 colony 
forming units (cfu) E. coli/g. These bacteria may persist for long periods, particularly 
under dry conditions (Harry, 1964; Barnes et al., 2003). Vertical infection results 
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from the transmission of E. coli from breeders, via contaminated shells during 
hatching, or in ovo, as a result of salpingitis.  
The virulence mechanisms of avian pathogenic E. coli have not been clearly 
characterized yet. A number of potential virulence factors have been identified in 
APEC strains isolated from diseased birds, but their role in causing disease is not 
completely understood (Barnes et al., 2003). Besides bacterial virulence factors, 
probably also host resistance is a great determinant of colibacillosis occurrence 
(Barnes et al., 2003). In fact, colibacillosis is usually considered to be a secondary 
disease, following a primary infection with respiratory pathogens and/or unfavorable 
environmental conditions (Barnes et al., 2003; Vandekerchove et al., 2004).  
 
1.2.3.2. Clinical findings and lesions  
One of the most common forms of colibacillosis begins as a respiratory tract 
infection and, if unattended, this infection may evolve into a bacteraemia and a 
generalized infection which manifests as a polyserositis (Pourbakhsh et al., 1997; 
Dho-Moulin and Fairbrother, 1999; Barnes et al., 2003). Barnes et al. (2003) and 
Dho-Moulin and Fairbrother (1999) described in detail other localized and systemic 
colibacillosis-associated disease syndromes. Respiratory-origin colisepticemia affects 
both chickens and turkeys and is the most common type of colisepticemia (Barnes et 
al., 2003). Lesions are prominent in respiratory tissues (trachea, lungs, and air sacs), 
pericardial sac and peritoneal cavities and are typical of the subacute polyserositis 
stage of colibacillosis. Infected air sacs are thickened and often have caseous 
exudates on the respiratory surface. Pneumonia is more common in turkeys than 
chickens. 
 
1.2.3.3. Diagnosis  
The diagnosis of colibacillosis is first suggested by the clinical picture and by 
the presence of typical macroscopic lesions such as airsacculitis, sometimes 
associated with pericarditis and perihepatitis. Diagnosis needs to be confirmed by the 
isolation of pathogenic E. coli from the heart blood and affected tissues, like liver, 
spleen, pericardium or bone marrow, on selective media like McConkey, eosin-
methylene blue or drigalki agar. Care must be taken to avoid faecal contamination of 
samples. Further identification of the isolated colonies is based on biochemical 
reactions (Dho-Moulin and Fairbrother, 1999). The diagnosis is strengthened if the 
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isolated culture belongs to a known pathogenic serogroup. Different ELISAs have 
been developed for detection of antibodies, although they have limited value because 
they can only detect homologous APEC types (Leitner et al., 1990; Bell et al., 2002). 
All currently known virulence-associated factors, detected in strains isolated from 
colibacillosis lesions, can also be detected in faecal isolates from clinically healthy 
chickens. For this reason, none of these traits can be used for APEC identification.  
 
1.2.3.4. Treatment and control  
Colibacillosis is mainly treated with antimicrobials. E. coli may be sensitive to 
many drugs such as ampicillin, chloramphenicol, chlortetracycline, enrofloxacin, 
neomycin, nitrofurans, gentamicin, nalidixic acid, oxytetracycline, polymyxin B, 
spectinomycin, streptomycin and sulphonamides (Barnes et al., 2003). E. coli isolates 
from poultry are frequently resistant to one or more drugs, since they have been 
largely used in the poultry industry over a long period (e.g. tetracyclines) (Barnes et 
al., 2003; Vandekerchove, 2004). It is not only important to analyse the isolates for 
their antimicrobial resistance patterns, one must also take care that the animals 
receive a sufficiently high dose of the antimicrobial and moreover, ingest it especially 
when they are diseased, to obtain the necessary therapeutic effect.  
Measures should be taken to prevent introduction of pathogens that promote 
infections with APEC (Barnes et al., 2003). The housing climate (humidity, 
ventilation, dust and ammonia) and the stocking density must be kept optimal (Dho-
Moulin and Fairbrother, 1999; Vandekerchove, 2004). The great diversity among 
APEC strains limits the possibilities of vaccination, and vaccines are not used on a 
large scale (Dho-Moulin and Fairbrother, 1999; Vandekerchove, 2004). 
 
1.2.4. Mycoplasma gallisepticum 
 
1.2.4.1. Etiology, epidemiology and pathogenesis 
M. gallisepticum is the most pathogenic and economically significant 
mycoplasma pathogen causing respiratory disease in chickens and turkeys. M. 
gallisepticum is a species of the family Mycoplasmataceae (class Mollicutes) (Ley, 
2003). Mycoplasmas (or mollicutes) are bacteria that lack a conventional bacterial 
cell wall and are surrounded only by a thin trilaminar membrane (Bradbury, 2005) 
and they represent the smallest known organisms in nature capable of self-replication 
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(Razin et al., 1998). The price they have to pay for their simplicity includes a slow 
growth cycle and a considerable dependence upon the host for many nutrients, and 
hence for survival (Bradbury, 2005). 
M. gallisepticum infections naturally occur primarily in gallinaceous birds, 
and are commonly known as chronic respiratory disease of chickens and infectious 
sinusitis of turkeys (Ley, 2003). However, M. gallisepticum has also been isolated 
from naturally occurring infections in pheasants, ducks, geese, chukar partridge, 
peafowl, bobwhite quail and Japanese quail (Ley, 2003; Levisohn and Kleven, 2000). 
M. gallisepticum probably can infect susceptible birds at any age, although it is stated 
that young birds are, in general, more susceptible to infection with M. gallisepticum 
(Bradbury and Levisohn, 1996; Ley, 2003). 
Horizontal transmission occurs readily by direct or indirect contact of 
susceptible birds with infected carriers or contaminated fomites (Levisohn and 
Kleven, 2000). The upper respiratory tract and/or conjunctiva are portals of entry for 
the organism in aerosol or droplets (Bradbury and Levisohn, 1996; Levisohn and 
Kleven, 2000). M. gallisepticum is considered to be primarily a surface parasite of the 
respiratory tract and conjunctiva, although spread to other organs indicates that 
transient systemic infections occur, resulting in acute and chronic diseases at multiple 
sites (Ley, 2003). Vertical transmission of M. gallisepticum is known to occur in eggs 
laid by naturally infected hens and has been induced following experimental 
infections (Ley, 2003). This is suggested to occur as a sequel to acute respiratory 
infection, due to contiguity of the abdominal air sacs to the oviduct (Levisohn and 
Kleven, 2000).  
 
1.2.4.2. Clinical findings and lesions  
Clinical signs, morbidity, and mortality associated with M. gallisepticum 
infection in turkeys may be highly variable depending on M. gallisepticum strain 
virulence, complicating infections, and environmental and other stressors (Ley, 
2003). Clinical signs attributed to M. gallisepticum seen in turkeys include sinusitis, 
respiratory distress, depression, decreased feed intake, and weight loss. As the disease 
progresses, tracheal rales, coughing, and laboured breathing may become evident if 
tracheitis or airsacculitis are present (Ley, 2003). The infection may last for months in 
untreated flocks and an important characteristic of M. gallisepticum is the frequent 
occurrence of asymptomatic infection (Levisohn and Kleven, 2000). Gross lesions 
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consist primarily of catarrhal exudates in nasal passages, trachea, bronchi, and air 
sacs. Sinusitis is usually most prominent in turkeys. Air sacs frequently contain 
caseous exudates, and some degree of pneumonia may be observed. In severe cases of 
typical air sac disease, there is the triad of airsacculitis, fibrinous or fibrinopurulent 
perihepatitis, and adhesive pericarditis resulting in high mortality and extensive 
condemnations at slaughter. However, these lesions may occur with other pathogens, 
and are not pathognomonic for M. gallisepticum (Ley, 2003). Razin et al. (1998) 
stated that the molecular mechanisms of mycoplasma pathogenicity have remained 
largely elusive and that the clinical picture of mycoplasma infections was more 
suggestive of damage due to host immune and inflammatory responses rather than to 
direct toxic effects by mycoplasmal cell components. Attachment to host cells is 
considered an important virulence factor, and in order to mediate adherence, M. 
gallisepticum organisms have specialized terminal tip structures (Bradbury, 2005). In 
spite of their remarkable reduction in genome size, mycoplasmas have a surprisingly 
great capacity for antigenic variation of major surface antigens, also named 
phenotypic plasticity (Levisohn et al., 1995; Razin et al., 1998). The ability of 
mycoplasmas to immunomodulate host immune responsiveness contributes to their 
pathogenic properties, enabling them to evade or suppress the host defense 
mechanisms and establish a chronic, persistent infection (carrier state) (Razin et al., 
1998; Ley, 2003; Rottem, 2003; Bradbury, 2005; Reinhardt et al., 2005). Another 
virulence factor is (possibly) the ability to invade cells. Indeed, in tissue culture M. 
gallisepticum was found capable of entering non-phagocytic host cells (Winner et al., 
2000; Ley, 2003). 
 
1.2.4.3. Diagnosis  
The gold standard for M. gallisepticum diagnosis is their isolation and 
identification using species-specific antibodies and/or PCR for detecting the DNA. 
For M. gallisepticum culture, suspensions of tracheal or air sac exudates, turbinates, 
lungs, or swabs from trachea and choanal cleft can be inoculated directly to complex 
media such as mycoplasma broth or agar medium (Ley, 2003). Immunofluorescence 
or immunoperoxidase procedures may be used for rapid identification of mycoplasma 
cultures and inoculation of 7-day-old embryonated chicken eggs may be employed as 
another means of isolating M. gallisepticum. Furthermore, various PCR based 
procedures are available that are relatively rapid, sensitive and specific (Ley, 2003; 
 22
General introduction 
____________________________________________________________________ 
Bencina, 2005). Serologic procedures are useful for flock monitoring in M. 
gallisepticum control programs and to aid in diagnosis when infection is suspected. 
The serum plate agglutination (SPA) test which is commercially available is a quick, 
inexpensive and relatively sensitive test, but non-specific reactions (false positive) 
have been frequently observed (Bencina, 2005). The hemagglutination inhibition (HI) 
test has been commonly used to confirm reactors detected by SPA or ELISA, but it is 
time-consuming, the reagents are not commercially available, and the test may lack 
sensitivity. ELISAs were developed to increase testing efficiency and improve 
sensitivity and specificity of results relative to the SPA and HI tests. In a recently 
performed study, Feberwee et al. (2005) compared the technical performance of 
different available tests and concluded that it is not advisable to rely completely on 
one test (system) only. At present, serology is not a valid screening method if any M. 
gallisepticum vaccines have been used, because current serological tests cannot 
differentiate between antibody responses to vaccine or field strains (Bencina, 2005).   
 
1.2.4.4. Treatment and control 
Because M. gallisepticum can be egg transmitted, maintaining breeder flocks 
free of M. gallisepticum is only possible by starting with stocks known to be free of 
the infection and then rearing them with adequate biosecurity to avoid introduction of 
the organism, something that has been proven very difficult. Vaccination with 
bacterins has been shown to reduce, but usually not eliminate colonization by M. 
gallisepticum following challenge and generally is felt to be of minimal value in long-
term control of infection (Ley, 2003). Live M. gallisepticum vaccines (strains F, ts-11 
and 6/95) are used rather frequently, particularly in multi-age commercial operations 
(Ley, 2003). However, they should be used only in jurisdictions where they are 
approved, administered with strict adherence to the manufacturer’s instructions, and 
with careful consideration for the safety on non-target flocks (Bencina, 2005). 
Currently available M. gallisepticum vaccines, however, have shown little potential 
for use in turkeys. M. gallisepticum has shown sensitivity in vitro and in vivo to 
several antimicrobials including macrolides (e.g. erythromycin), tetracyclines, 
pleuromutilins (e.g. tiamulin), fluoroquinolones (e.g. enrofloxacin), aminoglycosides 
(e.g. streptomycin) and others, but is intrinsically resistant to β-lactams (e.g. 
penicillins) since these work by inhibiting cell wall synthesis. Also acquired 
resistance has been noted (Ley, 2003; Bencina, 2005). Treatment can reduce severity 
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of disease, economic losses and shedding of M. gallisepticum, but does not eliminate 
M. gallisepticum from the infected poultry flock (Bencina, 2005). Egg injection or 
egg dipping were used to introduce antimicrobials into hatching eggs with the aim to 
obtain mycoplasma-free progeny flocks (Kleven, 2003; Ley, 2003). In general, these 
methods sometimes did not completely eliminate egg transmission, but it has made it 
possible to obtain sufficient M. gallisepticum -free chicken and turkey breeder flocks 
in the US (Ley, 2003). Egg heating (±46°C), an alternative method of reducing egg 
transmission, has also been practiced. Complete elimination of M. gallisepticum from 
all birds in an infected flock by mass antimicrobial therapy is an unrealistic 
expectation, and treatment should be regarded as a method for short-term 
amelioration of disease and economic effects, rather than as a long-term solution to 
the problem.  
 
1.2.5. Multicausal respiratory disease 
Although much is known about the individual agents responsible for 
respiratory diseases in poultry, uncomplicated infections with single agents are the 
exception. Under commercial conditions, complicated infections involving multiple 
etiologies with viruses, mycoplasmas and other bacteria, immunosuppressive agents, 
and unfavourable environmental conditions are more commonly observed than single 
infections. 
In turkeys, only a few studies have been performed to elucidate the effects of 
combined action of viruses and other micro-organisms. The virus being regarded as 
having a very important role in turkeys is APV, and as a consequence, most studies 
have included APV as triggering agent. Cook et al. (1991) demonstrated that B. 
avium and Pasteurella-like organisms were able to colonize after an APV infection. 
Infection was somewhat more severe (slightly more severe clinical symptoms and 
thickened air sacs) when bacteria were included in the inoculum, but no poults in any 
of the experiments appeared sick and no mortality was recorded. In 1992, Naylor et 
al. demonstrated that an infection with APV accelerated the colonization of the lower 
tract by M. gallisepticum and that simultaneous infection resulted in respiratory 
disease of greater morbidity than following infection with either agent alone. 
However, for the affected birds, the severity of disease in the mixed infection group 
was not greater than that in the M. gallisepticum group. In an experiment to 
investigate the possible pathogenicity of M. imitans for turkeys, Ganapathy et al. 
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(1998) showed that in 1-day-old turkey poults, the presence of APV enhanced the 
ability of M. imitans to invade and colonize. M. imitans was only isolated from the 
upper respiratory tract in single infection, but was recovered also from lung and air 
sacs in the presence of the virus. After dual infection, they saw a significant increase 
in clinical signs and lesions, although these still remained relatively mild. On the 
contrary, dual infection of turkey poults with APV and M. synoviae did not result in 
detectable synergism, i.e. no increase in severity of clinical disease, nor gross and 
microscopic lesions due to APV (Khehra et al., 1999). Several O. rhinotracheale 
strains, isolated from turkey, chicken or partridge, were used for aerosol challenge of 
turkeys of various ages (van Empel et al., 1996). In turkeys, infection was aggravated 
by the prior administration of APV or Newcastle disease virus (NDV). In these 
studies, no airsacculitis nor pneumonia were seen in the absence of virus. Van de 
Zande et al. (2001) reported that APV/E. coli dual infection in turkey poults results in 
respiratory disease with a higher morbidity, higher incidence of lesions, and higher 
isolation of E. coli from inoculated poults compared with groups given single 
infections. Clinical symptoms such as depression and anorexia were only seen with 
dually infected birds and correlated well with the high incidence of gross lesions such 
as pneumonia, airsacculitis, perihepatitis and pericarditis. Mortality, however, as 
often seen in the field in APV/E. coli infected birds, was not encountered in their trial. 
In 13-wk-old turkeys, dual infection with APV and E. coli resulted in more severe 
clinical signs compared with single infection (Van de Zande et al., 2002). In a study 
with a US APV isolate (Colorado strain), a dual infection in turkeys with either a 
turkey Newcastle disease virus isolate or broiler E. coli isolate resulted in increased 
morbidity rates and gross lesions compared with single infection, and more synergism 
was observed with the viral Newcastle infection than with E. coli (Turpin et al., 
2002). Most poults receiving APV/E. coli exhibited mild clinical signs (mild 
depression) early during infection, but swelling of sinuses, as frequently reported in 
the field, was not observed. In the APV/NDV infected birds more severe symptoms 
were found, ranging from decreased food consumption and in most of the birds nasal 
exudates with infraorbital, periocular and submandibular swelling. Very recently, 
Jirjis et al. (2004) used an APV subgroup C strain present in the US, to 
experimentally inoculate turkey poults together with different bacterial species. They 
found that infection was more severe (increase in severity or incidence of clinical 
scores, nasal discharge, swollen sinuses, microscopic inflammatory changes in both 
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upper and lower respiratory tract, and gross lesions in air sacs and lungs) in the turkey 
poults inoculated with APV when B. avium was administered either alone or in 
combination with E. coli and O. rhinotracheale. They concluded that B. avium had an 
additive effect on APV infection in turkeys, but this effect was not seen with APV in 
combination with E. coli or O. rhinotracheale. Very recently, Van Loock et al. (2006) 
examined the pathogenicity of an APV superinfection in C. psittaci predisposed 
turkeys. APV infection during the acute phase of a C. psittaci infection aggravated 
the severity of clinical signs, macroscopic lesions, pharyngeal APV excretion and 
histological tracheae lesions. Some of the single APV and single C. psittaci infected 
turkeys excreted nasal exudates with or without swollen sinus, whereas a higher 
percentage of dually infected turkeys showed similar and more long-lasting 
symptoms. In contrast, no clear interaction could be established after APV infection 
in latently C. psittaci infected SPF turkeys.  
In some studies, other viruses were used in turkeys in order to try to reproduce 
severe clinical respiratory disease. Back et al. (1997) infected SPF turkeys with O. 
rhinotracheale and with O. rhinotracheale in combination with Newcastle disease 
vaccine virus, but were not able to reproduce clinical signs nor mortality. Charles et 
al. (1993) experimented with dual P. anatipestifer and NDV infection via different 
inoculation routes in turkeys, but were unable to reproduce clinical symptoms. They 
were only able to demonstrate some differences in histopathology. Sivanandan et al. 
(1991) evaluated the effect of an apathogenic avian influenza virus (AIV) subtype 
(H5N2) on the ability of the respiratory tract of turkeys to clear bacterial infections 
and suggested that AIV infection contributed to increased numbers and decreased 
clearance of P. multocida. Clinical symptoms were not mentioned. Experiments in 
turkeys have also been done with two bacterial strains, e.g. De Rosa et al. (1997) 
found that B. avium may enhance pathogenicity of O. rhinotracheale, although no 
convincing results were reported, and Droual and Chin (1997) were not able to find a 
synergistic effect between O. rhinotracheale and E. coli after intra air sac inoculation. 
Ficken et al. (1986) found that the clearance of E. coli from the air sacs was little 
affected after infection with B. avium. Van Alstine and Arp (1987) found in an 
infection experiment designed to study the effects of B. avium infection on the 
pulmonary clearance of E. coli in turkeys, that B. avium had no effect on the numbers 
E. coli in the lungs, but was associated with increased numbers of E. coli in tracheae. 
Severe airsacculitis was found more often in B. avium pre-infected turkeys. 
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When considering the different results obtained from the various challenge 
studies, it can be noted that it is generally problematic to reproduce respiratory 
disease similar as seen in the field. For instance, mortality is frequently seen in 
natural outbreaks of respiratory disease, especially when E. coli is involved. None of 
the above mentioned studies was able to reproduce this phenomenon. Furthermore, it 
is very difficult to really compare the different experimental studies, since a lot of 
different variables have to be taken into account. For instance, the virulence and 
pathogenicity characteristics from the different challenge isolates, the different 
inoculation routes applied, the varying intervals between the different microbiological 
inoculations, the age, strain and health status of the inoculated hosts may influence 
the clinical outcome of an experimental inoculation. 
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AIMS 
 
Respiratory disease causes important financial losses in the turkey industry 
worldwide due to reduced growth, an increased mortality rate, high medication costs 
and a higher number of condemnations at slaughter. A variety of respiratory 
pathogens, both bacterial and viral, and adverse environmental conditions are the 
main factors contributing to the development of this disease. The pathogenesis of 
infections with these respiratory disease agents and their mutual interactions, are far 
from fully unraveled. This is partly responsible for the fact that therapeutic 
measurements against different bacterial infections are virtually entirely based on the 
administration of antimicrobials. In the literature, it is frequently mentioned that 
although different antimicrobial products are available, the clinical effects are very 
variable in the field. Hitherto, the actual in vivo efficacy of different antimicrobials 
for the treatment of different respiratory infections in poultry has only poorly been 
investigated. This is to a great extent rooted in the fact that often no suitable infection 
models are available. To extend our knowledge on the pathogenesis and control of 
respiratory infections in turkeys, the present thesis was initiated. Single and combined 
infections with avian metapneumovirus, Ornithobacterium rhinotracheale, 
Escherichia coli and Mycoplasma gallisepticum, all being important respiratory 
pathogens, were studied. Our main objective was to develop experimental infection 
models using these agents and subsequently use these models to study the 
pathogenesis and to compare the clinical efficacy of different antimicrobial 
compounds. 
 
More specific goals of the study were: 
- To develop in vivo experimental infection models for the reproduction of 
clinical respiratory disease in turkeys using different respiratory pathogens. 
- To evaluate the efficacy of different antimicrobials and/or antimicrobial 
treatment schemes using the above developed infection models in order to 
allow more judicious antimicrobial treatments. 
- To gain more insights in the pathogenesis of the different poultry pathogens 
and about the possible synergistic action between them. 
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Summary 
The purpose of this study was to assess the possible synergism between 
Ornithobacterium rhinotracheale and avian metapneumovirus (APV), inoculated into 
turkeys via the natural route, for the reproduction of respiratory disease. Three-week-
old SPF turkeys were inoculated oculonasally with either APV subtype A, O. 
rhinotracheale or both agents using two different time intervals (three or five days) 
between APV and O. rhinotracheale. The birds were observed clinically on a daily 
basis and swabbed intratracheally at short, regular intervals. They were euthanised at 
1, 3, 5, 8 and 15 days post single or dual inoculation and examined for gross lesions 
at necropsy. Samples of the turbinates, trachea, lungs, air sacs, heart, pericardium and 
liver were taken for bacteriological and/or histological examination. Combined 
APV/O. rhinotracheale infections resulted in overt clinical signs and a longer 
persistence of O. rhinotracheale in the respiratory tract and aggravated the 
macroscopic and histological lesions in comparison to the groups given single 
infections. In all O. rhinotracheale challenged turkeys, O. rhinotracheale was 
isolated from the turbinates, trachea and lungs, but in turkeys infected with both 
agents, O. rhinotracheale was frequently found in the air sacs and on a single 
occasion in the heart and pericardium. The time interval between APV and O. 
rhinotracheale inoculation did not have a significant effect on the outcome of the 
dual infection. A conspicuous important feature was the attachment of O. 
rhinotracheale to the cilia of the epithelium of the turbinates and trachea of both O. 
rhinotracheale and APV/O. rhinotracheale infected birds. In conclusion, the results 
show that O. rhinotracheale is able to adhere to and colonize the respiratory tract, but 
without viral priming is not capable of inducing respiratory disease, under the 
circumstances used in this study. 
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Introduction 
Viral and bacterial infections of the respiratory tract frequently result in 
disease in turkeys of all ages and may cause considerable financial losses due to 
reduced growth, an increased mortality rate, high medication costs and a higher 
number of condemnations at processing.  
Several pathogens play an important role in respiratory disease, alone, in 
synergy or triggered by non-infectious factors. The respiratory viruses influenza virus 
type A, paramyxovirus types 1, 2 and 3 and avian metapneumovirus (avian 
pneumovirus, turkey rhinotracheitis virus) (APV) have been shown to be able to elicit 
respiratory problems. Involved bacteria are Escherichia coli, Pasteurella spp., 
Bordetella avium, Ornithobacterium rhinotracheale, Mycoplasma spp., 
Chlamydophila psittaci and Riemerella anatipestifer. These bacterial agents differ 
from the viral pathogens in that it is not always straightforward to reproduce clinical 
signs following experimental infection. O. rhinotracheale, an emerging infectious 
pathogen in poultry, illustrates this apparent paradox. This organism is generally 
believed to be a facultative pathogen (Back et al., 1997; Droual and Chin, 1997; Back 
et al., 1998; Franz et al., 1997; van Empel et al., 1999). However there are indications 
that O. rhinotracheale may be of primary importance (Ryll et al., 1996; Travers et al., 
1996; van Empel et al., 1996; Sprenger et al., 1998). Some researchers believe that 
the different clinical outcome of O. rhinotracheale infections may be attributed to a 
variation in virulence (Travers et al., 1996). However, very little is known about the 
pathogenesis of O. rhinotracheale infections in turkeys and the virulence 
determinants of this agent.  
Respiratory disease in poultry is a multifactorial problem, with viral and 
bacterial respiratory pathogens often concurrently present and most probably 
influencing one another. Recently, in a longitudinal study performed by Van Loock et 
al. (2005), it was shown that both APV and O. rhinotracheale infections often occur 
between production onset and slaughter. Whether this virus, which belongs to the 
genus Metapneumovirus and this Gram-negative bacterium merely act separately or 
in a synergistic or additive way remains to be elucidated.  
Only a few experimental studies have been undertaken both in chickens and 
turkeys to study possible mutual interactions between viruses and O. rhinotracheale. 
In chickens, O. rhinotracheale infection and/or the resulting clinical signs were 
shown to be aggravated by administration of Newcastle disease virus, infectious 
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bronchitis virus and APV virus (van Empel et al., 1996; Franz et al., 1997). In 
turkeys, aerosol or intra-air sac inoculation with APV (European isolate, type A) five 
days prior to O. rhinotracheale administration, elicited a worse clinical picture than 
single administration of O. rhinotracheale (van Empel et al., 1996). More recently 
the research group of Jirjis et al. (2004) were not able to demonstrate the formerly 
noted additive effect between APV and O. rhinotracheale using oculonasal 
inoculation, although it should be noted that in contrast with the former study, a type 
C APV isolate present in the USA was used.  
The present study was undertaken to develop a dual infection model for APV 
and O. rhinotracheale in turkeys using the natural oculonasal inoculation route. Two 
time intervals were tested between infections, with clinical signs, gross lesions, 
histology and bacterial titration as parameters for evaluating possible synergistic 
potential between both agents. 
 
 
Materials and Methods 
 
Turkeys 
Seventy-five SPF turkeys (AFSSA, Ploufragan, France), hatched in our 
facilities, were used in this study. The birds received 16 hours of light per day, were 
housed on litter in separate HEPA-filtered isolation rooms and had free access to food 
and water.  
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during 
a respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The 
virus stock had a titre of 5.5 log10 50% ciliostatic dose (CD50)/ml after the third 
passage in tracheal organ cultures.  
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Bacterium 
The O. rhinotracheale strain LMG 9086T, originally isolated from a turkey 
with a respiratory tract infection, was used. The strain was serotyped as type A in an 
agar gel precipitation test (Hafez and Sting, 1999) by Professor H.M. Hafez (Institute 
of Poultry Diseases, Free University Berlin, Germany). The strain was stored at -
70°C. The organism was cultured for 48h at 37°C on Columbia agar (Oxoid LTD., 
Basingstoke, Hampshire, England) with 5% sheep blood in a 5% CO2 atmosphere. 
The O. rhinotracheale bacteria were transferred into 5 ml brain heart infusion (BHI) 
(Oxoid LTD) for 24h at 37°C with agitation (microaerophilic incubation). The 
bacterial challenge inoculum was prepared by washing 1 ml cultured bacteria twice in 
phosphate buffered saline (PBS). A suspension containing 8.6 log10 colony forming 
units (cfu)/ml was prepared.  
 
Experimental design 
Seventy-five SPF turkeys were randomly divided into five experimental 
groups of 15 birds at one day of age. By two weeks of age, the birds were shown to 
be free from maternally derived antibodies to O. rhinotracheale and APV, 
respectively by a commercially available ELISA (Biochek, Gouda, Netherlands) and 
an in-house serum neutralization test. At the age of three weeks, the birds of group V 
(virus inoculated) and group B (bacterium inoculated) only received APV or O. 
rhinotracheale, respectively. The turkeys of two groups received successively APV 
(virus, V) and O. rhinotracheale (bacterium, B) with two different time intervals: 
three days for group V/3/B and five days for group V/5/B. Group C was maintained 
as an uninoculated control group. Each bird in group V, V/3/B and V/5/B was 
inoculated with APV by the oculonasal route at a dose of 4.4 log10CD50 per bird. O. 
rhinotracheale was administered oculonasally to each bird of group B, V/3/B and 
V/5/B with a dosage of 8 log10cfu. For inoculation with APV and/or O. 
rhinotracheale, a total of 250 µl was divided equally over the nares and eyes.  
All birds were examined clinically on a daily basis until they were sacrificed. 
The clinical signs were scored as indicated in Table 1. The mean clinical score was 
calculated for each experimental group. 
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Table 1. Scoring system for quantification clinical signs (Van de Zande et al., 2001) 
Score Clinical signs                                                                                                                                   
0 Absence of clinical signs 
1 Clear nasal exudate 
2 Turbid nasal exudate 
3 Nasal exudate with mildly swollen infra-orbital sinuses 
4 Nasal exudate with extremely swollen sinuses 
5 Nasal exudate with extremely swollen sinuses and frothy eyes 
6 Score 5 + poor general condition 
7 Score 6 + anorexia 
 
 
Tracheal swabs were collected from groups V, V/3/B and V/5/B at three days 
post viral infection (dpvi) for virus titration. Tracheal swabs were also taken from 
birds belonging to groups B and C to detect adventitious exposure. Before inoculation 
with O. rhinotracheale, tracheal swabs were taken from all birds in all groups for 
bacteriological examination, which proved to be negative for O. rhinotracheale. 
Furthermore, tracheal swabs for bacteriological titration were collected from all 
groups experimentally inoculated with O. rhinotracheale (B, V/3/B, V/5/B) at 2, 4, 6 
and 7 days post bacterial inoculation (dpbi) and daily from 9 dpbi until 14 dpbi. The 
tracheal swabs were collected using cotton-tipped aluminium shafted swabs (Copan 
Diagnostics Inc., Corona, USA) and placed in transport medium. The latter consisted 
of 1 ml PBS supplemented with Ca2+ and Mg2+ for bacteriological examination and 
supplemented with 10% fetal calf serum (Gibco, Invitrogen Corporation, Merelbeke, 
Belgium), penicillin (1000 U/ml) (Biopharma, Rome, Italy) and kanamycin (0.5 
mg/ml) (Gibco) for virus titration. Processing occurred as described below.  
In all groups, three birds were sacrificed from control group and at 1, 3, 5, 8 
and 15 days post single (groups V and B) or dual inoculation (groups V/3/B and 
V/5/B). Euthanasia was performed by intravenous injection with an overdose (10 
mg/kg) of sodium pentobarbital 20% (Kela, Hoogstraten, Belgium). The birds were 
necropsied and examined for gross lesions. Samples of the turbinates, trachea 
(proximal and distal part) and lungs were collected from all sacrificed birds for 
bacteriological examination. A 10% suspension in PBS was made from these tissue 
samples. Air sacs, heart, pericardium and liver were likewise sampled with cotton 
swabs for bacteriological analysis. These swabs were suspended in 1 ml PBS 
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supplemented with Ca2+ and Mg2+. All samples for bacterial isolation were processed 
immediately after collection as described below. Finally, samples from the turbinates, 
trachea, lungs, heart and liver were collected and fixed in 10% neutral buffered 
formalin for histopathological examination. 
This experiment was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine, Ghent University. 
 
Virological titration of tracheal swabs 
After 20 minutes shaking in the transport medium at 4°C, the swabs were 
removed and the homogenate was centrifuged (5 min at 8800 × g) to sediment 
cellular debris. The supernatant was harvested in 1 ml aliquots and stored at -70°C 
until further processing. Serial tenfold dilutions of the supernatant were inoculated 
into tracheal organ cultures obtained from 26-day-old turkey embryos and 
individually maintained in tissue culture tubes (Cook et al., 1976). The tracheal organ 
cultures were incubated with 0.1 ml of supernatant and 0.9 ml organ culture medium, 
containing minimal essential medium supplemented with hepes buffer 1 M (2%) 
(Gibco), penicillin (100 U/ml) (Biopharma), streptomycin (0.1 g/ml) (Certa, Braine-
l’Alleud, Belgium), kanamycin (0.1 g/ml) (Gibco) and glutamine (0.3 g/ml) (BDH 
Laboratory Supplies, Poole, England). The tubes were then placed in a roller drum 
apparatus and were observed for 7 days and examined for ciliostasis. Virus titres are 
expressed as log10CD50 per g mucus obtained from the tracheal swabs.  
 
Bacteriological titration of tracheal swabs 
After 20 minutes shaking in the Ca2+ and Mg2+ supplemented PBS, the swabs 
were removed and undiluted supernatant and tenfold serial dilutions were inoculated 
in duplicate onto 5% sheep blood agar supplemented with 5 µg/ml gentamicin and 5 
µg/ml polymyxin to suppress growth of contaminant bacteria (van Empel and Hafez, 
1999). After 24-48h of incubation at 37°C in a 5% CO2 atmosphere, viable counts 
were performed. The number of cfu/ml was calculated. Bacterial titres were 
expressed as cfu per g mucus obtained from the tracheal swabs.  
 
Bacteriological titration of tissue suspensions 
From samples of the turbinates, proximal trachea, distal trachea and lungs, the 
number of O. rhinotracheale organisms was determined in threefold by incubating 
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undiluted tissue suspensions and tenfold serial dilutions of tissue suspensions on 5% 
sheep blood agar supplemented with 5 µg/ml gentamicin and 5 µg/ml polymyxin. 
After 24-48h of incubation at 37°C in a 5% CO2 atmosphere, viable counts were 
performed and the number of cfu/g tissue calculated. The swabs taken from the air 
sacs, pericardium, heart and liver were shaken for 20 minutes at 4°C in the Ca2+ and 
Mg2+ supplemented PBS. Consequently, the swabs were removed and 20 µl of the 
suspension was inoculated onto 5% sheep blood agar supplemented with 5 µg/ml 
gentamicin and 5 µg/ml polymyxin. After 24-48h of incubation at 37°C in a 5% CO2 
atmosphere, the number of cfu per plate was counted and scored on a scale from 0 to 
3: score 0 = 0 cfu; score 1 = 1 to 10 cfu; score 2 = 11 to 100 cfu; score 3 = more than 
100 cfu.  
 
Histopathology 
Following fixation in formalin, the tissues were embedded in paraffin, 
sectioned at 4 µm, mounted on glass slides and stained with hematoxylin and eosin 
(H&E) using standard procedures. Tissues from the turbinates and upper and lower 
trachea were additionally stained by the Periodic Acid Schiff (PAS)-reaction. When 
bacteria attached to the cilia were observed, a Giemsa and Gram-stain were also 
performed.  
 
 
Results 
 
Clinical signs 
The mean clinical score for each group is shown in Figure 1. Respiratory signs 
were not detected in birds from groups B or C (uninoculated control). Respiratory 
signs were seen in all APV-inoculated groups starting from 3 dpvi. In group V, mean 
clinical scores gradually increased from 3 until 6 dpvi at which time point the highest 
mean score (2.6) was seen. Then clinical symptoms declined and were absent in all 
birds at 9 dpvi. In group V/3/B, the mean clinical score augmented from 3 dpvi and 
reached a high level from 4 until 9 dpvi, with a peak score (2.9) observed at 6 dpvi 
and 9 dpvi. A gradual decline was noted starting from 9 dpvi with an absence of 
clinical signs from 12 dpvi onwards. In group V/5/B respiratory signs increased from 
3 dpvi onwards and peaked (2.9) at 9 dpvi. Clinical signs in this group could be 
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observed until 12 dpvi. In group V, V/3/B and V/5/B respiratory symptoms lasted for 
8, 11 and 12 days after viral inoculation, respectively. 
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Figure 1. Mean clinical scores in turkeys after single APV inoculation (    group V), 
single O. rhinotracheale inoculation (● group B) or dual APV/O. rhinotracheale 
inoculation with interval of three days (▲ group V/3/B) or five days ( ■ group V/5/B).  
 
Virological titration of tracheal swabs 
Confirmatory viral titrations of tracheal swabs collected at 3 dpvi showed that 
APV was recovered from every individual bird of all APV infected groups. With 
mean titres of 5.5, 5.7 and 5.5 log10CD50/g mucus for group V, V/3/B and V/5/B, 
respectively. No viral cross-infection between groups occurred as no APV was 
recovered from tracheal swabs from group B and C. 
 
Bacteriological titration of tracheal swabs 
O. rhinotracheale was not recovered from tracheal swabs from any of the 
birds of groups V and C. The results of O. rhinotracheale titrations of the tracheal 
swabs of the remaining groups are shown in Figure 2. Mean titres as well as titres for 
each individual bird are given. In group B the number of O. rhinotracheale was the 
highest (mean of 6.6 log10 cfu/g mucus) at 4 dpbi and after 7 dpbi, O. rhinotracheale 
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could not be isolated anymore. The highest value in group V/5/B was found at 4 dpbi 
(6.9 log10 cfu/g mucus). In group V/3/B bacterial titres peaked at 6 dpbi (6.7 log10 
cfu/g mucus). A high titre was still found at 7 dpbi. For groups V/3/B and V/5/B, O. 
rhinotracheale could not be recovered anymore from 10 dpbi onwards.  
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Figure 2. O. rhinotracheale titres (in log10cfu/g mucus) in tracheal mucus collected at 
different time points after O. rhinotracheale inoculation of single O. rhinotracheale 
(●,○ group B) and dually APV/O. rhinotracheale infected turkeys with an interval of 
three days (▲,∆ group V/3/B) or five days (■,□ group V/5/B). (Individual values are 
given with closed patterns; means are given with open patterns)  
 
Bacteriological titration of tissue samples 
As expected, O. rhinotracheale was never isolated from any of the tissues 
from the birds of groups V and C. The results of O. rhinotracheale titration in the 
other groups are shown in Table 2. 
 
 
 50
Experimental studies 
____________________________________________________________________ 
 
1 
3 
5 
8 
15
 
 
1 
3 
5 
8 
15
 
 
1 
3 
5 
8 
15
 
Tu
rb
in
at
es
 
7.
7/
6.
2/
4.
2a
 
7.
5/
7.
5/
6.
5 
9.
4/
9.
0/
6.
5 
0/
2.
9/
0 
0/
0/
0 
 
7.
1/
6.
4/
0 
8.
9/
7.
5/
8.
0 
8.
8/
6.
6/
8.
2 
3.
6/
0/
8.
0 
0/
0/
0 
 
4.
8/
4.
8/
. 
8.
5/
8.
3/
8.
1 
8.
5/
7.
2/
8.
3 
7.
7/
7.
6/
6.
7 
0/
0/
0 
Tr
ac
he
a 
(p
ro
xi
m
al
 p
ar
t) 
4.
0/
3.
8/
2.
7 
7.
6/
7.
7/
7.
7 
5.
9/
7.
9/
7.
2 
0/
0/
0 
0/
0/
0 
 
4.
0/
3.
2/
2.
9 
8.
3/
5.
6/
5.
6 
7.
4/
6.
5/
4.
3 
0/
0/
5.
9 
2.
2/
3.
5/
0 
 
0/
0/
0 
7.
6/
7.
8/
8.
3 
8.
0/
7.
2/
7.
1 
7.
3/
6.
7/
0 
0/
0/
0 
Tr
ac
he
a 
 
(d
ist
al
 p
ar
t) 
2.
9/
3.
9/
0 
4.
1/
6.
4/
2.
2 
3.
6/
7.
9/
7.
2 
0/
0/
0 
0/
0/
0 
 
3.
9/
2.
9/
2.
4 
8.
1/
5.
9/
6.
9 
8.
3/
7.
4/
7.
7 
0/
0/
7.
6 
0/
2.
9/
0 
 
0/
2.
2/
2.
5 
8.
0/
8.
1/
8.
0 
7.
8/
7.
4/
7.
3 
8.
1/
6.
6/
0 
0/
0/
0 
Lu
ng
s 
0/
0/
0 
0/
2.
2/
3.
9 
3.
2/
4.
5/
3.
9 
0/
0/
0 
0/
0/
0 
 
3.
5/
0/
2.
8 
3.
5/
5.
1/
4.
1 
6.
8/
6.
0/
5.
8 
0/
0/
5.
2 
0/
0/
0 
 
0/
0/
0 
6.
3/
6.
0/
6.
8 
6.
9/
5.
7/
6.
8 
6.
5/
4.
9/
4.
8 
0/
0/
0 
A
ir 
sa
cs
b  
0/
0/
0c
 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
 
0/
0/
0 
1/
0/
0 
3/
3/
3 
0/
0/
0 
0/
0/
0 
 
0/
0/
0 
2/
3/
0 
2/
0/
1 
0/
0/
0 
0/
0/
0 
Pe
ric
ar
di
um
b  
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
 
0/
0/
0 
0/
0/
0 
0/
0/
2 
0/
0/
0 
0/
0/
0 
 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
H
ea
rtb
 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
 
0/
0/
0 
1/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
0/
0/
0 
a 
: d
at
a 
fro
m
 th
re
e t
ur
ke
ys
 (l
og
10
 c
fu
 / 
g 
tis
su
e)
 
 
 
 
 
 
 
b 
: T
he
se
 o
rg
an
s 
w
er
e s
wa
bb
ed
. N
o 
tis
su
e s
us
pe
ns
io
n 
wa
s 
m
ad
e.
 
 
 
 
 
c 
: 0
 =
 0
 c
ol
on
ies
   
/  
 1
 =
 1
 to
 1
0 
co
lo
ni
es
   
/  
 2
 =
 1
1 
to
t 1
00
 c
ol
on
ies
   
/  
 3
 =
 m
or
e 
th
an
 1
00
 c
ol
on
ies
 
 
 
 
 
 
 
 
  T
ab
le
 2
. M
ea
n 
tit
re
 o
f O
. r
hi
no
tr
ac
he
al
e 
(lo
g 1
0c
fu
/g
 ti
ss
ue
) 
iso
la
te
d 
fr
om
 d
iff
er
en
t o
rg
an
s 
fr
om
 tu
rk
ey
s 
in
oc
ul
at
ed
 w
ith
 O
. r
hi
no
tr
ac
he
al
e 
al
on
e 
(g
ro
up
 B
) o
r w
ith
 A
PV
 a
nd
 O
. r
hi
no
tr
ac
he
al
e 
w
ith
 a
n 
in
te
rv
al
 o
f t
hr
ee
 d
ay
s 
(g
ro
up
 V
/3
/B
) o
r f
iv
e 
da
ys
 (g
ro
up
 V
/5
/B
). 
 
Gr
ou
p 
B 
 
Gr
ou
p 
V/
3/
B 
 
Gr
ou
p 
V/
5/
B 
O
rg
an
 
D
ay
s p
os
t O
. r
hi
no
tra
ch
ea
le
 in
oc
ul
at
io
n 
 
D
ay
s p
os
t O
. r
hi
no
tra
ch
ea
le
 in
oc
ul
at
io
n 
 
D
ay
s p
os
t O
. r
hi
no
tra
ch
ea
le
 in
oc
ul
at
io
n 
 51
Experimental studies 
____________________________________________________________________ 
In group B, O. rhinotracheale could be isolated from the turbinates from 1 
dpbi until 8 dpbi, with highest mean titre at 5 dpbi (mean of 8.3 log10 cfu/g tissue). O. 
rhinotracheale was found in the proximal and distal trachea from 1 dpbi until 5 dpbi 
(peak mean titre at 3 dpbi of 7.7 log10 cfu/g tissue for the proximal trachea and at 5 
dpbi of 6.2 log10 cfu/g tissue for distal trachea) and in the lungs from 3 dpbi until 5 
dpbi (highest mean titre at 5 dpbi, 3.9 log10 cfu/g tissue). O. rhinotracheale was not 
recovered from any other organ in group B.  
In group V/3/B, O. rhinotracheale was recovered from the turbinates and 
lungs between 1 and 8 dpbi (peak mean titre at 3 dpbi of 8.1 log10 cfu/g tissue for the 
turbinates and at 5 dpbi of 6.2 log10 cfu/g tissue for the lungs), and from the proximal 
(peak mean titre at 3 dpbi, 6.5 log10 cfu/g tissue) and distal trachea (peak mean titre at 
5 dpbi, 7.8 log10 cfu/g tissue) from 1 to 15 dpbi. Furthermore O. rhinotracheale was 
recovered from the air sacs at 3 and 5 dpbi. At 3 dpbi, O. rhinotracheale was isolated 
from the heart of one bird, and at 5 dpbi O. rhinotracheale was also found in the 
pericardium of one animal. O. rhinotracheale was never recovered from any of the 
liver samples. 
Finally in group V/5/B, O. rhinotracheale could be isolated from turbinates 
and distal trachea from 1 to 8 dpbi with peak mean titre at 3 dpbi of 8.3 log10 cfu/g 
tissue and 8 log10 cfu/g tissue respectively, and from the proximal trachea and lungs 
from 3 to 8 dpbi, with a peak mean titre at 3 dpbi of 7.9 log10 cfu/g tissue and 6.4 
log10 cfu/g tissue respectively. Furthermore O. rhinotracheale was isolated from the 
air sacs at 3 and 5 dpbi. O. rhinotracheale was never recovered from any of the heart, 
pericardium or liver samples. 
 
Macroscopic findings 
No marked macroscopic lesions were seen in group C. In the animals of group 
B, at 3 and 5 dpbi, a slight amount of serous to seromucous exudate was found in the 
turbinates and sinuses of most sacrificed birds. The turbinates, the proximal and on 
occasion medial trachea were moderately hyperaemic. From 8 dpbi onwards, no 
lesions were observed. In group V, most birds sacrificed at 4, 6 and 8 dpvi showed 
seromucous exudate in the turbinates and sinuses. A moderate to severe hyperaemia 
was also present in the nasal cavities and in the proximal and medial trachea. From 11 
dpvi no lesions were apparent. In groups V/3/B and V/5/B, lesions found at necropsy 
were similar. In birds that were necropsied between 1 and 8 dpbi, exudate was found 
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in the turbinates and sinuses that evolved from clear to seromucous. The amount of 
exudate varied from moderate to abundant with an aggravation seen with time. 
Hyperaemia of the turbinates, the proximal and sometimes medial trachea was 
prominently present between 3 and 8 dpbi. A moderate hyperaemia of the proximal 
trachea was seen at 15 dpbi.  
 
Histopathology 
In the control group (group C), no marked microscopic changes were 
observed in the turbinates, trachea or lungs.  
In the turbinates and trachea of animals in group V, the most severe lesions 
were observed at 4, 6 and 8 dpvi. The mucosa was infiltrated with large amounts of 
heterophils and monomorphonuclear cells. Furthermore, there was multifocal damage 
to epithelial cells, consisting of cellular necrosis and loss of cilia. In subepithelial 
mucous glands, a decreased mucus production and several apoptotic bodies were 
present. A mild, focal, heterophilic infiltration was found in the lungs of one animal 
at 6 dpvi.  
In group B only minor histological abnormalities were observed. A mild 
infiltration of mixed inflammatory cells was found in the turbinates and trachea at 3 
and 5 dpbi and loss of cilia was mildly present in these samples. In one animal 
euthanised at 5 dpbi, Gram-negative rod-shaped bacteria were seen attached to the 
cilia of the tracheal epithelium. In the lungs of one animal, a mild, focal infiltration of 
heterophilic granulocytes was found. 
In the dually infected animals, the histological lesions in the samples of the 
turbinates and trachea were more severe in comparison to the single viral or bacterial 
infection. In group V/3/B, a severe mixed inflammatory reaction was present in the 
mucosa of the turbinates and trachea from 3 to 11 dpvi and 3 to 8 dpvi, respectively. 
From approximately 3 dpvi onwards, loss of cilia and/or necrosis of epithelium, as 
well as degeneration of mucous glands, were found in the turbinates and trachea. The 
most severe lesions were observed from 6 to 8 dpvi. Gram-negative, rod-shaped 
bacteria attaching cilia of tracheal cells were present in one animal 8 dpvi. In lung 
samples collected at 8 and 11 dpvi, focal areas of suppurative pneumonia, bronchitis 
and bronchiolitis were observed in one bird. 
Compared to group V/3/B similar but slightly more severe tracheal and 
turbinate lesions were present in group V/5/B. Attachment of Gram-negative bacteria 
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to cilia of epithelial cells were observed in the trachea of two animals euthanised at 8 
dpvi, in the turbinates and/or trachea of two birds at 10 dpvi and in the trachea of two 
animals at 13 dpvi (Figure 3). Mild lesions in the lungs comparable with those 
observed in group V/3/B were also present. 
A correlation between the presence of bacteria on the cilia, severity of 
histopathological lesions and clinical scores was not obvious.  
 
 
Figure 3. Gram-negative rod-shaped bacteria attached to the cilia of the epithelium of 
the turbinates in a turkey of group V/5/B. Giemsa. Bar: 10 µm. 
 
 
Discussion 
In the present study, infection of turkeys with O. rhinotracheale without a 
concomitant viral trigger did not provoke overt clinical signs, although at necropsy a 
slight amount of serous to seromucous exudate was noted in the turbinates and 
sinuses of most birds, and histological examination revealed minor lesions in the 
trachea and turbinates. These results corroborate with the findings of several 
researchers who likewise came across difficulties in producing respiratory signs in 
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turkeys (Back et al., 1997; De Rosa et al., 1997; Droual and Chin, 1997; Jirjis et al., 
2004), but are in contrast with the results of other researchers. Some research groups 
did reproduce marked disease, occasionally evolving into death, following 
intratracheal and intrasaccular inoculation of O. rhinotracheale (Ryll et al., 1996; 
Sprenger et al., 1998). Also, van Empel et al. (1996) were able to evoke clinical 
symptoms, albeit fairly mild (growth retardation and airsacculitis), after intra-air sacs 
and aerosol challenge.  
Several issues are worth considering to attempt to clarify the divergence in 
success rate between the different studies. In the challenge experiments mentioned 
above, various O. rhinotracheale strains were used, which may differ in virulence. 
Apparent virulence differences have indeed been described among O. rhinotracheale 
strains isolated from chickens and turkeys (Ryll et al., 1996; Travers et al., 1996; van 
Veen et al., 2000b; El-Sukhon et al., 2002). The strain used in the present study 
originated from a turkey with respiratory disease and therefore was assumed to be at 
least capable of causing respiratory problems. Furthermore, different inoculation 
routes applied may explain study discrepancies. In the present study, O. 
rhinotracheale was administered oculonasally, which mimics best the natural disease 
exposure. In all experiments that were successful in reproducing acute clinical signs 
in turkeys, intratracheal or intrasaccular infection was applied (Ryll et al., 1996; 
Sprenger et al., 1998) and in this way the innate defence mechanisms situated at the 
upper respiratory tract are possibly bypassed. Other possible factors may be host 
related, with the age and health status as plausible determinants, although the 
occurrence of the disease does not seem to be correlated to a narrow age group, not in 
field outbreaks, nor under experimental conditions (De Rosa et al., 1996; Hafez, 
1996; Ryll et al., 1996; Travers, 1996; van Empel et al., 1996; Hinz and Hafez, 1997; 
Sprenger et al., 1998; van Veen et al., 2000a). Noteworthy is the observation that in 
all successful experiments conventional turkeys were used instead of SPF animals. 
Possibly, in conventional turkeys, undefined infectious agents lead to synergistic 
effects upon coinfection with O. rhinotracheale. Nonetheless we chose for SPF 
turkeys in our trial as such turkeys, compared to conventional birds, have a better 
defined bacterial status with better opportunity to conduct reproducible experiments.  
Although in the present study no highly acute disease with mortality was 
induced in association with O. rhinotracheale challenge, O. rhinotracheale was 
shown to be able to adhere to and colonize the upper respiratory tract of turkeys, and 
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could be recovered from the turbinates and trachea from 1 until 8 dpbi. Microscopic 
examination revealed Gram-negative, rod-shaped bacteria attached to the cilia of the 
epithelium of the trachea and turbinates of various infected birds. This is the first 
study reporting this distinct feature and hence constitutes the in vivo confirmation of 
the data generated by Soriano et al. (2002) having demonstrated in vitro adherence 
ability of O. rhinotracheale to chicken tracheal epithelial cells. The latter study did 
not prove actual adhesion to the cilia, again emphasising the value of the present 
study. The ability of bacteria to adhere to mucosal epithelium is dependent on the 
expression of adhesive molecules or structures, called adhesins, allowing attachment 
of the organisms to complementary molecules on mucosal surfaces, the receptors 
(Jacques and Paradis, 1998). The adherence of bacteria to host tissue is usually 
regarded as an important prerequisite for colonization and virulence manifestation of 
a microorganism. There is no information about the mechanism by which O. 
rhinotracheale adheres to the tracheal surface, nor about the alleged receptor. Hence 
our findings concerning tissue adhesion justify further investigations into adhesion 
mechanisms. 
Infection with APV caused clinical disease with various symptoms including 
nasal discharge evolving from serous to seromucous, swollen infraorbital sinuses, 
snicking, open mouth breathing and frothy ocular discharge. Upon histological 
examination, infiltration of heterophils and monomorphonuclears was noted in the 
mucosa of the turbinates and trachea. Furthermore, focal damage to the epithelium, 
loss of cilia, and degeneration of the mucous glands with excretion of mucus in the 
lumen were evident. All these lesions approximately had the same course, and by 11 
dpvi the histological picture was restored to normal. These APV-caused lesions are in 
agreement with other experiments. Inflammation and deciliation of the trachea and 
turbinates had already been observed in experiments performed by Jones et al. 
(1986), Randall and Reece (1996), Van de Zande et al. (1999), and Jirjis et al., (2002, 
2004). Degeneration of the mucous gland cells and damage to the respiratory 
epithelium were likewise previously demonstrated (Randall and Reece, 1996; Van de 
Zande et al., 1999).  
In the present study, viral priming with APV was necessary to evoke marked 
clinical disease. The APV/O. rhinotracheale dual infection resulted in a higher 
morbidity than single infections with either agent. The clinical symptoms in 
themselves were similar in nature to those caused by APV alone, but they were more 
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severe and persisted markedly longer. This aggravation of clinical disease was 
reflected in the necropsy findings in that the lesions found in the respiratory tract 
were clearly more outspoken in the dually infected birds. Furthermore, microscopical 
lesions in the birds having received both agents were generally more extensive and 
more prolonged in comparison to the singly-infected animals. Also, bacterial titres in 
the turbinates and trachea remained at a higher level for a longer period of time in 
comparison with the singly infected animals, a phenomenon especially noted in group 
V/3/B. APV priming appears not to be necessary for O. rhinotracheale to be able to 
infect the lungs, although it seems to facilitate this process with bacteria being 
isolated at an earlier stage and in larger amounts. Following the combined APV/O. 
rhinotracheale infection, O. rhinotracheale was able to infect the air sacs, a feature 
never encountered in the mono-infected birds. In one group of the dually infected 
birds (V/3/B), O. rhinotracheale was isolated from non-respiratory internal organs (in 
one bird the pericardium and in one bird the heart). At necropsy however, no signs of 
septicaemia were noticed. O. rhinotracheale has in the past occasionally been isolated 
from liver, spleen, kidney, ovary, oviduct, joints and brain after experimental 
infections (Travers et al., 1996; Back et al., 1998; Sprenger et al., 1998; van Veen et 
al., 2000b). Furthermore, pericarditis has been encountered under natural 
circumstances (Hafez, 1994; van Beek et al., 1994; Hafez, 1996). These findings all 
endorse our results that APV and O. rhinotracheale exert a synergistic pathogenic 
effect if given consecutively, spaced by three or five days, to susceptible turkeys. The 
results indicated that increasing the interval between APV and O. rhinotracheale 
infection from three to five days has no major influence on the outcome of the 
disease.   
The clinical signs resulting from the dual infection are similar to but generally 
milder than those seen in field cases (De Rosa et al., 1996; Roepke et al., 1998). This 
difference may be attributed to the often inadequate environmental and management 
conditions (high animal density, inadequate ventilation, high ammonia levels, too 
high and low a relative humidity) and additional pathogens encountered in the field, 
exacerbating any disease which has been brought about. The animals used in this 
study were in contrast, kept in spacious rooms with HEPA-filtered air with no 
extraneous pathogens interplaying. 
In conclusion, it was shown that the O. rhinotracheale strain LMG 9086 in 
itself is able to adhere to and colonize the respiratory tract, but without viral priming 
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does not induce respiratory disease. In contrast, dual infection with APV and O. 
rhinotracheale resulted in more severe clinical symptoms, macroscopic and 
histological findings, and longer persistence of O. rhinotracheale in the respiratory 
tract. The established O. rhinotracheale single and APV/O. rhinotracheale dual 
infection models can undoubtedly be used to further investigate the mechanism of O. 
rhinotracheale colonization and the APV/O. rhinotracheale synergy. Further, the 
APV/O. rhinotracheale dual infection model may be used to test preventive and 
curative measures to combat the respiratory disease.  
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Summary 
Three-week-old specified pathogen free turkeys were inoculated oculonasally 
with either avian metapneumovirus (APV), APV/Ornithobacterium rhinotracheale, 
APV/Escherichia coli, APV/E. coli/O. rhinotracheale or APV/O. rhinotracheale/E. 
coli with a three days interval between viral and bacterial inoculation and 
approximately eight hours between the two bacterial inoculations. The animals were 
observed clinically and swabbed intratracheally on a daily basis. Five and ten birds 
were euthanised at five and 15 days post bacterial inoculation (dpbi), respectively, 
and examined for gross lesions at necropsy. Samples of the turbinates, sinuses, 
trachea, lungs, air sacs, heart, pericardium and liver were taken for bacteriological 
and/or histological examination. 
Combined APV, E. coli and O. rhinotracheale infections resulted in more 
severe and longer persisting clinical signs and more severe macroscopic and 
microscopic lesions compared to dual APV/O. rhinotracheale and APV/E. coli 
infections, and the latter produced more severe disease than the single APV infection. 
The level of O. rhinotracheale and E. coli multiplication in the respiratory organs did 
not differ greatly between the dual and triple infection groups, although it should be 
noted that after triple infection E. coli could be isolated from the trachea two days 
longer in comparison with the dually infected group. Another conspicuous feature 
was that only in the triple infected birds O. rhinotracheale was frequently recovered 
from the pericardium, and once from the heart and from the liver.  
These findings all endorse our conclusions that APV, E. coli and O. 
rhinotracheale exercise an additive pathogenic effect in the reproduction of 
respiratory disease if given consecutively to susceptible turkeys. 
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Introduction 
Respiratory diseases cause financial losses in the turkey industry world-wide 
due to reduced growth, an increased mortality rate, high medication costs and a 
higher number of condemnations at slaughter (van Empel and Hafez, 1999). 
Several pathogens may play an important role in respiratory disease, alone, in 
synergy or triggered by other infectious pathogens or by non-infectious factors such 
as climatic conditions and management related problems. Respiratory disease may be 
produced by respiratory viruses such as influenza virus type A, paramyxovirus types 
1, 2 and 3 and avian metapneumovirus (turkey rhinotracheitis virus) (APV). 
However, clinical signs following experimental inoculation with these viruses are less 
severe than those observed in the field. It is generally accepted that secondary 
bacterial pathogens are often involved, with amongst others Escherichia coli, 
Pasteurella spp., Bordetella avium, Ornithobacterium rhinotracheale, Mycoplasma 
spp., Chlamydophila psittaci and Riemerella anatipestifer. 
Van Loock et al. (2005) demonstrated in a longitudinal study that both APV 
and O. rhinotracheale infections often occur between production onset and slaughter 
on Belgian turkey farms. In a previously performed experiment, we were able to 
demonstrate the synergistic effect between APV and O. rhinotracheale for the 
reproduction of respiratory disease, when inoculated into turkeys via the natural 
infection route (Marien et al., 2005). Nevertheless, the clinical signs resulting from 
the APV/O. rhinotracheale dual infection were similar, but generally milder than 
those seen in field cases (De Rosa et al., 1996; Roepke et al., 1998). Likewise, Van 
de Zande et al. (2001) were able to show an additive effect between APV and E. coli 
infection in turkeys, but again less severe symptoms (i.e. no mortality) were seen than 
those encountered in the field. This difference may be attributed to the often 
inadequate environmental and management conditions in the field and synchronous 
infections with several pathogenic agents. The natural presence of O. rhinotracheale 
and E. coli has often been demonstrated in poultry (El-Sukhon, 2002; Vandekerchove 
et al., 2004). In contrast to dual infection studies, very few triple infection 
experiments have been carried out in turkeys and chickens. Jirjis et al. (2004) 
demonstrated that infection of turkey poults with APV followed by a combination of 
B. avium, E. coli and O. rhinotracheale was more severe compared to the poults 
inoculated with APV alone. The additive effect was primarily attributed to B. avium.  
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The present study was undertaken to develop a triple infection model for 
APV, E. coli and O. rhinotracheale in turkeys using the natural oculonasal 
inoculation route. The objective was to reproduce respiratory disease with severe 
clinical symptoms as encountered in the field, more in particular septicaemia as 
frequently seen in practical conditions, in order to be able to evaluate amongst others 
antimicrobial treatment schemes and environmental or management factors. Clinical 
signs, gross lesions, histology and bacterial titration were enclosed as parameters for 
evaluating possible synergistic effects between the three agents.  
                                                              
                                   
Materials and Methods 
 
Turkeys 
Seventy-three specified pathogen free (SPF) turkeys (AFSSA, Ploufragan, 
France), hatched in our facilities, were used in this study. The birds received 16h of 
light per day, were housed on litter in HEPA-filtered isolation rooms and had free 
access to food and water.  
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during 
a respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The 
virus stock had a titre of 5.5 log10 50% ciliostatic dose (CD50)/ml after the third 
passage in tracheal organ cultures.  
 
Bacteria 
The O. rhinotracheale strain LMG 9086T, originally isolated from a turkey 
with a respiratory tract infection, was used. The strain was serotyped as type A in an 
agar gel precipitation test (Hafez and Sting, 1999) by Professor H. M. Hafez (Institute 
of Poultry Diseases, Free University of Berlin, Germany). The strain was stored at -
70°C. The organism was retrieved from the frozen suspension and cultured for 48h at 
37°C on Columbia agar (Oxoid LTD, Basingstoke, Hampshire, England) with 5% 
sheep blood in a 5% CO2 atmosphere. Ten colonies were transferred into 5 ml brain 
heart infusion (BHI) broth (Oxoid LTD) for 24h at 37°C with agitation 
(microaerophilic incubation). The bacterial challenge inoculum was prepared by 
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washing 1 ml cultured bacteria twice in phosphate buffered saline (PBS). A 
suspension containing 8.6 log10 colony forming units (cfu)/ml was prepared.  
A Belgian E. coli isolate retrieved from turkeys with colibacillosis was used. 
It was identified and serotyped as O2:K1 by Dr. Flemming Scheutz (Statens Serum 
Institute, The International Escherichia and Klebsiella Centre, Copenhagen, 
Denmark). The strain was stored at -70°C. The organism was retrieved from the 
frozen suspension and cultured overnight at 37°C on MacConkey agar (Oxoid LTD). 
Three colonies were transferred into BHI broth and cultured for 24h at 37°C. The 
bacterial challenge inoculum was prepared by washing 1 ml cultured bacteria two 
times in PBS. A suspension containing 8.6 log10 cfu/ml was prepared.  
 
Experimental design 
Seventy-three SPF turkeys were randomly divided into six groups at one day 
of age. Five groups consisted of thirteen animals and one group of eight animals 
(control group). At two weeks of age, the birds were shown to be free from 
maternally derived antibodies to O. rhinotracheale and APV, by a commercially 
available ELISA (Biochek, Gouda, the Netherlands) and an in-house serum 
neutralization test (Marien et al., 2006), respectively. Before bacterial inoculation, 
tracheal swabs were taken from all birds of each experimental group for 
bacteriological examination. All animals were negative for O. rhinotracheale and E. 
coli. 
At the age of three weeks, turkeys of two groups first received APV followed 
by O. rhinotracheale (A/O) or E. coli (A/E) three days later. The animals from the 
groups A/O/E and A/E/O first received APV, followed by O. rhinotracheale and E. 
coli three days after APV inoculation. The animals of group A/O/E were inoculated 
with O. rhinotracheale at 8 am and with E. coli at 5 pm. In group A/E/O, the turkeys 
were inoculated with E. coli at 8 am and with O. rhinotracheale at 5 pm. In group A, 
turkeys received only APV and group C was maintained as an uninoculated control 
group. The inoculation with APV occurred by the oculonasal route at a dose of 4.4 
log10CD50/per bird (250µl). O. rhinotracheale and E. coli were administered 
oculonasally at a dose of 8 log10 cfu/250µl per bird. 
All birds were clinically examined on a daily basis throughout the experiment. 
The clinical signs were scored as described in Van de Zande et al. (2001). Shortly, the 
clinical condition of each bird was adjudged a score from 0 (absence of clinical signs) 
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to 7 (nasal exudate with extremely swollen sinuses and frothy eyes, poor general 
condition and anorexia). The mean clinical score was calculated for each 
experimental group. 
Tracheal swabs were collected from groups A, A/O, A/E, A/O/E and A/E/O at 
three days post viral infection (dpvi) for virus titration and from birds belonging to 
group C to demonstrate the absence of an adventitious exposure. Furthermore, 
tracheal swabs were collected daily from all turkeys for titration of O. rhinotracheale 
and E. coli. The tracheal swabs were collected using cotton-tipped aluminium shafted 
swabs (Copan Diagnostics Inc., Corona, USA) and placed in transport medium. The 
latter consisted of 1 ml PBS supplemented with Ca2+ and Mg2+ for bacteriological 
examination and supplemented with 10% fetal calf serum (Gibco, Invitrogen 
Corporation, Merelbeke, Belgium), penicillin (1000 U/ml) (Biopharma, Rome, Italy) 
and kanamycin (0.5 mg/ml) (Gibco) for virus titration. Processing occurred as 
described below.  
Five birds of each group were randomly selected and were sacrificed at 8 dpvi 
(i.e. 5 days post bacterial infection (dpbi) for groups A/O, A/E, A/O/E and A/E/O). 
The remaining eight (three for group C) birds of the different groups were sacrificed 
at 18 dpvi. Euthanasia was performed by intravenous injection with an overdose (10 
mg/kg) of sodium pentobarbital 20% (Kela, Hoogstraten, Belgium). The birds were 
necropsied and examined for gross lesions. Samples of the turbinates, trachea and 
lungs were collected from all sacrificed birds for bacteriological examination. A 10% 
suspension in PBS was made from these tissue samples. The sinuses, air sacs, heart, 
pericardium and liver were sampled with cotton swabs for bacteriological analysis. 
These swabs were suspended in 1 ml PBS supplemented with Ca2+ and Mg2+. For the 
animals sacrificed at 18 dpvi the sinuses, turbinates, trachea, lungs, air sacs, heart, 
pericardium and liver were sampled with cotton swabs for bacteriological analysis. 
All samples for bacterial isolation were processed immediately after collection as 
described below. Finally, samples from the air sacs, turbinates, trachea, lungs, heart 
and liver were collected and fixed in 10% neutral buffered formalin for 
histopathological examination.  
This experiment has been approved by the Ethical Committee of the Faculty 
of Veterinary Medicine, Ghent University. 
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Virological and bacteriological titration 
Viral and bacterial titrations of swabs and tissue suspensions were done using 
the procedures described by Marien et al. (2005), with the following addition to the 
protocol: for the isolation of E. coli, samples were inoculated on MacConkey agar 
and incubated for 24h at 37°C. The isolated E. coli strains were serotyped by a slide-
agglutination test using the antiserum against the E. coli O2:K1 strain (Veterinary 
Laboratories Agency, Surrey, United Kingdom). 
 
Histopathology 
Following fixation in formalin, the tissues were embedded in paraffin, 
sectioned at 4 µm, mounted on glass slides and stained with haematoxylin and eosin 
using standard procedures. Tissues from the turbinates and trachea were additionally 
stained by the Periodic Acid Schiff-reaction to visualize the mucus layer.  
 
 
Results 
 
During the experiment, mortalities did not occur in any of the experimental groups. 
 
Clinical signs 
The mean clinical scores for all groups are shown in Figure 1. Respiratory 
disease was not detected in birds from group C (control group).  
Signs of respiratory distress were seen in all APV-inoculated groups starting 
from 4 dpvi. In group A, peak mean score (1.9) appeared at 6 dpvi, after which a 
gradual decline was noted, with clinical symptoms lasting until 9 dpvi. Both in groups 
A/E and A/O, a peak mean score of 2.5 was seen at 3 dpbi, followed by a gradual 
decline until at 7 dpbi (group A/E) and 8 dpbi (group A/O), no clinical signs were 
observed. The highest mean score (2.8) was found in group A/E/O at 3 and 6 dpbi. 
Consequently, a decline was noted with an absence of clinical signs from 9 dpbi 
onwards. Finally, in group A/O/E, the peak mean score was present at 3, 4 and 6 dpbi 
(2.6). After 6 dpbi the mean scores dropped rapidly and at 9 dpbi all clinical signs had 
disappeared.  
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Figure 1. Mean clinical scores in turkeys after single APV inoculation ( × group A), 
dual APV/O. rhinotracheale (▲ group A/O) or APV/E. coli (   group A/E) 
inoculation with an interval of three days, or triple APV/O. rhinotracheale/E. coli ( ■ 
group A/O/E) or APV/E. coli/O. rhinotracheale ( ● group A/E/O) inoculation with an 
interval of three days between viral and bacterial inoculation, and an interval of 9 
hours between the two bacterial inoculations, and in the turkeys of the control group 
(  group C). Arrow indicates day of bacterial inoculation (O. rhinotracheale and/or 
E. coli). 
 
Macroscopic findings  
Marked macroscopic lesions were absent in group C. In some birds of group 
A, a slight amount of serous exudate in the sinuses and the turbinates and a slight 
hyperaemia in the turbinates and trachea were noted. In the groups with dual (groups 
A/O and A/E) or triple (groups A/O/E and A/E/O) inoculations, the observed 
macroscopic lesions were comparable, although slightly more severe in the birds with 
triple infection. Serous to seromucous exudate was found in the turbinates and 
sinuses, and the amount of mucus varied from moderate to abundant. Hyperaemia of 
the turbinates and the trachea was frequently encountered. A slightly decreased 
lucidity of the air sacs was found in one animal of group A/O/E and A/O and in two 
animals of group A/E/O. A haemorrhage of the lungs was observed in one animal of 
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group A/O and A/E/O and hyperaemia of the lungs was seen in one bird of group 
A/O/E. On one occasion in group A/E, the pericardium had a foamy appearance. One 
animal of group A/E had a mucus plug in the trachea.  
 
Viral titrations of tracheal swabs 
Viral titrations of tracheal swabs collected at 3 dpvi showed that APV was 
recovered from every individual bird of all APV infected groups. Mean titres were 
4.0, 4.1, 4.4, 4.2 and 4.6 log10CD50/g mucus for group A, A/O, A/E, A/E/O and 
A/O/E, respectively. APV was not recovered from tracheal swabs from group C. 
 
Bacterial titration of tracheal swabs 
O. rhinotracheale and E. coli were not recovered from any of the birds of 
groups C, A, A/E and groups C, A, A/O, respectively. 
The results of O. rhinotracheale and E. coli titrations of the tracheal swabs of the 
remaining groups are shown in Figure 2. Mean titres for each experimental group are 
depicted.  
The highest amount of O. rhinotracheale in group A/O was found at 6 dpbi (6.5 log10 
cfu/g mucus). After the peak, mean titres declined rapidly, until at 9 dpbi no more O. 
rhinotracheale was recovered from tracheal swabs. In groups A/E/O and A/O/E, O. 
rhinotracheale titres peaked at 6 dpbi with titres of 6.7 and 6.4 log10 cfu/g mucus, 
respectively. Titres remained at a higher level for a longer period of time compared to 
group A/O, with no more O. rhinotracheale bacteria being retrieved from 10 dpbi 
onwards.  
The highest amount of E. coli in group A/E was found at 3 dpbi (4.7 log10 cfu/g 
mucus). Titres remained at approximately the same level until 6 dpbi, after which 
bacterial titres dropped until at 12 dpbi no more E. coli was recovered from tracheal 
swabs. Although in group A/O/E and A/E/O the peak mean titre (4.1 log10 cfu/g 
mucus) was seen at 3 dpbi and 8 dpbi, respectively, the isolation rate of E. coli out of 
tracheal mucus in groups A/E/O and A/O/E, approximately had the same course, with 
a rise to higher mean titres at 3 to 5 dpbi (approximately 4 log10 cfu/g mucus), 
followed by a gradual decline until at 14 dpbi, no more E. coli was isolated.  
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Figure 2. Mean E. coli titres (closed symbols) and O. rhinotracheale titres (open 
symbols) (log10 cfu/g mucus) in tracheal mucus collected daily after E. coli and/or O. 
rhinotracheale inoculation of dually APV/O. rhinotracheale (▲, ∆ group A/O) and 
APV/E. coli (     ,     group A/E) infected turkeys, or triple APV/O. rhinotracheale /E. 
coli (■, □ group A/O/E) and APV/E. coli/O. rhinotracheale (●,○ group A/E/O) 
infected turkeys. 
 
Bacterial titration of tissue samples 
O. rhinotracheale was never found in any of the tissues from the birds from 
groups C, A and A/E and E. coli was never isolated from any of the tissues from the 
animals belonging to groups C, A and A/O. The results of O. rhinotracheale and E. 
coli titrations in the other groups are shown in Table 1 and 2.  
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Table 1. Bacterial titre of O. rhinotracheale (log10 cfu/g tissue) isolated from 
different organs of turkeys inoculated with APV followed by O. rhinotracheale three 
days later (group A/O), with APV followed three days later by O. rhinotracheale and 
E. coli (A/O/E), or with APV followed three days later by E. coli and O. 
rhinotracheale (group A/E/O). Turkeys were euthanised at 5 dpbi. 
 
O. rhinotracheale titre (log10 cfu / g tissue) 
Organ 
Group A / O  Group A / O / E  Group A / E / O 
 1a 2 3 4 5  1 2 3 4 5  1 2 3 4 5 
Turbinates 8.6 7.7 7.9 9.0 6.6  7.5 7.2 7.4 8.7 6.2  10.2 9.0 5.6 9.9 9.0 
Trachea 5.9 7.4 7.7 6.0 6.5  7.1 5.9 7.0 8.0 8.1  8.0 7.6 6.7 7.2 7.0 
Lungs 2.7 5.4 5.9 6.8 7.2  5.7 5.3 5.8 5.2 6.5  6.1 6.0 5.5 4.8 6.8 
Sinusb 3c 0 3 3 3  1 3 3 1 3  3 3 3 3 3 
Air sacsb 0 0 0 3 2  0 1 0 1 3  2 3 1 2 1 
Pericardium
b 0 0 0 0 0  1 1 1 0 1  1 1 0 0 1 
Heartb 0 0 0 0 0  0 0 0 0 0  0 0 0 1 0 
Liverb 0 0 0 0 0  0 0 0 0 0  0 0 0 0 2 
a: number of turkey 
b: these organs were swabbed; no tissue suspensions were made 
c: 0 = 0 colonies   /   1 = 1 to 10 colonies   /   2 = 11 tot 100 colonies   /   3 = more than 100 colonies 
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Table 2. Bacterial titre of E. coli (log10 cfu/g tissue) isolated from different organs of 
turkeys inoculated with APV followed by E. coli three days later (group A/E), with 
APV followed three days later by O. rhinotracheale and E. coli (A/O/E), or with 
APV followed three days later by E. coli and O. rhinotracheale (group A/E/O). 
Turkeys were euthanised at 5 dpbi.  
E. coli titre (log10 cfu / g tissue) 
Organ 
Group A / E  Group A / O / E  Group A / E / O 
 1a 2 3 4 5  1 2 3 4 5  1 2 3 4 5 
Turbinates 9.2 6.8 10 6.7 6.3  4.4 10 8.1 7.7 5.7  9.8 8.4 4.4 9.5 7.5 
Trachea 7.0 7.5 8.6 7.5 8.2  4.0 3.6 6.1 7.8 5.0  6.5 3.0 6.3 6.7 3.9 
Lungs 0.0 3.4 0.0 4.5 0.0  4.4 0.0 0.0 0.0 4.8  4.3 0.0 0.0 3.3 4.3 
Sinusb 3c 1 1 3 3  3 3 3 0 3  3 2 3 3 3 
Air sacsb 0 0 0 0 0  0 0 1 0 0  0 0 0 0 0 
Pericardiumb 1 0 0 0 0  0 0 0 0 0  0 0 0 0 0 
Heartb 0 0 0 0 0  0 0 0 0 0  0 0 0 1 0 
Liverb 0 0 0 0 0  0 0 0 0 0  0 0 0 0 1 
a: number of turkey 
b: these organs were swabbed; no tissue suspensions were made 
c: 0 = 0 colonies   /   1 = 1 to 10 colonies   /   2 = 11 tot 100 colonies   /   3 = more than 100 colonies 
 
Histopathology 
In the control group (group C), no marked microscopic changes were 
observed in the air sacs, turbinates, trachea or lungs. The histological preparations of 
the animals of group A displayed mild infiltration of heterophils and 
monomorphonuclear cells in the mucosa of the turbinates and trachea, degeneration 
of the mucous glands in the turbinates and trachea, loss of cilia in the trachea, and in 
one animal mild infiltration of heterophils in the air sacs. No lung lesions were 
encountered.  
Histopathological lesions were similar in groups A/O, A/E, A/O/E and A/E/O: 
infiltration of heterophils and monomorphonuclear cells in the mucosa of the 
turbinates and trachea, degeneration of the mucous glands and epithelium in the 
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turbinates and trachea, loss of cilia in trachea, activation of lymph nodules in the 
turbinates, suppurative exudate in the lumen of trachea and turbinates, and foci of 
pneumonia, suppurative bronchitis and bronchiolitis in the lung. Furthermore, 
infiltration of heterophils and monomorphonuclear cells in the air sacs was noted. In 
general, it can be stated that all lesions were more severe in the groups with triple 
infection (group A/O/E and A/E/O), especially the infiltration by heterophils and 
monomorphonuclear cells in the mucosa of the turbinates and trachea and in the air 
sacs.  
 
 
Discussion 
In the present study, it was demonstrated that APV, E. coli O2:K1 and O. 
rhinotracheale triple infections of turkeys were able to cause similar, but more severe 
and longer persisting respiratory symptoms compared to dual APV/O. rhinotracheale 
and APV/E. coli infections, with the latter causing more severe signs of  respiratory 
distress than single APV infection. It should also be noted that from 4 dpbi onwards, 
APV/O. rhinotracheale dual infection resulted in slightly higher clinical scores in 
comparison with APV/E. coli dual infection. The aggravation of clinical disease by 
combined action of APV, O. rhinotracheale and E. coli was reflected in the necropsy 
findings and the microscopical observations, in that the lesions found in the 
respiratory tract were slightly more pronounced and extensive in comparison with 
dual APV/O. rhinotracheale and APV/E. coli infections, and certainly compared to 
single APV infection.  
Concerning the number of O. rhinotracheale and E. coli bacteria recovered from the 
tracheal mucus in the dual and triple infection groups, the most conspicuous 
observation was that in the triple infection groups, E. coli could be isolated from the 
tracheal mucus to slightly lower numbers from 1 to 7 dpbi, with the reverse situation 
from 8 dpbi onwards, i.e. E. coli being isolated to somewhat higher numbers in the 
triple infected groups as compared to the dually infected group. Further, E. coli could 
in the triple infected groups be isolated two days longer from the tracheal mucus 
compared to the dually infected group.  
The level of O. rhinotracheale multiplication in the respiratory organs of the 
euthanised animals at 5 dpbi did not show marked differences between the dual and 
triple infection groups, with bacteria being isolated from turbinates, trachea, lungs, 
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sinuses and air sacs almost in equal amounts. In most E. coli challenged turkeys of 
the dual and triple infection groups, E. coli was isolated from the turbinates, trachea, 
sinuses and to a lesser extent from the lungs, but could however be isolated from the 
air sacs of only one animal (group A/O/E).  
Thus, both O. rhinotracheale and E. coli O2:K1 were, after APV priming, 
able to colonize the upper respiratory tract and invade the lower respiratory tract of 
turkeys. This is in accordance with experiments performed by Van de Zande et al. 
(2001) and Marien et al. (2005). Marien et al. (2005) demonstrated that, although O. 
rhinotracheale on itself was able to adhere to and colonize the upper respiratory tract 
of turkeys, APV priming facilitated infection of the lungs and was necessary to allow 
O. rhinotracheale to infect the air sacs. Van de Zande et al. (2001) demonstrated that 
E. coli was only able to colonize the turbinates of turkeys that had been infected 
previously with APV and hence concluded that E. coli takes advantage of the damage 
caused by the virus to colonize.  
Furthermore, this study clearly shows that combined action of O. 
rhinotracheale and E. coli enhances the invasion of O. rhinotracheale but not of E. 
coli in the non-respiratory internal organs. Only in birds infected with both bacteria 
could at 5 dpbi O. rhinotracheale be isolated out of the pericardium of most of the 
animals and out of the heart and liver of one bird. 
These findings all endorse our results that APV, E. coli and O. rhinotracheale 
exert a synergistic pathogenic effect if given consecutively, spaced by three days 
between the viral and the bacterial challenges, to susceptible turkeys. The results 
further indicate that the sequence in which the turkeys are infected with O. 
rhinotracheale and E. coli has no major influence on the outcome of the disease. 
Although in the present study respiratory disease caused by APV inoculation 
was clearly aggravated by co-infection with E. coli and O. rhinotracheale, not all the 
typical disease symptoms of these bacterial infections were observed. One of the most 
common forms of colibacillosis begins as a respiratory tract infection and may be 
referred to as airsacculitis. If unattended, this infection may evolve into a bacteraemia 
and a generalized infection which manifests as a polyserositis (Pourbakhsh et al., 
1997a; Dho-Moulin and Fairbrother, 1999; Barnes et al., 2003). In the present study 
however, no pathological signs of airsacculitis or generalized infection were seen, 
although the isolate was cultured from a necropsy case with typical polyserositis 
lesions. The virulence mechanisms of avian pathogenic E. coli have not been clearly 
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characterised yet. In order to produce colisepticemia, E. coli must find an appropriate 
receptor for adhesion, must be able to multiplicate in the tissues and to resist the 
immunological defenses of the host so it can finally enter and survive in the blood 
(Dho-Moulin, 1993; Pourbakhsh et al., 1997a; 1997b). Previously, it has been shown 
that the lower respiratory tract (lungs and air sacs) is an important site of entrance of 
E. coli into the bloodstream of birds (Cheville and Arp, 1978; Ackermann and 
Cheville, 1991; Pourbakhsh et al., 1997a). Since the presently adopted E. coli strain 
was able to invade the lungs and the air sacs of some birds but still did not cause 
typical colisepticemia, the strain was possibly lacking certain characteristics 
necessary for invasion of the bloodstream. Still we should also keep in mind that 
differences in severity of clinical disease after experimental infection compared to 
field cases may also be attributed to the often inadequate environmental and 
management conditions (high animal density, inadequate ventilation, high ammonia 
levels, too high and low a relative humidity) and additional pathogens encountered in 
the field. Avian pathogenic E. coli infections for instance are enhanced or initiated by 
predisposing factors such as environmental conditions and viral or Mycoplasma 
infections (Dho-Moulin and Fairbrother, 1999). The animals used in the present study 
were in contrast SPF animals kept in spacious rooms with HEPA-filtered air with no 
extraneous pathogens interplaying. Several studies have been performed to elucidate 
the effects of the combined action of APV and other microorganisms in turkeys and 
chickens. In turkeys, following infection with APV, disease may be exacerbated by 
concurrent infection with various bacteria such as B. avium and a Pasteurella-like 
organism (Cook et al., 1991; Jirjis et al., 2004), with O. rhinotracheale (van Empel et 
al., 1996; Marien et al., 2005), with E. coli (Van de Zande et al., 2001; Turpin et al., 
2002), with Mycoplasma gallisepticum (Naylor et al., 1992) and with Mycoplasma 
imitans (Ganapathy and Bradbury, 1999). Very recently, Van Loock et al. (2006) 
demonstrated the exacerbating role of APV during acute Chlamydophila psittaci 
infection in young turkeys. In chickens, different researchers observed that the 
clinical disease due to infection with APV was worsened by E. coli (Al-Ankari et al., 
2001; Majo et al., 1997) or O. rhinotracheale inoculation (van Empel et al., 1996). In 
these experimental challenge studies, many researchers also came across difficulties 
in reproducing disease symptoms identical as encountered in the field.  
In conclusion, it was shown that in the present experiment, respiratory disease 
in turkeys was more severe after triple APV, E. coli and O. rhinotracheale infection 
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compared to dual APV/E. coli and APV/O. rhinotracheale infection. The established 
dual and triple infections models may undoubtedly be used to further investigate the 
mechanisms of O. rhinotracheale and E. coli colonization and the synergistic 
relations between APV, E. coli and O. rhinotracheale. Furthermore, these models can 
also be used to test preventive and curative measures to combat respiratory disease. 
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infections in turkeys 
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Summary 
The purpose of this study was to assess the possible synergism between 
Mycoplasma gallisepticum, Ornithobacterium rhinotracheale, Escherichia coli and 
avian metapneumovirus (APV) infections in turkeys. The parameters used for the 
evaluation of synergism were clinical signs, gross lesions, histology and viral and 
bacterial titration. Eighty-five specified pathogen-free (SPF) turkeys were inoculated 
with either M. gallisepticum, M. gallisepticum/APV, M. gallisepticum/APV/O. 
rhinotracheale or M. gallisepticum/APV/E. coli/O. rhinotracheale with a 10 day 
interval between M. gallisepticum and APV inoculations, a three day interval between 
viral and E. coli and/or O. rhinotracheale inoculations, and an 8h interval between E. 
coli and O. rhinotracheale inoculations. A non-infected negative group was included 
as control. The M. gallisepticum infection was induced via the intratracheal route, 
while all other inoculations (APV, O. rhinotracheale, E. coli) were done via the 
oculonasal route. Clinical observations of the experimental animals were performed 
daily (upper and lower respiratory tract symptoms) and intratracheal swabs were 
performed on a regular basis. Five birds out of a total of 17 birds of each group were 
sacrificed 18 days after M. gallisepticum inoculation and the remaining birds at the 
end of the experimental period, i.e. 33 days after M. gallisepticum inoculation. The 
birds were examined for gross lesions at necropsy and samples of the turbinates, 
sinuses, trachea, lungs, air sacs, heart, pericardium and liver were taken for 
bacteriological and/or histological examination.  
After a single M. gallisepticum inoculation the birds suffered from very 
serious respiratory distress, caused by severe airsacculitis, resulting in high mortality 
rates up to 50% (range 16.7% - 50%). Upper respiratory tract symptoms (nasal 
exudate and swollen sinuses) were seen in all the M. gallisepticum/APV dually 
infected turkeys, and the severity of the symptoms was exacerbated by inoculation 
with E. coli and/or O. rhinotracheale. The peak in the clinical scores, especially in the 
groups with additional infection with E. coli and O. rhinotracheale, coincided with a 
second peak of mortality. The isolation of M. gallisepticum from the respiratory 
organs (tracheae, lungs and air sacs) did not substantially differ between the various 
M. gallisepticum infected groups (average reisolation rate 83.3 %). On the other hand, 
M. gallisepticum seemed to exert an impeding effect on the clearance of O. 
rhinotracheale and E. coli, especially from the upper respiratory tract. In general, 
gross lesions at necropsy were similar in groups M. gallisepticum/APV, M. 
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gallisepticum/APV/O. rhinotracheale and M. gallisepticum/APV/E. coli/O. 
rhinotracheale. A remarkable finding at necropsy was the presence of septicaemia in 
the M. gallisepticum/APV/E. coli/O. rhinotracheale infected poults. 
In conclusion, the results obtained in the present study clearly indicate the 
existence of marked synergism between four distinct respiratory pathogens, i.e. M. 
gallisepticum, APV, O. rhinotracheale and E. coli, important in commercial poultry. 
This was evidenced by the higher mortality rates and the aggravated clinical 
symptoms whenever the birds were infected with an additional pathogen. Similarly 
necropsy and microscopical lesions were more severe in case two or more pathogens 
were inoculated. Especially concurrent infection of M. gallisepticum and APV 
infected birds with O. rhinotracheale and E. coli seemed to aggravate the clinical 
symptoms and caused higher mortality rates.  
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Introduction 
Respiratory disorders are one of the important diseases affecting turkeys and 
are continuing to cause high economic losses in many areas world-wide due to 
reduced growth, increased feed conversion rates, an increased mortality rate, high 
medication costs and a higher number of condemnations at slaughter (van Empel and 
Hafez, 1999). Management failures as well as pathogen interplay between various 
viral and bacterial pathogens are largely involved in this multifactorial disease 
complex. 
In two previously performed experiments, synergistic effects were 
demonstrated between avian metapneumovirus (APV), Ornithobacterium 
rhinotracheale and Escherichia coli for the reproduction of respiratory disease, when 
inoculated into turkeys via the natural infection route (Marien et al., 2005; 
unpublished results). Nevertheless, the clinical signs resulting from these mixed 
infections were similar, albeit still generally markedly milder than those seen in field 
cases (De Rosa et al., 1996; Roepke et al., 1998). In the latter airsacculitis and 
septicaemia are frequently noted, resulting in severely diseased chickens and turkeys 
and even mortalities (van Empel and Hafez, 1999; Vandekerchove, 2004). These 
features were never encountered in the formerly mentioned experimental trials. This 
difference may be attributed to the often inadequate environmental and management 
conditions in the field and synchronous infections with several pathogenic agents, 
which are very difficult to reproduce experimentally. 
The present study was undertaken to develop a mixed infection model for M. 
gallisepticum, APV, E. coli and O. rhinotracheale in turkeys, with the objective of 
reproducing respiratory disease with severe clinical symptoms as noted in the field, in 
order to be able to evaluate amongst others antimicrobial treatment schemes and 
environmental or management factors. The parameters that were used for evaluating 
possible synergistic effects between the four agents were clinical signs, gross lesions, 
histology and bacterial titration.  
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Materials and Methods 
 
Turkeys 
Eighty-five specified pathogen-free (SPF) turkeys (AFSSA, Ploufragan, 
France), hatched in our facilities, were used in this study. The birds were housed in 
separate isolation units of 1.2 m2 (height: 0.70m) with HEPA (high efficiency 
particulate air)-filtered air and had free access to food and water. 
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during 
a respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The 
virus stock had a titre of 5.5 log10 50% ciliostatic dose (CD50)/ml after the third 
passage in tracheal organ cultures.  
 
Bacteria 
The O. rhinotracheale type strain LMG 9086T originally isolated from a 
turkey with a respiratory tract infection was used. The strain was serotyped as type A 
in an agar gel precipitation test (Hafez and Sting, 1999) performed by Professor H. 
M. Hafez (Institute of Poultry Diseases, Free University of Berlin, Germany). The 
strain was stored at -70°C. The organism was cultured for 48h at 37°C on Columbia 
agar (Oxoid LTD, Basingstoke, Hampshire, England) with 5% sheep blood in a 5% 
CO2 atmosphere. The O. rhinotracheale bacteria were transferred into brain heart 
infusion (BHI) broth (Oxoid) for 24h at 37°C with agitation (microaerophilic 
incubation). The bacterial challenge inoculum was prepared by washing the cultured 
bacteria twice in phosphate-buffered saline (PBS) followed each time by five minutes 
of centrifugation at 3,000 rpm at 4°C. The resulting pellet was re-suspended in PBS 
to obtain a final concentration of 8.6 log10 colony-forming units (cfu)/ml.  
A Belgian E. coli isolate originating from turkeys with colibacillosis was 
used. It was identified and serotyped as O2:K1 by Dr. Flemming Scheutz (Statens 
Serum Institute, The International Escherichia and Klebsiella Centre, Copenhagen, 
Denmark). This strain had been used previously by Van de Zande et al. (2001) for the 
induction of E. coli infection in APV infected turkeys and was stored at -70°C. The 
organism was retrieved from the frozen suspension and cultured overnight at 37°C on 
MacConkey agar. The E. coli bacteria were transferred into BHI and cultured for 
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another 24h at 37°C. The bacterial challenge inoculum was prepared by washing the 
cultured bacteria twice in PBS followed each time by five minutes of centrifugation at 
3,000 rpm at 4°C. The resulting pellet was re-suspended in PBS to obtain a final 
concentration of 8.6 log10 cfu/ml.  
An M. gallisepticum field isolate from broilers with respiratory symptoms 
(chicken/NL/Dev/SP-1608Vin/99) was used as inoculum. It had been isolated on 
Mycoplasma Experience agar (ME, Mycoplasma Experience, Reigate, Surrey, UK), 
identified by immunofluorescence test (IFA) (Kiernan, 1990), conventional PCR 
(IDEXX Laboratories Inc., Schiphol-Rijk, the Netherlands) and stored at -70°C in 
ME broth (Mekkes and Feberwee, 2005; Feberwee et al., 2005a). One ml of the 
stored broth (-70°C) was added to 50 ml ME broth, which was then incubated for two 
days at 37°C until change of colour was observed. At the start and at the end of the 
inoculations control of the bacterial concentration of the inoculum was performed by 
means of a quantitative PCR (Q-PCR) as described by Mekkes and Feberwee (2005). 
This Q-PCR was shown to correlate well with standard counting techniques using 
culture. 
 
Experimental design 
Eighty-five SPF turkeys were randomly divided into five groups of 17 animals 
at ten days of age. At nine days of age, the birds were shown to be free from 
maternally derived antibodies to M. gallisepticum, O. rhinotracheale and APV, by 
commercially available ELISA tests (BioChek, Gouda, the Netherlands) for M. 
gallisepticum and O. rhinotracheale, and by an in-house serum neutralization test 
(Marien et al., 2006) for APV. 
At ten days of age the birds of groups M (single M. gallisepticum inoculation) 
M/A (dual M. gallisepticum and APV inoculation), M/A/O (M. gallisepticum, APV 
and O. rhinotracheale inoculation) and M/A/E/O (M. gallisepticum, APV, O. 
rhinotracheale and E. coli inoculation) were inoculated with M. gallisepticum and 
placed into the HEPA-filtered isolation units. Ten days later, the birds of group M/A, 
M/A/O and M/A/E/O were inoculated with APV. Three days later, in group M/A/O, 
turkeys subsequently received O. rhinotracheale, and the animals of group M/A/E/O 
were inoculated with E. coli and O. rhinotracheale. Inoculation with O. 
rhinotracheale in group M/A/E/O was done approximately eight hours after E. coli 
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inoculation. Group C was used as an uninoculated control group and was kept on 
litter in an HEPA-filtered isolation room. 
All the birds of the respective groups were infected with M. gallisepticum by 
intratracheal inoculation with 0.5 ml ME broth containing approximately 7.8 log10 
cfu/ml. APV was inoculated oculonasally at a dose of 4.4 log10CD50, O. 
rhinotracheale and E. coli were given at a dosage of 8 log10 cfu per bird. For 
inoculation with APV, O. rhinotracheale and/or E. coli, a total of 250 µl was divided 
equally over the nares and eyes. 
All birds were examined clinically on a daily basis throughout the experiment 
until they were sacrificed. The clinical symptoms were divided into lower respiratory 
tract and upper respiratory tract symptoms. Dyspnoea was regarded as a sign of lower 
respiratory tract distress. The clinical signs of the upper respiratory tract (nasal 
exudate, swollen sinuses and frothy eyes were scored as described by Van de Zande 
and colleagues (2001). Shortly, the clinical condition of each bird was assigned a 
score from 0 (absence of clinical signs) to 7 (nasal exudate with extremely swollen 
sinuses and frothy eyes, poor general condition and anorexia). The mean clinical 
score was calculated for each experimental group. 
All the birds were weighed at the beginning of the experiment (day of M. 
gallisepticum inoculation) and subsequently on the day that they were sacrificed.  
Tracheal swabs were collected at 11 days post M. gallisepticum inoculation 
(dpmi) for quantitative M. gallisepticum polymerase chain reaction (PCR) and at 3 
days post viral infection (dpvi) (13 dpmi) for virus titration. Before O. rhinotracheale 
and E. coli inoculation, tracheal swabs were taken from all birds of each experimental 
group for examination of O. rhinotracheale and E. coli O2:K1, which proved to be 
negative. 
Tracheal swabs were also collected on 14, 16, 18, 20, 22, 24, 26, 29 and 33 
dpmi from all groups for bacteriological titration of O. rhinotracheale and E. coli and 
for quantitative M. gallisepticum PCR. The tracheal swabs were collected using 
cotton-tipped aluminium shafted swabs (Copan Diagnostics Inc., Corona, USA) and 
placed in transport medium. The latter consisted of 1.5 ml PBS for M. gallisepticum, 
O. rhinotracheale and E. coli examination, supplemented with 10% fetal calf serum 
(Gibco, Invitrogen Corporation, Merelbeke, Belgium), penicillin (1000 U/ml) 
(Biopharma, Rome, Italy) and kanamycin (0.5 mg/ml) (Gibco) for virus titration. 
Processing occurred as described below. 
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Five birds of each group including group C were sacrificed at 18 dpmi. The 
remaining birds of each group were sacrificed 15 days later, i.e. 33 dpmi. Euthanasia 
was performed by intravenous injection with an overdose (10 mg/kg) of sodium 
pentobarbital 20% (Kela, Hoogstraten, Belgium). The birds were necropsied and 
examined for gross lesions.  
Samples of the turbinates, trachea and lungs were collected from each of the five 
birds of each group sacrificed at 18 dpmi for O. rhinotracheale and E. coli 
examination. A 10% suspension in PBS was made from these tissue samples. Sinus, 
air sacs, heart, pericardium and liver were also sampled, however with cotton swabs, 
for O. rhinotracheale and E. coli analysis. All samples for O. rhinotracheale and E. 
coli isolation were processed immediately after collection (see later). Swabs from the 
trachea, lungs and air sacs were additionally collected for M. gallisepticum culture. 
The swabs were dipped in Mycoplasma Adler medium (Avian Mycoplasma Liquid 
Medium; Mycoplasma Experience, Reigate, UK) just prior to sampling. Processing 
occurred as described below.  
For the remaining birds sacrificed at 33 dpmi, turbinates, trachea, lungs, sinuses, air 
sacs, liver, heart and pericardium were sampled with cotton swabs for O. 
rhinotracheale and E. coli analysis and swabs, dipped in Adler, were collected from 
trachea, lungs and air sacs for culture of M. gallisepticum. 
From all the birds that spontaneously died during the experiment from 13 dpmi 
onwards, swabs of the turbinates, trachea, lungs, sinuses, air sacs, pericardium, heart 
and liver were taken for O. rhinotracheale and E. coli analysis. No swabs for M. 
gallisepticum culture were taken from these animals. 
Finally, samples from the turbinates, trachea and lungs were taken and fixed in 10% 
neutral buffered formalin for histopathological examination.  
This experiment was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine, Ghent University. 
 
Virological (APV) and bacteriological (M. gallisepticum, O. rhinotracheale and E. 
coli) titration of tracheal swabs  
The virus titre in log10 CD50 per g mucus and the number of cfu of O. 
rhinotracheale and E. coli per g mucus were determined. This was done using the 
procedures described by Marien and others (2005), with the following addition to the 
protocol: for the isolation of E. coli, samples were inoculated on MacConkey agar 
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and incubated for 24h at 37°C. The retrieved E. coli isolates were serotyped by a 
slide-agglutination test using the antiserum against the E. coli O2:K1 strain 
(Veterinary Laboratories Agency, Surrey, United Kingdom). Concentration of M. 
gallisepticum in the tracheal samples was performed using the Q-PCR described 
previously (Mekkes and Feberwee, 2005). 
 
Bacteriological (M. gallisepticum, O. rhinotracheale and E. coli) titration of tissue 
suspensions and swabs 
O. rhinotracheale and E. coli numbers were quantified in samples of the 
turbinates, trachea and lungs of the 25 birds sacrificed at 18 dpmi. The number of cfu 
of O. rhinotracheale or E. coli per g tissue was determined as described (Marien et 
al., 2005) with the following addition to the protocol: for the isolation of E. coli, 
samples were inoculated on MacConkey agar and incubated for 24h at 37°C.  
The swabs taken from the sinuses, air sacs, pericardium, heart and liver from the 25 
birds sacrificed at 18 dpmi and the swabs from the turbinates, trachea, lungs, sinuses, 
air sacs, pericardium, heart and liver from the birds sacrificed at 33 dpmi, were 
inoculated onto 5% sheep blood agar supplemented with 5 µg/ml gentamicin and 5 
µg/ml polymyxin for O. rhinotracheale isolation and on MacConkey agar for E. coli 
isolation. After 24-48h of incubation at 37°C in a 5% CO2 atmosphere (O. 
rhinotracheale) and after 24h of incubation at 37°C (E. coli), the agar was examined 
for presence of O. rhinotracheale or E. coli.  
The obtained E. coli isolates were serotyped by a slide-agglutination test using the 
antiserum against the E. coli O2:K1 strain (Veterinary Laboratories Agency). 
Swabs from the trachea, lungs and air sacs were cultured for M. gallisepticum 
as described by Feberwee and others (2005b) using ME agar plates supplemented 
with ampicillin (0.2 mg/ml), with the modification that swabs were dipped in 
Mycoplasma Adler medium before sampling and that a commercial PCR (IDEXX 
Laboratories Inc.) was used for species identification instead of immunofluorescence. 
 
Histopathology 
Following fixation in formalin, the tissues were embedded in paraffin, 
sectioned at 4 µm, mounted on glass slides and stained with haematoxylin and eosin 
using standard procedures. Tissues from the turbinates and trachea were additionally 
stained by the Periodic Acid Schiff-reaction to visualize the mucus layer. 
 89
Experimental studies 
____________________________________________________________________ 
Results 
 
Mortality  
During the experiment, high mortality rates were observed in the different 
experimental groups, except in group C where no mortality was noted. The birds 
started to die from 5 dpmi onwards. In Figure 1, the cumulative mortality given as a 
percentage of the total number of animals, is presented. Overall, the highest mortality 
rates were seen in group M/A/E/O (91.7%) and group M/A/O (83.3%). 
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○    M. gallisepticum                 APV   O. rhinotracheale/E. coli 
∆    M. gallisepticum                 APV   O. rhinotracheale 
×    M. gallisepticum                 APV         - 
□    M. gallisepticum                   -             -     
◊        -                                -           - 
 
Figure 1. Cumulative mortality with time, given as a percentage of the total number 
of animals, after single M. gallisepticum inoculation (□ group M), dual M. 
gallisepticum/APV inoculation (× group M/A), triple M. gallisepticum/APV/O. 
rhinotracheale inoculation (∆  group M/A/O), and M. gallisepticum/APV/E. coli/O. 
rhinotracheale inoculation (○ group M/A/E/O), with a ten day interval between M. 
gallisepticum and APV inoculations, a three day interval between APV and O. 
rhinotracheale/E. coli inoculations, and an interval of eight hours between the E. coli 
and O. rhinotracheale inoculations. No mortalities were seen in the negative control 
group (◊ group C). 
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Clinical signs 
The mean clinical scores and the number of animals from which the mean 
clinical score was calculated for each group are presented in Figure 2. 
No respiratory symptoms were observed in birds from the uninoculated 
control group (C). 
Lower respiratory tract symptoms were seen in all the M. gallisepticum 
inoculated groups. Severe dyspnoea was noted in a few birds at 5 dpmi and gradually 
affected all animals. In group M, dyspnoea was apparent during approximately one 
week after which the symptoms gradually decreased in severity, until at 15 dpmi at 
which moment the birds only presented dyspnoea after manipulation (i.e. tracheal 
swabbing). A few days later signs of dyspnoea could not be noticed. In the groups 
subsequently challenged with APV and in two groups subsequently infected with E. 
coli and/or O. rhinotracheale, the signs of dyspnoea lasted several days longer.  
Upper respiratory tract symptoms were seen in all APV-inoculated groups 
starting from 3 dpvi (13 dpmi) but not in groups M and C.  
In group M/A, the peak in mean score (2.8) appeared at 6 and 8 dpvi (16 and 18 
dpmi), after which a gradual decline was noted, with clinical symptoms lasting until 
the end of the experiment. The peak in mean score of group M/A/O (4.5) was noted at 
9 dpvi (19 dpmi), followed by a gradual diminution with an absence of clinical signs 
from 22 dpvi (32 dpmi) onwards. The highest mean score (5.0) was found in group 
M/A/E/O at 11 dpvi (21 dpmi). Thereafter, a decline was noted however clinical signs 
lasted until the end of the experiment. Poor general condition and anorexia was seen 
in a number of birds, especially in groups M/A/O and M/A/E/O. 
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○  Mga            APV     O. rhinotracheale/E. coli 
∆   Mg            APV     O. rhinotracheale 
×  Mg             APV             -  
 
 
Figure 2. Mean clinical scores (upper respiratory tract symptoms) in turkeys after 
dual M. gallisepticum/APV inoculation ( × group M/A), triple M. 
gallisepticum/APV/O. rhinotracheale inoculation (∆ group M/A/O) or quadruple M. 
gallisepticum/APV/E. coli/O. rhinotracheale inoculation ( ○ group M/A/E/O) with an 
interval of ten days between M. gallisepticum and APV inoculations, an interval of 
three days between APV and O. rhinotracheale/E. coli inoculations, and an interval 
of eight hours between the E. coli and O. rhinotracheale inoculations. Because upper 
respiratory signs were not detected in the turkeys of the single M. gallisepticum 
infected group (group M) and in the negative control group (Group C), these groups 
are not shown in the figure. The clinical scores are outlined following days after APV 
inoculation. * For each mean value, the number of animals for which the mean value 
was calculated, is depicted. a: Mg = M. gallisepticum.
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Macroscopic lesions  
Macroscopic lesions were absent in birds of group C during the entire study 
period.  
All the birds that died during the first mortality peak, between 5 and 11 dpmi, 
were diagnosed with severe airsacculitis as main macroscopic finding.  
For the five birds of each experimental group, sacrificed at 18 dpmi, the 
following macroscopic findings were noted. In group M, severe suppurative 
airsacculitis and multiple foci of pneumonia were seen. One of the five animals 
showed no apparent macroscopical lesions. Almost all birds in group M/A, M/A/O 
and M/A/E/O presented large amounts of serous to seromucous exudate in the 
turbinates and sinuses, very severe suppurative airsacculitis, and moderate to very 
severe pneumonia. Hyperaemia of the turbinates and the trachea was also frequently 
encountered. In one animal of group M/A, serous inflammation of the pericardium 
was noticed. In group M/A/E/O, the pneumonia was more suppurative in nature. In 
one animal of group M/A/E/O, severe pericarditis and perihepatitis were noticed and 
in another animal of the same group a suppurative pericarditis. 
In the three animals that died one day after infection with APV, thus before 
infection with O. rhinotracheale and/or E. coli, at postmortem only severe 
airsacculitis was found. Except two animals from group M/A and one animal of group 
M, five and seven birds of groups M/A/O and M/A/E/O, respectively, died during the 
time period going from 2 to 8 days after O. rhinotracheale and/or E. coli infection (15 
to 21 dpmi). In all the animals that died in this period, severe seromucous exudate in 
the turbinates and sinuses, severe suppurative airsacculitis, severe (suppurative) 
pneumonia and hyperaemia of the turbinates and trachea were observed. Furthermore, 
in group M/A, in one animal, and in group M/A/E/O in six of the seven dead birds, 
severe, sometimes suppurative pericarditis and in one animal perihepatitis, were 
found.  
In the animals euthanised at 33 dpmi, the macroscopic lesions were less 
severe, nevertheless serous to seromucous exudates in turbinates and conchae, 
airsacculitis, and pneumonia were found in most of the M. gallisepticum infected 
birds. Additionally, serous fluid in the pericardium was found in four of the nine 
euthanised birds of group M, and in one of the three birds of group M/A. These 
findings were not seen in the birds of groups M/A/O and M/A/E/O, although it should 
be noted that in these two groups only two and one animals survived, respectively. 
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Virological (APV) and bacteriological (M. gallisepticum, O. rhinotracheale and E. 
coli) titration of tracheal swabs  
As shown by the virus titrations of tracheal swabs collected at 3 dpvi, APV 
was recovered from every APV infected bird. Mean titres were 4.1, 4.0 and 3.9 log10 
CD50/g mucus for group M/A, M/A/O and M/A/E/O, respectively. APV was not 
recovered from tracheal swabs from group C and M. 
M. gallisepticum DNA was recovered from some of the birds of group C. 
More specifically, in nine out of the 17 birds M. gallisepticum DNA was detected 
although in low amounts (average of 2.9 log10 cfu/mucus of the positive birds; range 
1.7 – 4.3 log10 cfu/g mucus), and from six of these nine birds, the DNA was only 
found at one sampling point (out of the ten samplings done). In the other three birds, 
M. gallisepticum DNA was found at two sampling points. O. rhinotracheale and E. 
coli were not recovered from any of the birds of groups C, M, and M/A and groups C, 
M, M/A and M/A/O, respectively. 
The results of M. gallisepticum, O. rhinotracheale and E. coli titrations of the 
tracheal swabs of the remaining groups are shown in Figure 3 (a, b and c). The 
highest mean amount of O. rhinotracheale in group M/A/O (7.58 log10 cfu/g mucus) 
and group M/A/E/O (7.50 log10 cfu/g mucus) was found at 3 days post O. 
rhinotracheale inoculation (16 dpmi). After the peak, mean titres declined gradually 
until the end of the experiment (20 days post O. rhinotracheale inoculation) at which 
time O. rhinotracheale was detected in tracheal swabs with a mean titre of 4.44 log10 
cfu/g mucus for group M/A/O and 4.40 log10 cfu/g mucus for group M/A/E/O.  
The highest amount of E. coli in group M/A/E/O (7.20 log10 cfu/g mucus) was 
found at 3 days post E. coli inoculation (16 dpmi). With the exception of a one log 
decrease at 7 days post E. coli inoculation, titres remained at approximately the same 
level until the end of the experimental period at 20 days post E. coli inoculation (33 
dpmi). 
The M. gallisepticum titres determined by quantitative PCR in the different M. 
gallisepticum inoculated groups remained at a similar level (between 6 and 7 log10 
cfu/g mucus) throughout the whole measurement period. It should however be noted 
that because of the high mortality rates in some groups, the means were based on a 
variable number of individuals. 
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Figure 3a 
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Figure 3b 
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Figure 3c 
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Figure 3. Mean M. gallisepticum (a), O. rhinotracheale (b) and E. coli (c) titres (log10 
cfu/g mucus) (and the number of animals from which the mean titres were calculated 
for each experimental group) in tracheal mucus collected at different time points after 
inoculation of single M. gallisepticum inoculation (□ group M), dual M. 
gallisepticum/APV inoculation (× group M/A), triple M. gallisepticum/APV/O. 
rhinotracheale inoculation (∆ group M/A/O), and quadruple M. gallisepticum/APV/E. 
coli/O. rhinotracheale inoculation (○ group M/A/E/O). The negative control group (◊   
group C) is included. a: Mg = M. gallisepticum. 
 
Bacteriological (M. gallisepticum, O. rhinotracheale and E. coli) titration of tissue 
suspensions and swabs 
M. gallisepticum was never isolated from any of the tissues from the animals 
belonging to group C. This was also the case for O. rhinotracheale considering 
groups C, M, and M/A and for E. coli regarding groups C, M, M/A and M/A/O. The 
results of the M. gallisepticum culture of the birds euthanised at 18 dpmi and at 33 
dpmi in the different M. gallisepticum inoculated groups are shown in Table 1. The 
results of the O. rhinotracheale and E. coli titrations of the birds euthanised at 18 
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dpmi and of the birds that died during the experiment (from 13 dpmi onwards) of 
groups M/A/O and M/A/E/O, are presented in Table 2. It should be noted that the 
clinical signs were very similar in nature and severity in all five euthanised (at 18 
dpmi) birds of each group. At 33 dpmi, in the two remaining animals of group 
M/A/O, O. rhinotracheale was isolated only from the turbinates and the trachea, and 
in the only remaining animal of group M/A/E/O, O. rhinotracheale and E. coli were 
isolated only from the turbinates and trachea.  
 
Table 1. Culture of M. gallisepticum of different organs of turkeys after single M. 
gallisepticum inoculation (group M), dual M. gallisepticum/APV inoculation (group 
M/A), triple M. gallisepticum/APV/O. rhinotracheale inoculation (group M/A/O), 
and quadruple M. gallisepticum/APV/E. coli/O. rhinotracheale inoculation (group 
M/A/E/O), with a ten day interval between M. gallisepticum and APV inoculations, a 
three day interval between APV and O. rhinotracheale/E. coli inoculations, and an 
interval of eight hours between the E. coli and O. rhinotracheale inoculations 
M. gallisepticum isolation 
Turkeys euthanised 18 days after M. gallisepticum inoculation
 Group M M/A M/A/O M/A/E/O 
 1a 2 3 4 5  1 2 3 4 5  1 2 3 4 5  1 2 3 4 5 
Trachea +b + + + +  + + + + +  + c c + +  + + + + + 
Lungs + - + + +  + + + + +  + c + + +  + + + - - 
Air sacs + + + + +  + + + c +  - + + + +  + - + - + 
Turkeys euthanised 33 days after M. gallisepticum inoculation
Group M  M/A  M/A/O  M/A/E/O 
 1a 2 3 4 5 6 7 8 9  1 2 3 4  1 2  1 
Trachea +b + + + + + + + +  + + + +  - +  + 
Lungs - - - - - - - + -  - - c +  - -  + 
Air sacs - - - - - + + - -  - + c -  - +  + 
a: bird number. 
b: +: positive for M. gallisepticum culture; -: negative for M. gallisepticum culture. 
c: contamination of medium, no result for M. gallisepticum culture. 
 
 
 
 
 
 
 
 97
Experimental studies 
____________________________________________________________________ 
Table 2. Bacterial isolation of O. rhinotracheale and E. coli from different organs of 
turkeys inoculated with M. gallisepticum, ten days later with APV, and finally three 
days later with O. rhinotracheale (group M/A/O) or with E. coli and O. 
rhinotracheale (group M/A/E/O) 
Turkeys (n=5 per group) euthanised at 18 days post M. gallisepticum inoculation
 O. rhinotracheale (log10 cfu/g tissue)  E. coli (log10 cfu/g tissue) 
Group M/A/E/O  M/A/O M/A/E/O 
 1a* 2 3 4 5*  6 7 8 9 10 1* 2 3 4 5*
Trachea 10.8 7.9 7.2 7.0 3.6  7.4 8.5 7.4 6.5 8.7 11 7.9 6.6 6.1 4.0 
Lungs 7.3 8.1 7.1 6.6 6.9  6.6 7.7 7.4 6.4 7.0 6.9 7.8 7.0 5.7 6.2 
Air sacs 6.5 4.9 6.2 6.2 4.1  5.7 4.6 7.4 6.0 6.7 6.2 4.7 5.1 4.2 3.7 
Sinusb +c + + + +  + + + + + + + + + + 
Air sacsb + - + + +  - - + + + - - + - - 
Pericardiumb - - - - -  - - - + - + - - + - 
Heartb - - + - -  - - + - + + + - - - 
Liverb - - + - -  - - + - - + - - + - 
Turkeys that died during the experiment
 O. rhinotracheale isolation  E. coli isolation 
Group M/A/E/O M/A/O  M/A/E/O 
 1a* 2 3* 4* 5* 6* 7  8 9 10 11 12  1* 2 3* 4* 5* 6* 7 
Days post 
bacterial 
inoculation 
2 2 4 5 6 6 8  2 4 5 6 6  2 2 4 5 6 6 8 
                      
Turbinatesb +c + + + + + +  + + + + +  + + + + + + + 
Tracheab + + + + + + +  + + + + +  + + + + + + + 
Lungsb + + + + + + -  + + + + +  + + + + + + + 
Sinusb - + + + + + -  + + + + +  + - - + + + - 
Air sacsb - + + + - + -  - - - + -  + + + + - + - 
Pericardiumb - - - - - - -  - - - - -  + + - + + + - 
Heartb - - + - - - -  - - - - -  - + + - + + - 
Liver - + - - - - -  - + - - -  + + - - - + - 
a: bird number. 
b: these organs were swabbed and only qualitative bacteriological analysis was performed. 
c: +: O. rhinotracheale or E. coli isolated ; -: no O. rhinotracheale or E. coli isolated. 
*: pericarditis and/or perihepatitis seen at necropsy. 
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Histopathology 
In the control group (C), no marked microscopic changes were observed in the 
turbinates, trachea or lungs in any of the examined turkeys.  
For the five birds of each group, euthanised at 18 dpmi, the following 
histopathological lesions were found.  The histological preparations of the turbinates 
of animals of group M showed no histological abnormalities. In the tracheae however, 
mild infiltration of heterophils and monomorphonuclear cells in the mucosa and loss 
of cilia were seen, and in the lungs, foci of pneumonia were noticed. 
Histopathological lesions were similar in groups M/A, M/A/O and M/A/E/O, i.e. 
mostly severe infiltration of heterophils and monomorphonuclear cells in the mucosa 
of the turbinates and trachea, degeneration of the mucous glands and epithelium in the 
turbinates and trachea, loss of cilia in trachea and turbinates, activation of lymph 
nodules in the turbinates, suppurative exudate in the lumen of trachea and turbinates, 
and foci of pneumonia, suppurative bronchitis and bronchiolitis in the lung. Although, 
overall the lesions were similar in all mentioned groups, they tended to be more 
severe in group M/A/E/O, followed by group M/A/O, both compared with group 
M/A. The histopathological lesions of the animals that died during the experiment 
from 13 dpmi onwards, were comparable with those of the animals of the same group 
euthanised at 18 dpmi. 
At the end of the experiment period (33 dpmi), the microscopical lesions in 
the different groups were less severe. In the mucosa of the turbinates and trachea, 
infiltrations of heterophils and monomorphonuclear cells could still be found, and 
although epithelial regeneration (hyperplasia) was already seen, regeneration of the 
cilia had not yet occurred. Recovery of the damaged mucous glands was evidenced by 
the reappearance of mucus in the mucous glands, an obvious feature in the PAS 
stained tissue sections. In a few birds some foci of pneumonia could be observed, 
although markedly less severe.  
 
Weight 
At the beginning of the experimental period, the mean weights of each group 
did not differ greatly. At the end of the experiment the lowest mean weight per group 
was seen in groups M/A/E/O (1070 g; n=1) and M/A/O (1088 g; n=2), followed by 
groups M (1198 g; n=9), M/A (1211 g; n=4) and C (1314 g; n=12). 
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Discussion 
The M. gallisepticum strain administrated had been used previously in various 
experimental studies concerning adult chickens. However it caused no or very mild 
respiratory symptoms (personal communication, Wil Landman, GD Deventer). After 
single M. gallisepticum inoculation in the present study, however, the birds suffered 
from very serious respiratory distress, caused by severe airsacculitis, resulting in high 
mortality rates. A number of explanations may clarify the difference in disease 
expression found between the formerly mentioned studies in adult chickens and the 
present work. First, the fact that we used turkeys instead of chickens has probably 
been of major importance, since turkeys are known to be more susceptible to M. 
gallisepticum than chickens, commonly developing more severe clinical signs (Ley, 
2003). Secondly, the age of the infected birds may have been of great significance, 
since it is known that young birds are, in general, more susceptible to infection with 
M. gallisepticum (Bradbury and Levisohn, 1996). Gaunson et al. (2006), examined 
the age-related differences in the immune response to vaccination and infection with 
M. gallisepticum, and stated that it is likely that different cells of the immune system 
do not fully mature until a number of weeks after hatching and may contribute to the 
different responses seen in younger birds. According to this research group there is a 
complex age-related response to M. gallisepticum infection, with the age of birds 
appearing to influence how quickly the bird is able to clear the infection. Finally, the 
applied inoculation route may have been of influence on the disease outcome. 
Through intratracheal inoculation, compared with for instance oculonasal inoculation, 
M. gallisepticum may have bypassed some of the innate defence mechanisms of the 
upper respiratory tract, possibly resulting in more severe disease. 
Clinical signs attributed to M. gallisepticum seen in turkeys include sinusitis, 
respiratory distress, depression, decreased feed intake, and weight loss. As the disease 
progresses, tracheal rales and labored breathing may become evident if tracheitis and 
airsacculitis is present (Ley, 2003). In our study however, turkeys did not seem to 
suffer from sinusitis. It is mentioned already that turkeys sometimes do not develop 
sinusitis in experimentally induced infections unless cultures are injected directly into 
the sinus (Dingfelder et al., 1991). 
The macroscopical (severe airsacculitis, foci of pneumonia) and microscopical lesions 
(thickening of mucosa due to heterophilic and monomorphonuclear infiltrations in the 
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trachea, loss of cilia, focal pneumonia) seen after single M. gallisepticum infection, 
are in accordance with those described in the literature (Ley, 2003). 
As mentioned in the results, M. gallisepticum DNA was recovered from some of the 
tracheae of birds in group C. This was regarded as contamination during processing 
of the samples for different reasons. First, animals which were shown to be positive 
by the Q-PCR (which has a low detection limit), were not consistently positive, i.e. 
they proved negative at later time points (data not shown). Secondly, the Q-PCR 
positive animals showed negative upon M. gallisepticum isolation from their organs 
at post mortem. Finally, serologic examination (ELISA-test BioChek) of serum 
collected from all euthanised birds, indicated that only the M. gallisepticum 
inoculated birds showed seroconversion, as opposed to the birds in group C which 
remained negative throughout the trial period (data not shown). However, this last 
argument can not be considered as conclusive, since seroconversion after infection 
usually appears after two to three weeks. 
Upper respiratory tract symptoms (nasal exudates and swollen sinuses) were only 
seen in the M. gallisepticum infected turkeys after they were inoculated with APV. 
These upper respiratory symptoms were exacerbated by inoculation with E. coli 
and/or O. rhinotracheale. These findings are in accordance with previous experiments 
executed by our research group (Marien et al., 2005; 2006) in which it was shown 
that co-infection with O. rhinotracheale and/or E. coli had a synergistic effect both on 
the severity and on the duration of clinical symptoms of APV infection. The peak in 
the clinical scores, especially in the groups with additional infection with O. 
rhinotracheale and E. coli, coincided with a second peak of mortality. It appears that 
by the time the birds were slowly starting to recover from the acute respiratory 
problems caused by the M. gallisepticum inoculation, the additional bacterial 
infections were too overwhelming for these poults. After this peak, both the mortality 
rate and the severity of clinical symptoms decreased, although it should be noted that 
only few animals were left at this time in some of the experimental groups. From 19 
dpmi, only 4, 2 and 1 birds were left in group M/A, M/A/O and M/A/E/O, 
respectively. 
Because of the poor general condition and anorexia in some birds, the mean weight in 
groups M/A/O and M/A/E/O was lower compared with the groups M/A and M, the 
latter in their turn having lower mean weights compared with the negative control 
group. 
 101
Experimental studies 
____________________________________________________________________ 
Besides the severity of clinical symptoms and mortality, the isolation of the 
different bacterial pathogens in the organs of the infected turkeys was also examined. 
The amount of M. gallisepticum bacteria isolated from the tracheae with time did not 
substantially differ between the various M. gallisepticum infected groups. Apparently, 
co-infection with APV, E. coli and/or O. rhinotracheale does not seem to have an 
effect on the M. gallisepticum multiplication in the trachea, at least not during the 
evaluated period. Furthermore, at 18 dpmi, M. gallisepticum was cultured from the 
trachea, lungs and air sacs of almost all M. gallisepticum inoculated animals. At 33 
dpmi, M. gallisepticum was still present in the trachea, but to a lesser extent in the 
lungs and air sacs of al M. gallisepticum inoculated groups, indicating that M. 
gallisepticum clearance in these organs was initiated. The observation that the M. 
gallisepticum titres remained at a high level in the upper respiratory tract throughout 
the experimental period, is in agreement with the many reports describing the 
persistent character of M. gallisepticum infections in poultry (Razin et al., 1998; Ley, 
2003; Bradbury, 2005; Reinhardt et al., 2005). The ability of mycoplasmas to 
modulate the host immune responsiveness most probably contributes to their 
pathogenicity, enabling them to evade or suppress the host defense mechanisms and 
establish a chronic, persistent infection (Razin et al., 1998; Rottem, 2003; Bradbury, 
2005). Furthermore, mycoplasmas, including M. gallisepticum, are able to vary the 
expression of surface antigens, thus expressing a continuously changing ‘antigenic 
profile’ to the immune system. This is a property of the mycoplasmas which is also 
named phenotypic plasticity. 
Infection with M. gallisepticum did seem to have lengthened the presence of 
O. rhinotracheale and E. coli in the upper respiratory tract if the outcome of this work 
is compared with previous experiments in which the same APV, O. rhinotracheale 
and E. coli strains (Marien et al., 2005; 2006; unpublished results) were used. In those 
studies O. rhinotracheale could not be isolated after 10-12 days post O. 
rhinotracheale inoculation, while E. coli was cleared from the trachea at 14 days post 
E. coli inoculation or present only in very low numbers. More specifically, in the 
present study, O. rhinotracheale and E. coli remained present in the trachea until 20 
days post O. rhinotracheale/E. coli inoculation, and titres were still at high levels, 
especially the O. rhinotracheale titres (Figure 3b and 3c). This suggests that M. 
gallisepticum exerts an important impeding effect on the clearance of O. 
rhinotracheale and E. coli, especially from the upper respiratory tract. Indeed, at the 
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end of the experiment (20 days post E. coli/ O. rhinotracheale inoculation), O. 
rhinotracheale and E. coli appeared to be cleared from the lungs, air sacs, and non-
respiratory organs, but not from the turbinates and trachea, suggesting that the host’s 
immune response at this level might have been impaired.  
In general, gross lesions at necropsy were similar in group M/A, M/A/O and 
M/A/E/O, with severe airsacculitis, serous to seromucous exudates in the turbinates 
and sinuses, and moderate to severe pneumonia. A very conspicuous feature, 
however, was that in almost all birds that died in group M/A/E/O after O. 
rhinotracheale and E. coli inoculation, signs of septicaemia  were seen. Also, in two 
out of the five animals euthanised at five days post E. coli and O. rhinotracheale 
infection (group M/A/E/O), pericarditis and perihepatitis were seen at necropsy. It is 
frequently stated in the literature that in poultry, more severe M. gallisepticum 
outbreaks with high morbidity and mortality, frequently result from the involvement 
of complicating infections and environmental or other stressors (Bradbury and 
Levisohn, 1995; Levisohn and Kleven, 2000; Ley, 2003). Respiratory-origin 
colisepticemia is the most common type of colisepticemia in poultry, and it is thought 
that E. coli gains access to the circulation following damage to the respiratory 
mucosa. As opposed to the present work (applying M. gallisepticum inoculation), we 
were not able in previous trials to experimentally reproduce colibacillosis in turkeys 
by inoculation with APV, O. rhinotracheale and E. coli. These findings indicate that 
compared with bacterial virulence factors, pathogenic interactions are probably at 
least as important for the induction of colibacillosis (Barnes et al., 2003). Although 
O. rhinotracheale was isolated in some birds from non-respiratory organs, the 
majority of reisolates were obtained from the respiratory tract, moreover signs of 
septicemia were never encountered in the M/A/O infected turkeys. The high number 
of deaths in this group was therefore attributed to the severe respiratory symptoms 
and anorexia of the birds. In contrast, E. coli was isolated most frequently from the 
non-respiratory organs of the birds diagnosed with septicaemia (Table 2). 
In conclusion, the results obtained in the present study clearly indicate the 
occurrence of a marked synergism between four distinct respiratory pathogens 
important in poultry, i.e. M. gallisepticum, APV, O. rhinotracheale and E. coli. This 
was evidenced by the higher mortality rates and the clinical symptoms, which were 
aggravated whenever the birds were infected with an additional pathogen. This 
synergism was further confirmed by the more severe necropsy findings and 
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microscopical lesions found in groups inoculated with more than one pathogen. In 
this regard a concurrent infection with M. gallisepticum, APV, O. rhinotracheale and 
E. coli seemed the most detrimental to the birds.  
An interesting finding was that we were able to experimentally induce colisepticemia, 
which has proven to be very difficult in the past (Van de Zande et al., 2001). This 
experimental model could therefore have some important benefits for future research, 
e.g. the evaluation of antimicrobial strategies or even vaccines. 
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Chapter 3: EXPERIMENTAL STUDIES 
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Summary 
The clinical efficacy of drinking-water administration of enrofloxacin for 
three and five days, amoxicillin for five days and florfenicol for five days for the 
treatment of respiratory disease induced by an experimental Ornithobacterium 
rhinotracheale infection in turkeys pre-infected with avian metapneumovirus (APV) 
was assessed based on clinical, bacteriological and histopathological examinations. 
Experimental groups of 15 susceptible three-week-old turkeys were each inoculated 
oculonasally with APV subtype A and three days later with susceptible O. 
rhinotracheale bacteria. Antimicrobial treatment started one day after O. 
rhinotracheale inoculation. After infection, the birds were examined and scored for 
clinical signs, swabbed daily and weighed at different times. Five birds were 
euthanised and examined for macroscopic lesions at necropsy at five days post 
bacterial inoculation (dpbi), and the remainder at 15 dpbi. Samples of the turbinates, 
trachea, lungs, air sacs, heart and pericardium were collected for bacteriological 
and/or histological examination. 
Recovery from respiratory disease caused by an APV/O. rhinotracheale dual 
infection was most successful after enrofloxacin treatment, irrespective of treatment 
duration, followed by florfenicol. Amoxicillin treatment was not efficacious. Clinical 
signs and the number of O. rhinotracheale organisms re-isolated from the trachea and 
the different respiratory organs were significantly reduced by enrofloxacin treatment 
for three and five days. O. rhinotracheale bacteria were not re-isolated from the 
tracheas of the birds treated with enrofloxacin except for one in the five-day group, as 
early as one day after medication onset. In the group treated with enrofloxacin for 
five days, O. rhinotracheale organisms with a higher minimal inhibitory 
concentration (MIC) value (x 8) were isolated starting two days following treatment 
onset initially from a single turkey and subsequently from the other animals. 
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Introduction 
Viral and bacterial respiratory tract infections frequently occur in diseased 
turkeys of all ages and may cause considerable financial losses due to reduced 
growth, an increased mortality rate, high medication costs and a higher number of 
condemnations at slaughter (van Empel and Hafez, 1999).  
Ornithobacterium rhinotracheale is an infectious pathogen that has been 
ascribed an etiological role in the respiratory disease complex in turkeys. This Gram-
negative bacterium is mostly regarded as a facultatively pathogenic organism, and in 
field cases, simultaneous isolation of O. rhinotracheale, respiratory viruses and/or 
other bacteria is frequently encountered. One of the viruses judged to have a 
triggering role is avian metapneumovirus (genus Metapneumovirus - MPV) (APV) 
(van Empel et al., 1996). Recently, in a longitudinal study performed by Van Loock 
et al. (2005), it was shown that both APV and O. rhinotracheale infections often 
occur between hatch and slaughter on Belgian turkey farms. In a previous study using 
an optimized experimental in vivo model, it was demonstrated that O. rhinotracheale 
following APV inoculation in three-week-old turkeys has a synergistic effect on the 
course of respiratory disease (Marien et al., 2005). Dual infection with APV and O. 
rhinotracheale indeed resulted in more severe clinical signs, macroscopic and 
histological findings, and a longer persistence of O. rhinotracheale in the respiratory 
tract compared with the single infections.  
Disease caused by O. rhinotracheale may be reduced by preventing 
predisposing factors including inadequate ventilation, high ammonia levels, too high 
or too low relative humidity and infection with additional pathogenic agents (van 
Empel and Hafez, 1999). In practice, however, O. rhinotracheale infections are 
mostly dealt with using different antimicrobials such as amoxicillin, ampicillin, 
doxycycline, tetracycline, trimethoprim/sulphonamide, enrofloxacin and florfenicol. 
Hitherto, the actual in vivo efficacy of antimicrobials for the treatment of O. 
rhinotracheale infections in poultry has not yet been investigated. This is to a great 
extent rooted in the fact that, only until very recently (Marien et al., 2005), no 
suitable infection model was available. The objectives of the present study are to 
compare the efficacy of enrofloxacin, amoxicillin and florfenicol for treatment of 
respiratory disease due to experimental O. rhinotracheale infection in three-week-old 
turkeys following APV challenge. The efficacy was evaluated on the basis of several 
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parameters, i.e., clinical signs, histopathological findings, re-isolation and titration of 
the bacterium, and weight gain. 
 
 
Materials and methods 
 
Turkeys 
Seventy-five specific pathogen free (SPF) turkeys (AFSSA, Ploufragan, 
France) were used in this study. The turkeys were hatched in our facilities. The birds 
were housed on litter in separate isolation rooms with HEPA-filtered air, had free 
access to food and water and received 16 hours of light per day. At two weeks of age 
the birds were shown to be free from maternally-derived antibodies to O. 
rhinotracheale and APV by means of an ELISA available commercially (Biochek, 
Gouda, the Netherlands) and an in-house serum neutralization test, respectively. 
Neutralization was tested on Vero cells in 96-well cell culture microplates using 
standard procedures. Briefly, serial twofold dilutions of the sera were made and 
incubated for 1 h at 37°C with an equal volume of virus suspension (subtype A), 
containing 100 tissue culture infectious dose with a 50% endpoint (TCID50) APV. 
The reading was based on the absence or presence of a cytopathic effect over seven 
days. The SN-titres were the reciprocal of the highest serum dilution that inhibited the 
cytopathic effect in 50% of the wells. 
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during 
a respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The 
virus stock had a titre of 5.0 log10 50% ciliostatic dose (CD50)/ml after the third 
passage in tracheal organ cultures.  
 
Bacterium 
The O. rhinotracheale type strain LMG 9086T was used, which was originally 
isolated from a turkey with a respiratory tract infection. The strain was serotyped as 
type A in an agar gel precipitation test (Hafez and Sting, 1999) performed by 
Professor H. M. Hafez (Institute of Poultry Diseases, Free University of Berlin, 
Germany). The strain was stored at -70°C. The organism was cultured for 48h at 
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37°C on Columbia agar (Oxoid LTD, Basingstoke, Hampshire, England) with 5% 
sheep blood in a 5% CO2 atmosphere. The O. rhinotracheale bacteria were 
transferred into brain heart infusion broth (Oxoid) for 24h at 37°C with agitation 
(microaerophilic incubation). The bacterial challenge inoculum was prepared by 
washing the cultured bacteria twice in phosphate-buffered saline (PBS) followed each 
time by five minutes of centrifugation at 2000 × g at 4°C. The resulting pellet was re-
suspended in PBS to obtain a final concentration of 8.6 log10 colony-forming units 
(cfu)/ml. Confirmation of the number of cfu/ml was done by inoculating ten-fold 
dilutions in PBS on Columbia agar with 5% sheep blood and counting the number of 
colonies. The minimal inhibitory concentrations (MICs) of amoxicillin, florfenicol 
and enrofloxacin for this challenge strain were 2 µg/ml, 1 µg/ml and ≤0.03 µg/ml, 
respectively, as determined according to Devriese et al. (2001). 
 
Antimicrobial agents 
Three antimicrobial agents were used in this study: enrofloxacin (Baytril® 
10% oral solution, Bayer, Leverkusen, Germany), amoxicillin (powder form) 
(Suramox 50®, soluble powder, Virbac S.A., Carros, France) and florfenicol (soluble 
form) (Nuflor®, Schering-Plough S.A., Xochimilco, Mexico) with manufacturer-
recommended doses of 10 mg/kg for enrofloxacin and 20 mg/kg for amoxicillin and 
florfenicol.  
 
Experimental design 
Seventy-five SPF turkeys were randomly divided into five groups of 15 birds 
at one day of age.  
In all groups, turkeys first received APV, and subsequently received O. 
rhinotracheale three days later. Each bird was inoculated with APV by the oculonasal 
route at a dose of 4.4 log10CD50. O. rhinotracheale was likewise administered 
oculonasally with a dosage of 8 log10 cfu. For inoculation with APV and O. 
rhinotracheale, a total of 250 µl was divided equally over the nares and eyes.  
Four groups received antimicrobial treatment: enrofloxacin 10 mg/kg for three 
days (group E3), enrofloxacin 10 mg/kg for five days (group E5), florfenicol 20 
mg/kg for five days (group F), and amoxicillin 20 mg/kg for five days (group A). 
Starting at 24 hours post bacterial inoculation, the drinking water was medicated with 
the appropriate antimicrobial agent. The birds were continuously dosed and received 
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their daily medication over a 24h period. To enable correct dosing, the daily water 
uptake and mean group body weights were determined. All turkeys were weighed 
immediately before APV inoculation, before O. rhinotracheale inoculation, at day 
five after O. rhinotracheale inoculation, and finally at the end of the experiment (15 
days post bacterial inoculation (dpbi)). The concentration of each antimicrobial to be 
administered in the water could be calculated accurately on the basis of the water 
consumption and body weight data. The fifth group was included as an untreated 
control group (group C). 
All birds were clinically examined on a daily basis throughout the experiment. 
The clinical signs were scored as described in Van de Zande et al. (2001). Briefly, the 
clinical condition of each bird was assigned a score from 0 (absence of clinical signs) 
to 7 (nasal exudate with extremely swollen sinuses and frothy eyes, poor general 
condition and anorexia). The mean clinical score was calculated for each 
experimental group. 
Tracheal swabs were collected from the animals in all groups at 3 days post 
viral inoculation (dpvi) to confirm infection with APV, and daily until 11 dpbi for O. 
rhinotracheale titration. The tracheal swabs were taken using cotton-tipped 
aluminium-shafted swabs (Copan Diagnostics Inc., Corona, USA) and placed in 1 ml 
PBS supplemented with Ca2+ and Mg2+ and in the case of virus titration an additional 
10% fetal calf serum (Gibco, Invitrogen Corporation, Merelbeke, Belgium), penicillin 
(1000 U/ml) (Biopharma, Rome, Italy) and kanamycin (0.5 mg/ml) (Gibco). 
Processing occurred as described below. 
Five birds of each group were randomly selected and were sacrificed at 5 dpbi. 
The remaining ten birds were sacrificed at 15 dpbi. The birds were necropsied and 
examined for gross lesions. Samples of the turbinates, trachea, lungs, air sacs, heart 
and pericardium were collected for bacterial isolation and processed immediately as 
described below. Finally, samples from the turbinates, trachea and lungs were taken 
and fixed in 10% neutral buffered formalin for histopathological examination.  
 
Virological and bacteriological titration of tracheal swabs 
The viral titre in log10CD50 per g mucus and the number of cfu of O. 
rhinotracheale per g mucus were determined. This was done using the procedures 
described in Marien et al. (2005). 
 
 116
Experimental studies 
____________________________________________________________________ 
Bacteriological titration of tissue suspensions and swabs 
Samples of the turbinates, trachea and lungs were titrated for O. 
rhinotracheale from the 25 birds sacrificed at 5 dpbi. The number of cfu of O. 
rhinotracheale per g mucus was determined as described in Marien et al. (2005). 
The swabs taken from the heart, pericardium and air sacs were inoculated onto 
5% sheep blood agar supplemented with 5 µg/ml gentamicin and 5 µg/ml polymyxin. 
After 24-48h of incubation at 37°C in 5% CO2 atmosphere, the agar was examined 
for presence of O. rhinotracheale. The same procedure was followed for samples 
from the turbinates, trachea, lungs, heart, pericardium and air sacs from the birds 
sacrificed at 15 dpbi. 
 
Histopathology 
Following fixation in formalin, the tissues were embedded in paraffin, 
sectioned at 4 µm, mounted on glass slides and stained with haematoxylin and eosin 
using standard procedures. Tissues from the turbinates and trachea were additionally 
stained by the Periodic Acid Schiff-reaction in order to visualize the mucus layer. The 
degree of severity of the various histological lesions in the trachea and turbinates was 
assessed, including infiltration of heterophils and/or monomorphonuclear cells, 
degeneration of the mucous glands in the respiratory epithelium and damage to the 
ciliated epithelial cells and cilia). Each histological parameter was assigned a score 
from 0 (absence of particular lesion) to 4 (abundant presence of particular lesion).  
 
MIC of the parent and re-isolated O. rhinotracheale isolates 
The MIC values of 124 O. rhinotracheale isolates retrieved from the tracheal 
swabs before, during and after antimicrobial treatment were determined, specifically 
for the isolates from enrofloxacin group E3 and E5, for amoxicillin group A and 
finally for florfenicol group F.  
Determination of the MIC values was performed as described by Devriese et 
al. (2001), although modified slightly in that in this study MIC values were 
determined on Mueller Hinton II agar (BBL, Sparks, MD, USA) supplemented with 
5% sheep blood. The antimicrobials used for the antimicrobial susceptibility test were 
enrofloxacin (Baytril® 10% oral solution, Bayer, Leverkusen, Germany), amoxicillin 
(Suramox 50®, Virbac S.A., Carros, France) and florfenicol (Nuflor®, Schering-
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Plough S.A., Xochimilco, Mexico). Final concentrations ranging from 0.03 to 128 
µg/ml (serial doubling dilutions) were tested. 
 
Statistical analyses 
The clinical scores and tracheal swabbing data of all animals were first 
analysed by a fixed-effects model with area under the curve between 0 and 5 dpbi as 
response variable, and treatment group as fixed effect, to study the early effects of the 
infection based on all treated animals. 
Next, the repeated clinical scores between 0 and 9 dpbi, using only animals 
that were not euthanised at 5 dpbi, were analysed by a mixed proportional odds model 
with the clinical score as the response variable, animal as a random effect and 
treatment group and time as categorical fixed effects. 
Tracheal swabbing values between 0 and 9 dpbi, involving only animals that 
were not euthanised at 5 dpbi, were analysed by a mixed model with log10cfu/g as 
response variable, animal as a random effect, and treatment group and time as 
categorical fixed effects. O. rhinotracheale titres from the different organs were 
analysed by a fixed effects model, and weight by a mixed model with animal as 
random effect and time, treatment group and initial weight as fixed effects. Finally, 
the histopathological scores were analysed by the Kruskal-Wallis test.  
All tests were performed at a global 5% significance level, and the seven 
relevant pairwise comparisons (C vs E3, C vs E5, E3 vs E5, E5 vs A, E5 vs F, E3 vs 
A, E3 vs F), were tested at a significance level adjusted using Bonferroni’s technique. 
Only these seven comparisons will be considered throughout the paper.  
 
 
Results 
During the experiment, mortalities did not take place in any of the 
experimental groups. 
 
Clinical signs 
The mean clinical score for each group is shown in Figure 1. Respiratory signs 
were seen in all APV-inoculated groups starting from 3 dpvi. From 10 dpbi onwards, 
clinical signs were not detected in any of the animals in the different experimental 
groups.  
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Figure 1. Mean clinical scores in turkeys inoculated with APV and O. rhinotracheale 
and subsequently treated with different antimicrobial agents: ■ group E3, 3 days of 
enrofloxacin (10 mg/kg); ●group E5, 5 days of enrofloxacin (10 mg/kg); ▲ group A, 
5 days of amoxicillin (20 mg/kg); ×group F, 5 days of florfenicol (20 mg/kg) or no 
treatment =       control group. Arrow indicates first day of antimicrobial treatment.  
 
Using the area under the curve from 0 to 5 dpbi, there is a significant 
difference between the five treatments (P=0.0007). Group C has the highest total 
score (10.33), followed by A, F, E5 and E3 (7). Significant differences are shown in 
Table 2. In the proportional odds model, both a significant change in time (P<0.0001) 
and a significant difference (P<0.0001) between the treatments were detected. E3 had 
the lowest odds ratio followed by E5, F, A and C. 
Thus, compared with the non-treated control group, clinical signs were significantly 
reduced by the enrofloxacin treatments, irrespective of treatment duration, but not by 
treatment with florfenicol or amoxicillin. 
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Virological titration of tracheal swabs 
APV was recovered from tracheal swabs from every individual bird. The 
mean titres for groups C, E3, E5, A and F were 6.1, 5.9, 6.2, 5.8 and 6.1 log10CD50 / g 
mucus, respectively. 
 
Bacteriological titration of tracheal swabs 
The results of the O. rhinotracheale titrations of the tracheal swabs are shown 
in Figure 2. Mean titres as well as titres for each individual bird are depicted. From 11 
dpbi onwards, O. rhinotracheale bacteria were not isolated in any of the animals in 
the different experimental groups. 
0
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log10 cfu/g mucus
 
Figure 2. Bacterial titres (log10 cfu/g mucus) in tracheal mucus collected at different 
times after O. rhinotracheale inoculation in APV/O. rhinotracheale dually infected 
turkeys receiving different antimicrobial treatments: ■ group E3, 3 days of 
enrofloxacin, (10 mg/kg); ● group E5, 5 days of enrofloxacin (10 mg/kg); ▲ group 
A, 5 days of amoxicillin (20 mg/kg); × group F, 5 days of florfenicol (20 mg/kg), or 
no treatment (=      control group). (Individual values are indicated with small 
symbols; means are indicated with larger symbols.) Arrow indicates first day of 
antimicrobial treatment.
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Using area under the curve in the fixed-effects model, there is a significant 
difference between the five treatments (P<0.0001), and in the mixed model, both a 
significant change in time (P<0.0001) and a significant difference between treatments 
(P<0.0001) were detected. In both analyses, group C has the highest total score 
followed by groups A, F, E5 and E3 and all seven pairwise comparisons (C vs E3, C 
vs E5, E3 vs E5, E5 vs A, E5 vs F, E3 vs A, E3 vs F) are significant as indicated in 
Table 2.  
Compared with the non-treated control group, the number of O. rhinotracheale 
organisms in the tracheal mucus was hence significantly reduced by both 
enrofloxacin treatments (three- and five-day treatment) and by the five-day florfenicol 
treatment. Compared with the non-treated group, treatment with amoxicillin did not 
cause a significant reduction in the O. rhinotracheale titres in the trachea. 
 
Bacteriological titration of tissue samples 
The results of O. rhinotracheale titrations in the various organs sampled at 5 
dpbi are shown in Table 1. It should be noted that the clinical signs were very similar 
in terms of severity in all five euthanised birds of one group. For results from the 
turbinates, trachea and lungs, there were significant differences between the 
treatments (P<0.0001). Pairwise significant differences are shown in Table 2. 
Compared with the non-treated control group, the number of O. rhinotracheale in the 
trachea and lungs was significantly reduced by the enrofloxacin treatments and by the 
florfenicol treatment, as opposed to treatment with amoxicillin. Furthermore, the 
number of O. rhinotracheale isolated from the turbinates was significantly reduced by 
the 3-day enrofloxacin treatment. For the air sacs, pericardium and heart, very few 
positive samples were encountered (in group C and group A), and significant 
differences between the treatments did not occur. 
O. rhinotracheale was recovered from none of the organs (turbinates, trachea, 
lungs, pericardium, and air sacs) of the birds in the five groups swabbed at 15 dpbi. 
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Histopathology 
Similar microscopical changes were encountered in all experiment groups. In 
the mucosa of the turbinates and the trachea, a mixed inflammatory reaction was 
seen. Furthermore, focal loss of cilia and/or necrosis of the epithelium, as well as 
degeneration of mucous glands, were found in the turbinates and trachea. In the lung 
samples focal areas of bronchitis and bronchiolitis were observed.  
No significant difference between the five treatments was found for any of the 
different parameters considered. 
 
Weight 
Significant differences occurred between the different treatments (P<0.0001). 
Weight evolves differently over time from treatment to treatment, i.e., there is a 
significant interaction between time and treatment (P<0.0001). Pairwise significant 
differences (0.7%) are shown in Table 2.  
 
Antimicrobial therapy 
The theoretically consumed dose of antimicrobials per group of birds was very 
close (within 10%) to the target dose of 10 mg/kg for enrofloxacin and 20 mg/kg for 
amoxicillin and florfenicol. The mean actual daily dose (mg/kg) for the total 
medication period was 10.2 (range: 9.1-11.3) for group E3, 10.2 (range: 9.4-11.9) for 
group E5, 20.4 (range: 19.0-22.5) for group F, and 19.9 (range: 17.5-22.7) for group 
A. 
 
MIC of the parent and re-isolated O. rhinotracheale isolates.  
In the O. rhinotracheale bacteria re-isolated from birds in groups C, E3, A and 
F, no changes in MIC values were observed compared with the challenge strain. 
However, two days after initiation of enrofloxacin treatment onwards, the MICs of 
the O. rhinotracheale bacteria isolated from tracheal swabs from group E5 had values 
that increased from 0.03 to 0.25 µg/ml.  
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Discussion 
This study is the first to experimentally investigate the clinical efficacy of 
different antimicrobial therapies for treatment of dual APV/O. rhinotracheale 
infection in turkeys. Statistical analysis of the obtained results revealed that under the 
circumstances used in this study, recovery from respiratory disease caused by 
APV/O. rhinotracheale dual infection in three-week-old turkeys was most successful 
overall after enrofloxacin treatment (three or five days of treatment), followed by 
florfenicol treatment. Clinical signs as well as the number of O. rhinotracheale 
bacteria recovered from the trachea and different respiratory organs (turbinates, 
trachea and lungs), were significantly reduced by enrofloxacin treatment for three or 
five days, compared with the non-treated group. Compared with the non-treated 
group, five-day treatment with amoxicillin did not cause a significant reduction in any 
of the afore mentioned parameters and although five-day florfenicol treatment 
significantly diminished the amount of O. rhinotracheale isolated out of the trachea 
and lungs, this did not seem to result in a significant reduction in clinical symptoms. 
These results are in accordance with data presented by Froyman and Cooper (2003), 
who demonstrated that enrofloxacin treatment was most efficacious for the treatment 
of colisepticemia in chickens, followed by florfenicol, and that amoxicillin was not 
effective.  
A possible explanation for the observed differences between antimicrobials 
relates to their different pharmacokinetic and pharmacodynamic properties. An 
important pharmacokinetic parameter for assessing the ability of antimicrobial agents 
to distribute throughout the tissues is the apparent volume of distribution at steady 
state (Vd(ss)). Vd(ss) gives an indication of the diffusion of the active antimicrobial 
compound in the body tissues. A relatively low Vd(ss) value indicates a drug that is 
less extensively distributed in extravascular tissues. Different pharmacokinetic studies 
with enrofloxacin, florfenicol and amoxicillin in either turkeys or chickens have been 
performed (Carceles et al., 1995; Anadón et al., 1996; Rios et al., 1997; Bugyei et al., 
1999; Knoll et al., 1999; Shen et al., 2003; Cox et al., 2004; Switala et al., 2004; 
Dimitrova et al., 2006). From these studies, it may be concluded that the Vd(ss) of 
amoxicillin (0.042 - 1.52 l/kg) is generally lower than that of florfenicol (1.5 - 4.99 
l/kg) and enrofloxacin (2.92 - 3.9 l/kg). 
Another perhaps influential parameter may be the elimination half-life of the different 
antimicrobials. When comparing half-life values determined in different experiments, 
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it may be concluded that enrofloxacin has long half-life values (Brown, 1996; Bugyei 
et al., 1999; Garcia Ovando et al., 1999; Knoll et al., 1999; Dimitrova et al., 2006) 
and that the values for florfenicol are generally lower (Afifi and El-Sooud, 1997; 
Shen et al., 2002; Shen et al., 2003), with the lowest half-life values noted for 
amoxicillin (Lashev and Pashov, 1992; Carceles et al., 1995; Anadon et al., 1996). 
Although both enrofloxacin and amoxicillin have good bactericidal activity, as 
opposed to florfenicol which is bacteriostatic, e.g., for E. coli and Salmonella spp. 
(Graham et al., 1988), it seems that the bactericidal effect of amoxicillin is impaired 
because it is less efficiently distributed throughout the tissues and in addition is 
eliminated quickly (Goren et al., 1981). The prominent results for enrofloxacin may 
be explained by its rapid bactericidal activity at relatively low concentrations (Brown, 
1996) and its excellent distribution throughout tissues for longer periods of time 
(Brown, 1996; McKellar, 1996). 
The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
breakpoints for amoxicillin vary greatly according to the bacteria involved. For 
instance, enterobacteriaceae are considered to be resistant when they have MIC 
values as high as 32 µg/ml or more, whereas staphylococci are already designated as 
resistant with MIC values of 0.5 µg/ml or more (CLSI guidelines, 2002). No CLSI 
breakpoints have been established for O. rhinotracheale, but from the results of the 
present investigation it can be concluded that an infection caused by O. 
rhinotracheale strains with an MIC of 2 µg/ml, does not seem to respond to 
antimicrobial treatment with amoxicillin. According to Devriese and colleagues 
(2001) who tested 45 O. rhinotracheale strains from poultry, MIC values for 
ampicillin generally varied between 1 and 8 µg/ml. According to Bush (2003), the 
antibacterial spectrum of amoxicillin is identical to that of ampicillin and there are 
few differences in antibacterial activity, especially against Gram-negative bacteria. 
No increase in the amoxicillin or florfenicol MIC value for the bacteria re-
isolated from the respective groups was noted. Likewise, no change in antimicrobial 
sensitivity was observed in O. rhinotracheale bacteria reisolated from group E3. In 
group E5, O. rhinotracheale could only be isolated from one bird after the first day 
after onset of treatment, but on the second day of the five-day treatment course, O. 
rhinotracheale organisms with an eight-fold higher MIC value (from ≤ 0.03 to 0.25 
µg/ml) were isolated, first from one turkey, then successively from the other 
penmates. This increase in enrofloxacin MIC value concurred with a slight O. 
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rhinotracheale re-excretion in the trachea, also reflected in the higher counts in 
different organs (turbinates and lungs) at 5 dpbi, compared with the almost negative 
O. rhinotracheale counts post-treatment in the turkeys treated for three days.  
The re-emergence of O. rhinotracheale isolates with increased MIC value was first 
seen in one animal on day two of antimicrobial treatment, and subsequently, each 
following day, isolates with increased MIC were found in more birds (data not 
shown). This may suggest that the less susceptible O. rhinotracheale isolate might 
have spread from one turkey to other penmates, although further epidemiological 
studies need to be performed to confirm this. Since O. rhinotracheale isolates with a 
rise in MIC value were already found after two days of enrofloxacin treatment, this 
suggests that this rise in MIC may also have occurred in the three-day treatment 
group.  
Although the MIC of the re-isolated bacteria increased from ≤ 0.03 to 0.25 
µg/ml, the O. rhinotracheale isolates are not to be considered resistant to 
enrofloxacin (Devriese et al., 2001; CLSI guidelines, 2002). The term “reduced 
susceptibility” is more appropriate to characterize the antimicrobial sensitivity status 
of the isolates with an eight-fold increase in MIC value. It should be noted that in the 
present study, this emergence of decreased sensitivity did not lead to a clinical 
relapse. Experimental infection studies, including the fully susceptible O. 
rhinotracheale strain and the O. rhinotracheale strain with slightly higher MIC value, 
would be necessary to be able to conclude anything about the impact of this MIC rise 
on the in vivo efficacy of enrofloxacin. Froyman and Cooper (2003) reported that in 
chickens, enrofloxacin was less efficacious for the treatment of disease caused by an 
E. coli strain with reduced sensitivity (MIC of 0.5 µg/ml) when compared with the 
treatment of disease caused by a fully sensitive E. coli strain (MIC of 0.015 µg/ml).  
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Summary 
This study determines the genetic background of the change in antimicrobial 
susceptibility to enrofloxacin of Ornithobacterium rhinotracheale isolates with 
increased minimal inhibitory concentration (MIC) values, isolated either from the 
field or from turkeys treated with enrofloxacin under experimental challenge 
conditions. In the field O. rhinotracheale strains that were either less susceptible or, 
occasionally, resistant to enrofloxacin, point mutations had occurred in amino acids at 
positions 83 (serine) or 87 (aspartic acid) of the GyrA subunit. 
In the isolates showing reduced susceptibility following experimental enrofloxacin 
treatment (increase in MIC from ≤0.03 to 0.25 µg/ml), molecular analysis revealed a 
constantly recurring point mutation (G → T) at nucleic acid position 646 (E. coli 
numbering) of gyrA resulting in an amino acid change from aspartic acid to tyrosine 
at position 87 of the GyrA subunit, which is a known hot spot for fluoroquinolone 
resistance. This study hence indicates that a single course of enrofloxacin treatment 
may contribute to the selection of the first mutant with reduced fluoroquinolone 
susceptibility in O. rhinotracheale. 
Acquired fluoroquinolone resistance is commonly encountered in O. rhinotracheale 
isolates, and this is the first time that the causal mechanism of fluoroquinolone 
resistance in O. rhinotracheale has been investigated.  
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Introduction 
Ornithobacterium rhinotracheale is an emerging infectious pathogen that has 
been ascribed an etiological role in the respiratory disease complex in turkeys and 
chickens, possibly causing considerable financial losses due to reduced growth, an 
increased mortality rate, high medication costs and a higher number of 
condemnations at slaughter (van Empel and Hafez, 1999). 
Generally, O. rhinotracheale infections are treated mainly with different 
antimicrobials, but treatment is becoming more and more difficult as a lot of isolates 
have acquired resistance to the antimicrobials most commonly used (Devriese et al., 
1995; 2001; Malik et al., 2003; Soriano et al., 2003). 
A challenge experiment conducted previously was carried out to test the 
efficacy of four antimicrobial treatment schemes against O. rhinotracheale infection 
in turkeys (Marien et al., 2006). In the experimental group receiving 5 days 
enrofloxacin treatment, O. rhinotracheale organisms with a higher enrofloxacin MIC 
(0.25 µg/ml) compared to that of the inoculated O. rhinotracheale strain (≤ 0.03 
µg/ml), were isolated initially from the trachea of one turkey, and subsequently from 
the other turkeys within that group.  
In most Gram-negative organisms, a reduction in the susceptibility to 
fluoroquinolones is caused by successive point mutations clustered in the quinolone 
resistance-determining region (QRDR) of the gyrA gene (Hooper, 1999; Barnard and 
Maxwell, 2001; Gibello et al., 2004). However, there are no data whatsoever on the 
genetic basis for fluoroquinolone resistance in O. rhinotracheale. This work was 
therefore carried out to investigate the resistance mechanism responsible for this in 
vivo selection of reduced enrofloxacin susceptibility in O. rhinotracheale following 
enrofloxacin treatment in turkeys. In addition to the O. rhinotracheale isolates 
derived from the experimentally infected animals, other O. rhinotracheale field 
strains with different in vitro sensitivity levels for enrofloxacin, were also included in 
this study for comparative purposes.  
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Materials and Methods 
 
Bacterial strains 
Twenty-three O. rhinotracheale isolates recovered during a previously 
conducted challenge experiment, designed to test the efficacy of four antimicrobial 
treatment schemes against O. rhinotracheale infection in turkeys, were included in 
this study (Marien et al., 2006). In brief, four groups of SPF turkeys received 
continuous drinking water treatment (enrofloxacin, 10 mg/kg, three or five days; 
florfenicol, 20 mg/kg, five days; amoxicillin, 20 mg/kg, five days) after oculonasal 
inoculation with avian metapneumovirus and O. rhinotracheale. In the experimental 
group receiving five days enrofloxacin, O. rhinotracheale organisms with a higher 
enrofloxacin MIC (0.25 µg/ml) compared to that of the inoculated O. rhinotracheale 
strain (≤ 0.03 µg/ml), were isolated initially from the trachea of one turkey, and 
subsequently from the other turkeys within that group.  
Additionally, one O. rhinotracheale strain with lowered enrofloxacin 
sensitivity (MIC 0.5 µg/ml), five enrofloxacin sensitive (MIC ≤ 0.03 µg/ml) and 17 
strains with unusually high enrofloxacin MIC values (MIC 1 - 2 µg/ml), close to or 
equal to the clinical breakpoint of 2 µg/ml (CLSI, 2002), all isolated from turkeys in 
France and broiler chickens in Belgium were likewise part of this study. The strains 
were stored at -70°C. They were retrieved from the frozen suspension and cultured 
for 48h at 37°C on Columbia agar (Oxoid LTD, Basingstoke, Hampshire, England) 
with 5% sheep’s blood in a 5% CO2 atmosphere.  
The origins and corresponding enrofloxacin MIC values of the different O. 
rhinotracheale isolates are given in Table 1. 
 
Determination of gyrA sequences 
To determinate the gyrA sequences, DNA was extracted using an alkaline lysis 
method of Baele et al. (2000), and the QRDR of the GyrA subunit of O. 
rhinotracheale was first amplified using a consensus degenerate universal primer 
pair, gyrAF and gyrAR (Maurin et al., 2001). On the basis of the determined 
sequences of 14 O. rhinotracheale isolates and type strain LMG9086, amplified with 
the universal primers, specific primers for the O. rhinotracheale gyrA gene were 
designed, namely ORTgyrAF (5’ CACAGAAGGGTGCTCTATGGG 3’) and 
ORTgyrAR (5’ TTCCAGCGGCACCATTTACC 3’). PCR reactions were performed 
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in a volume of 40µl containing a final primer concentration of 1µM for each of the 
oligonucleotides, 40 µM of each deoxynucleoside triphosphate (Amersham 
Pharmacia Biotech, Puurs, Belgium), 3mM MgCl2, 0.03 U/µl Polymerase Taq 
platinum (Invitrogen Life Technologies, Merelbeke, Belgium), and 1x PCR buffer 
(Invitrogen Life Technologies). Two microliters of template DNA were added to the 
vials. The conditions used for the amplifications were the following: initial 
denaturation at 95°C for 5 min, 35 cycles of 1 min denaturation at 95°C, 1 min of 
annealing at 48°C for the PCR with the universal primer pair and at 58°C with the 
specific primer pair, 1 min of elongation at 72°C, and a final extension of 5 min at 
72°C. Five microliters of the PCR products of each sample were mixed with 3 µl of 
sample buffer 5X (50% glycerol, 1 mM cresol red) and were electrophoresed through 
a 1.5% agarose gel for 60 minutes at 160 V in 0.5 x TBE (0.45 M Tris-HCl, 0.45 M 
boric acid, 0.01 M EDTA). After purification of the PCR products with the Qiaquick 
PCR purification kit (Qiagen, Westburg, Leusden, The Netherlands), the sequences of 
the PCR-products from the O. rhinotracheale strains were determined using the 
BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Lennik, Belgium) on 
an ABI PrismTM310 Genetic Analyser. The electropherograms were exported and 
converted to Kodon (Applied Maths, Sint-Martens-Latem, Belgium) using Abiconv 
(Applied Maths).  
The obtained amino acid sequences were numbered aligned with the 
Escherichia coli gyrA amino acid sequence for DNA gyrase A subunit (GenBank 
accession number X06373) and the amino acid sequences of the QRDR of gyrA of the 
O. rhinotracheale strains with different enrofloxacin susceptibilities were mutually 
compared.  
 
 
Results 
 
Screening gyrA mutations 
The nucleotide and corresponding amino acid sequences of the QRDR of the 
different O. rhinotracheale strains are presented in Figure 1 and the different 
mutations are summarized in Table 1.  
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Aa 517 GTTCACAGAAGGGTGCTCTATGGGATGAATGAAATGGGATTACTCTCTAATCGTGGATACAAAAAATCCGCTCGTGTGGTAGGAGAAGTG  
        V  H  R  R  V  L  Y  G  M  N  E  M  G  L  L  S  N  R  G  Y  K  K  S  A  R  V  V  G  E  V   
B      GTTCACAGAAGGGTGCTCTATGGGATGAATGAAATGGGATTACTCTCTAATCGTGGATACAAAAAATCCGCTCGTGTGGTAGGAGAAGTG  
        V  H  R  R  V  L  Y  G  M  N  E  M  G  L  L  S  N  R  G  Y  K  K  S  A  R  V  V  G  E  V   
C      GTTCACAGAAGGGTGCTCTATGGGATGAATGAAATGGGATTACTCTCTAATCGTGGATACAAAAAATCCGCTCGTGTGGTAGGAGAAGTG  
        V  H  R  R  V  L  Y  G  M  N  E  M  G  L  L  S  N  R  G  Y  K  K  S  A  R  V  V  G  E  V   
D      GTTCACAGAAGGGTGCTCTATGGGATGAATGAAATGGGATTACTCTCTAATCGTGGATACAAAAAATCCGCTCGTGTGGTAGGAGAAGTG  
        V  H  R  R  V  L  Y  G  M  N  E  M  G  L  L  S  N  R  G  Y  K  K  S  A  R  V  V  G  E  V   
E      GTTCACAGAAGGGTGCTCTATGGGATGAATGAAATGGGATTACTCTCTAATCGTGGATACAAAAAATCCGCTCGTGTGGTAGGAGAAGTG  
        V  H  R  R  V  L  Y  G  M  N  E  M  G  L  L  S  N  R  G  Y  K  K  S  A  R  V  V  G  E  V   
 
A  607 ATGGGTAAATTCCACCCTCACGGCGACTCTTCTGTATACGACACTATGGTGCGTATGGCACAAGACTGGTCTATGCGATATATGCTGGTA  
        M  G  K  F  H  P  H  G  D  S  S  V  Y  D  T  M  V  R  M  A  Q  D  W  S  M  R  Y  M  L  V   
B      ATGGGTAAATTCCACCCTCACGGCGACTCTTCTGTATACT CACTATGGTGCGTATGGCACAAGACTGGTCTATGCGATATATGCTGGTA  A
        M  G  K  F  H  P  H  G  D  S  S  V  Y  Y  T  M  V  R  M  A  Q  D  W  S  M  R  Y  M  L  V   
C      ATGGGTAAATTCCACCCTCACGGCGACTCTTCTGTATACA CACTATGGTGCGTATGGCACAAGACTGGTCTATGCGATATATGCTGGTA  A
        M  G  K  F  H  P  H  G  D  S  S  V  Y  N  T  M  V  R  M  A  Q  D  W  S  M  R  Y  M  L  V   
D      ATGGGTAAATTCCACCCTCACGGCGACTTTTCTGTATACGACACTATGGTGCGTATGGCACAAGACTGGTCTATGCGATATATGCTGGTA  
        M  G  K  F  H  P  H  G  D  F  S  V  Y  D  T  M  V  R  M  A  Q  D  W  S  M  R  Y  M  L  V   
E      ATGGGTAAATTCCACCCTCACGGCGACTATTCTGTATACGACACTATGGTGCGTATGGCACAAGACTGGTCTATGCGATATATGCTGGTA  
        M  G  K  F  H  P  H  G  D  Y  S  V  Y  D  T  M  V  R  M  A  Q  D  W  S  M  R  Y  M  L  V   
 
A  697 GATGGGCAAGGGAACTTTGGTTCTGTGGATGGCGACCCGCCAGCGGCGATGCGTTATACCGAGGCAAGAATGCAAAAAATTTCTGAGGAA  
        D  G  Q  G  N  F  G  S  V  D  G  D  P  P  A  A  M  R  Y  T  E  A  R  M  Q  K  I  S  E  E   
B      GATGGGCAAGGGAACTTTGGTTCTGTGGATGGCGACCCGCCAGCGGCGATGCGTTATACCGAGGCAAGAATGCAAAAAATTTCTGAGGAA  
        D  G  Q  G  N  F  G  S  V  D  G  D  P  P  A  A  M  R  Y  T  E  A  R  M  Q  K  I  S  E  E   
C      GATGGGCAAGGGAACTTTGGTTCTGTGGATGGCGACCCGCCAGCGGCGATGCGTTATACCGAGGCAAGAATGCAAAAAATTTCTGAGGAA  
        D  G  Q  G  N  F  G  S  V  D  G  D  P  P  A  A  M  R  Y  T  E  A  R  M  Q  K  I  S  E  E   
D      GATGGGCAAGGGAACTTTGGTTCTGTGGATGGCGACCCGCCAGCGGCGATGCGTTATACCGAGGCAAGAATGCAAAAAATTTCTGAGGAA  
        D  G  Q  G  N  F  G  S  V  D  G  D  P  P  A  A  M  R  Y  T  E  A  R  M  Q  K  I  S  E  E   
E      GATGGGCAAGGGAACTTTGGTTCTGTGGATGGCGACCCGCCAGCGGCGATGCGTTATACCGAGGCAAGAATGCAAAAAATTTCTGAGGAA  
        D  G  Q  G  N  F  G  S  V  D  G  D  P  P  A  A  M  R  Y  T  E  A  R  M  Q  K  I  S  E  E   
 
A  787 ATGCTTGCCGACATCGACAAAGAAACGGTAGACCAAAAATTAAACTTCGATGATACTTTGTATGAGCCTACTGTACTCCCTACCCGTATT  
        M  L  A  D  I  D  K  E  T  V  D  Q  K  L  N  F  D  D  T  L  Y  E  P  T  V  L  P  T  R  I   
B      ATGCTTGCCGACATCGACAAAGAAACGGTAGACCAAAAATTAAACTTCGATGATACTTTGTATGAGCCTACTGTACTCCCTACCCGTATT  
        M  L  A  D  I  D  K  E  T  V  D  Q  K  L  N  F  D  D  T  L  Y  E  P  T  V  L  P  T  R  I   
C      ATGCTTGCCGACATCGACAAAGAAACGGTAGACCAAAAATTAAACTTCGATGATACTTTGTATGAGCCTACTGTACTCCCTACCCGTATT  
        M  L  A  D  I  D  K  E  T  V  D  Q  K  L  N  F  D  D  T  L  Y  E  P  T  V  L  P  T  R  I   
D      ATGCTTGCCGACATCGACAAAGAAACGGTAGACCAAAAATTAAACTTCGATGATACTTTGTATGAGCCTACTGTACTCCCTACCCGTATT  
        M  L  A  D  I  D  K  E  T  V  D  Q  K  L  N  F  D  D  T  L  Y  E  P  T  V  L  P  T  R  I   
E      ATGCTTGCCGACATCGACAAAGAAACGGTAGACCAAAAATTAAACTTCGATGATACTTTGTATGAGCCTACTGTACTCCCTACCCGTATT  
        M  L  A  D  I  D  K  E  T  V  D  Q  K  L  N  F  D  D  T  L  Y  E  P  T  V  L  P  T  R  I   
 
A  877 CCAAACTTATTGGTAAATGGTGCCGCTGGAATCGCTGTCGGAATGGCA  924  
        P  N  L  L  V  N  G  A  A  G  I  A  V  G  M  A        
B      CCAAACTTATTGGTAAATGGTGCCGCTGGAATCGCTGTCGGAATGGCA    
        P  N  L  L  V  N  G  A  A  G  I  A  V  G  M  A        
C      CCAAACTTATTGGTAAATGGTGCCGCTGGAATCGCTGTCGGAATGGCA    
        P  N  L  L  V  N  G  A  A  G  I  A  V  G  M  A        
D      CCAAACTTATTGGTAAATGGTGCCGCTGGAATCGCTGTCGGAATGGCA    
        P  N  L  L  V  N  G  A  A  G  I  A  V  G  M  A        
E      CCAAACTTATTGGTAAATGGTGCCGCTGGAATCGCTGTCGGAATGGCA    
        P  N  L  L  V  N  G  A  A  G  I  A  V  G  M  A        
a: Sequences from strains given in Table 1.  
 
Figure 1. DNA sequence and deduced amino acid sequence of the quinolone 
resistance determining region (QRDR) and surrounding region of the GyrA subunit of 
DNA gyrase of the different O. rhinotracheale isolates. Differing nucleic acid bases 
between isolates are depicted in bold, differing amino acids are marked in bold and 
underlined. Nucleic acid position according to E. coli numbering (GenBank accession 
number X06373). 
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Table 1. MIC values for enrofloxacin and the nucleic acid changes in gyrA in 
different O. rhinotracheale strains. 
 Isolate 
n° Origin Sequence
a MIC (µg/ml) Amino acid change (codon) 83b
Amino acid change 
(codon) 87b
1 LMG9086c A ≤ 0.03 - - 
2-6 Subset 1d A ≤ 0.03 - - 
7-9 Subset 2e A ≤ 0.03 - - Iso
la
te
s 
ch
al
le
ng
e 
st
ud
y*
 
10-23 Subset 3f B 0.25 - D(GAC) → Y(TAC) 
24 Franceg A ≤ 0.03 - - 
25 France A ≤ 0.03 - - 
26 France A ≤ 0.03 - - 
27 France A ≤ 0.03 - - 
28 France A ≤ 0.03 - - 
29 Franceh C 0.5 - D(GAC) → N(AAC) 
30 Francei D 2 S(TCT) → F(TTT) - 
31 France D 2 S(TCT) → F(TTT) - Fi
el
d 
is
ol
at
es
 fr
om
 
Fr
an
ce
 
32 France E 2 S(TCT) → Y(TAT) - 
33 Belgiumj D 1 S(TCT) → F(TTT) - 
34 Belgium D 1 S(TCT) → F(TTT) - 
35 Belgium E 1 S(TCT) → Y(TAT) - 
36 Belgium E 1 S(TCT) → Y(TAT) - 
37 Belgium D 1 S(TCT) → F(TTT) - 
38 Belgium E 1 S(TCT) → Y(TAT) - 
39 Belgium D 1 S(TCT) → F(TTT) - 
40 Belgium D 1 S(TCT) → F(TTT) - 
41 Belgium E 1 S(TCT) → Y(TAT) - 
42 Belgium D 1 S(TCT) → F(TTT) - 
43 Belgium E 1 S(TCT) → Y(TAT) - 
44 Belgium D 1 S(TCT) → F(TTT) - 
45 Belgium E 1 S(TCT) → Y(TAT) - 
Fi
el
d 
is
ol
at
es
 fr
om
 B
el
gi
um
 
46 Belgium A 1 - - 
a: A, B, C, D or E: sequences presented in Figure 1.  
b: amino acid position according to E. coli numbering 
c: reference O. rhinotracheale isolate used for inoculation of experimental groups 
d: O. rhinotracheale from 3-day enrofloxacin treatment group, before and after treatment 
e: O. rhinotracheale from 5-day enrofloxacin treatment group, isolated before treatment 
f: O. rhinotracheale from 5-day enrofloxacin treatment group, isolated on different days post treatment 
g: O. rhinotracheale from turkeys in France, enrofloxacin sensitive 
h: O. rhinotracheale from turkeys in France, lowered enrofloxacin sensitivity 
i : O. rhinotracheale from turkeys in France, enrofloxacin resistant 
j : O. rhinotracheale from broiler chickens in Belgium, lowered enrofloxacin sensitivity 
*: Reference: Marien et al., 2006 
 
Compared to the sensitive O. rhinotracheale strain (MIC ≤ 0.03 µg/ml) used 
for inoculation in the experimental infection trial (Marien et al., 2006), an acquired 
G646T transition (corresponding to an amino acid change from aspartic acid to 
tyrosine at position 87 of the GyrA subunit; E. coli numbering) was found in the gyrA 
gene of all the reisolated O. rhinotracheale organisms with a rise in enrofloxacin MIC 
(0.25 µg/ml).  
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In seven and six of the 14 O. rhinotracheale strains with an MIC of 1 µg/ml 
isolated from broilers in Belgium, an acquired C635T transition and a C635A 
transition were noted, respectively. This resulted in an amino acid change from serine 
to phenylalanine and from serine to tyrosine at position 83, respectively. In one 
isolate with an MIC of 1 µg/ml, no nucleotide change in the QRDR of gyrA was 
found in comparison with the sensitive isolates. No mutations in gyrA were found in 
the enrofloxacin sensitive O. rhinotracheale strains from turkeys originating from 
France. In the three enrofloxacin-resistant strains (MIC of 2 µg/ml), a C635T 
transition at position 83 (change of serine into phenylalanine) and a C635A transition 
at position 83 (change of serine into tyrosine) was found in two and one strain(s), 
respectively. In the O. rhinotracheale strain with an MIC value of 0.5 µg/ml, a 
G646A transition at position 87 (change of aspartic acid into aspargine) was noticed. 
The nucleotide sequence of the QRDR of O. rhinotracheale isolates without point 
mutations has been submitted to the GenBank database (accession number 
DQ358690). 
 
 
Discussion 
Resistance to fluoroquinolones primarily occurs by two different mechanisms, 
that is, either through alterations in the two target enzymes, DNA gyrase and 
topoisomerase IV, or by inhibiting the drug from reaching its intracellular target 
through modifications in the outer membrane proteins or by active efflux systems. 
Recently, plasmid-borne quinolone-resistance was reported in Klebsiella pneumoniae, 
E. coli and Salmonella enterica serotype Enteritidis (Hooper, 2001; Drlica and Malik, 
2003; Cheung et al., 2005; Van Bambeke et al., 2005). In most Gram-negative 
organisms, fluoroquinolone resistance is selected by point mutations in the gyrA gene, 
clustered in the QRDR (Hooper, 1999). In E. coli, the most extensively studied 
organism, the QRDR region spans amino acids 51 to 106 (Drlica and Malik, 2003). 
Molecular analysis of the O. rhinotracheale strains with increased MIC value (0.25 
µg/ml), as reisolated during the in vivo experiment (Marien et al., 2006), consistently 
revealed a point mutation (G→T) at nucleic acid position 646 (E. coli numbering) of 
gyrA resulting in an amino acid change from aspartic acid to tyrosine at position 87 of 
GyrA, a known hot spot for fluoroquinolone resistance (Hooper, 1999). 
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All point mutations observed in the examined O. rhinotracheale field strains 
occurred in amino acids at positions 83 (serine) or 87 (aspartic acid), two amino acids 
indeed most commonly mutated in resistant Gram-negative bacteria (Hooper, 1999). 
In one isolate with MIC 1 µg/ml, no mutation in the QRDR of gyrA was found, 
suggesting that in this strain the decreased enrofloxacin susceptibility is caused by a 
mutation in another gene such as parC, gyrB or parE (Hooper, 1999; Jones et al., 
2000). To confirm this hypothesis, an option could be to sequence the latter genes. In 
the present study, however, we decided to focus on mutations in gyrA, the gene most 
frequently mutated in Gram-negative organisms (Hooper, 1999). 
Resistance to fluoroquinolones develops progressively, through stepwise 
mutations that arise spontaneously in bacterial populations, and fluoroquinolone 
treatment only needs to enrich the mutant subpopulation for resistance to develop 
(Sanders, 2001; Drlica and Malik, 2003). Usually organisms that are highly 
susceptible to fluoroquinolones remain within the susceptible range after single-step 
mutations and require multiple mutations before clinically relevant resistance 
becomes apparent (Hooper, 2001; Andriole, 2003). The MIC of the reisolated bacteria 
from the turkeys that had been treated with enrofloxacin increased from ≤0.03 to 0.25 
µg/ml and although this is an eight-fold increase, the O. rhinotracheale isolates are, 
according to the current CLSI guidelines, not considered as resistant to enrofloxacin 
(Devriese et al., 2001; CLSI, 2002). It will be necessary, however, to obtain clinical 
data or to carry out experimental infection studies including strains of different 
sensitivities to be able to make a final conclusion about the impact of these mutations 
on the in vivo efficacy of enrofloxacin. Froyman and Cooper reported that in 
chickens, enrofloxacin was less efficacious for the treatment of disease caused by an 
E. coli strain with reduced susceptibility (MIC 0.5 µg/ml) when being compared with 
treatment of disease caused by a fully susceptible E. coli strain (MIC 0.015 µg/ml) 
(Froyman and Cooper, 2003). 
In conclusion, this study hence indicates that a single course of enrofloxacin 
treatment may contribute to the selection of the first mutant with reduced 
fluoroquinolone susceptibility, which could eventually contribute to the emergence of 
fluoroquinolone resistance in O. rhinotracheale. 
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Summary 
Experimental groups of 15 susceptible three-week-old turkeys were inoculated 
oculonasally with avian metapneumovirus (APV) subtype A and susceptible 
Escherichia coli O2:K1 and Ornithobacterium rhinotracheale bacteria, with a three 
days interval between viral and bacterial inoculation and approximately eight hours 
between the two bacterial inoculations. The aims of the present study were to assess 
the efficacy of drinking-water administration of enrofloxacin for three and five days, 
amoxicillin for five days and florfenicol for five days for the treatment of the 
resulting respiratory disease, based on clinical and bacteriological examinations. 
Antimicrobial treatment started one day after dual bacterial inoculation. After 
infection, the birds were examined and scored for clinical signs daily, weighed at 
different times, and their tracheae swabbed daily. Five birds were euthanised and 
examined for macroscopic lesions at necropsy at 5 days post bacterial inoculation 
(dpbi) and the remainder at 15 dpbi. Samples of the turbinates, trachea, lungs, sinuses, 
air sacs, heart, pericardium and liver were collected for bacteriological examination. 
Recovery from respiratory disease caused by an APV/E. coli/O. rhinotracheale triple 
infection in three-week-old turkey poults was overall most successful after 
enrofloxacin treatment, irrespective of treatment duration, followed by florfenicol 
treatment. Compared with the untreated group, clinical signs as well as O. 
rhinotracheale and E. coli multiplication in the respiratory tract were significantly 
reduced by both enrofloxacin treatments and the florfenicol treatment, with the 
enrofloxacin treatments showing significantly better reductions than the florfenicol 
treatment. Five-day treatment with amoxicillin, compared with the untreated group, 
did not cause a significant reduction in any of the aforementioned parameters. 
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Introduction 
Respiratory problems are one of the main disorders leading to economic 
losses on turkey farms world-wide. They may be induced by various viral and 
bacterial agents, either alone or in combination. Besides these infectious organisms, 
non-infectious factors, such as climatic conditions and management-related problems, 
may also contribute to the occurrence or the severity of respiratory problems in 
turkeys (van Empel and Hafez, 1999).  
 Viral agents are mostly being attributed a triggering role, since the clinical 
signs following experimental inoculation with these viruses are less severe than those 
observed in the field. Viral infections generally cause rather acute respiratory 
problems from which birds usually can recover fairly easily. The problems, however, 
become more critical when bacterial pathogens are involved. Several bacteria such as 
Ornithobacterium rhinotracheale, Escherichia coli, Mycoplasma spp., Bordetella 
avium, Pasteurella spp. and Chlamydophila psittaci, have already been proven to 
make a contribution to the respiratory disease complex in turkeys (Hafez, 2005). 
When bacterial organisms are involved in an outbreak of respiratory disease, the only 
option is treatment with antimicrobials. Hitherto, few studies concerning the actual in 
vivo efficacy of antimicrobials for the treatment of bacterial infections in poultry have 
been performed. Very recently, the efficacy of different antimicrobials for the 
treatment of respiratory disease caused by avian metapneumovirus (APV) and O. 
rhinotracheale dual infection was evaluated experimentally (Marien et al., 2006). 
In a previous study using an optimized experimental in vivo model, it was 
demonstrated that a combined E. coli and O. rhinotracheale infection following 
APV-triggering in three-week-old turkeys caused more severe respiratory disease 
compared with single E. coli or O. rhinotracheale infection following APV-priming 
(Marien et al., submitted). The objectives of the present study are to compare the 
efficacy of enrofloxacin, amoxicillin and florfenicol for the treatment of respiratory 
disease due to experimental E. coli and O. rhinotracheale infection in three-week-old 
turkeys following APV challenge. The efficacy was evaluated on the basis of several 
parameters, i.e., clinical signs, re-isolation and titration of the bacterial challenge 
agents, and weight gain. 
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Materials and methods 
 
Turkeys 
Seventy-five specified pathogen-free (SPF) turkeys (AFSSA, Ploufragan, 
France), hatched in our facilities, were used in this study. The birds received 16h of 
light per day, were housed on litter in HEPA-filtered isolation rooms and had free 
access to food and water. At two weeks of age the birds were shown to be free from 
maternally-derived antibodies to O. rhinotracheale and APV by means of an ELISA 
available commercially (Biochek, Gouda, the Netherlands) and an in-house serum 
neutralization test (Marien et al., 2006), respectively. 
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during 
a respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The 
virus stock had a titre of 5.5 log10 50% ciliostatic dose (CD50)/ml after the third 
passage in tracheal organ cultures.  
 
Bacteria 
The O. rhinotracheale type strain LMG 9086T was used, which was originally 
isolated from a turkey with a respiratory tract infection. The strain was serotyped as 
type A in an agar gel precipitation test (Hafez and Sting, 1999) performed by 
Professor H. M. Hafez (Institute of Poultry Diseases, Free University of Berlin, 
Germany). The strain was stored at -70°C. The organism was retrieved from the 
frozen suspension and cultured for 48h at 37°C on Columbia agar (Oxoid LTD, 
Basingstoke, Hampshire, England) with 5% sheep blood in a 5% CO2 atmosphere. 
Ten colonies were transferred into 5 ml brain heart infusion broth (BHI) for 24h at 
37°C with agitation (microaerophilic incubation). The bacterial challenge inoculum 
was prepared by washing the cultured bacteria twice in phosphate buffered saline 
(PBS) followed each time by five minutes of centrifugation at 3,000 rpm at 4°C. The 
resulting pellet was re-suspended in PBS to obtain a final concentration of 8.6 log10 
colony-forming units (cfu)/ml. Confirmation of the number of cfu/ml was done by 
inoculating ten-fold dilutions in PBS on Columbia agar with 5% sheep blood and 
counting the number of colonies. The Minimal Inhibitory Concentrations (MICs) for 
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this challenge strain are as follows: amoxicillin, 2 µg/ml; florfenicol, 1 µg/ml; 
enrofloxacin, 0.03 µg/ml, as determined according to Devriese et al. (2001). 
A Belgian E. coli isolate retrieved from turkeys with colibacillosis was used. 
It was identified and serotyped as O2:K1 by Dr. Flemming Scheutz (Statens Serum 
Institute, The International Escherichia and Klebsiella Centre, Copenhagen, 
Denmark). This strain was used previously by Van de Zande et al. (2001) for 
establishing an E. coli infection in APV-infected turkeys, and is stored at -70°C. The 
organism was retrieved from the frozen suspension and cultured overnight at 37°C on 
MacConkey agar. Ten colonies were transferred into 5 ml BHI for 24h at 37°C. The 
bacterial challenge inoculum was prepared by washing the cultured bacteria twice in 
PBS followed each time by five minutes of centrifugation at 3,000 rpm at 4°C. The 
resulting pellet was re-suspended in PBS to obtain a final concentration of 8.6 log10 
cfu/ml. Confirmation of the number of cfu/ml was done by inoculating ten-fold 
dilutions in PBS on Columbia agar with 5% sheep blood and counting the number of 
colonies. The MICs for this challenge strain are as follows: amoxicillin, 2 µg/ml; 
florfenicol, 1 µg/ml; enrofloxacin, 0.03 µg/ml, as determined according to Devriese et 
al. (2001). 
 
Antimicrobial compounds 
Three antimicrobial compounds were used in this study: enrofloxacin 
(Baytril®  10%, Bayer AG, Leverkusen, Germany), amoxicillin (Suramox 50®, 
powder form, Virbac S.A., Carros, France) and florfenicol (Nuflor® 10% soluble 
form, Schering-Plough S.A., Xochimilco, Mexico), with manufacturer-recommended 
doses of 10 mg/kg for enrofloxacin and 20 mg/kg for amoxicillin and florfenicol.  
 
Experiment design 
Seventy-five SPF turkeys were randomly divided into five groups at one day 
of age. 
In all groups, turkeys were first infected with APV, and subsequently received 
E. coli and O. rhinotracheale three days later. Each bird was inoculated with APV by 
the oculonasal route at a dosage of 4.4 log10CD50  (250 µl per bird), and E. coli and O. 
rhinotracheale, with an interval of approximately eight hours, were likewise 
administered oculonasally at a dosage of 8 log10 cfu (250 µl per bird) for each bird. 
Four groups received antimicrobial treatment: group E3 enrofloxacin received 10 
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mg/kg for three days, group E5 received enrofloxacin 10 mg/kg for five days, group F 
received florfenicol 20 mg/kg for five days, and group A received amoxicillin 20 
mg/kg for five days. Starting at 24 hours post bacterial inoculation, the drinking water 
was medicated with the appropriate antimicrobial agent. The birds were continuously 
dosed and received their daily medication over a 24h period. To enable correct 
dosing, the daily water uptake was determined. Additionally, all animals were 
weighed immediately before APV inoculation, before bacterial inoculation, at day 5 
post bacterial inoculation (dpbi), and finally at 15 dpbi. The concentration of each 
antimicrobial to be administered in the water could be calculated accurately on the 
basis of the water consumption and body weight data. The fifth group was included as 
an untreated control group (group C). 
All birds were clinically examined on a daily basis throughout the experiment. 
The clinical signs were scored as described in Van de Zande et al. (2001). Shortly, the 
clinical condition of each bird was given a score from 0 (absence of clinical signs) to 
7 (nasal exudate with extremely swollen sinuses and frothy eyes, poor general 
condition and anorexia). The mean clinical score was calculated for each 
experimental group. 
Tracheal swabs were collected from the animals in all groups on day 3 post 
viral inoculation (dpvi) to confirm infection with APV, and daily for E. coli and O. 
rhinotracheale analysis. Before bacterial inoculation, tracheal swabs were taken from 
all birds of each experimental group for bacteriological examination, which proved to 
be negative for O. rhinotracheale and E. coli O2:K1. The tracheal swabs were taken 
using cotton-tipped aluminium-shafted swabs (Copan Diagnostics Inc., Corona, USA) 
and placed in 1 ml PBS supplemented with Ca2+ and Mg2+, and in the case of virus 
titration also with 10% fetal calf serum (Gibco, Invitrogen Corporation, Merelbeke, 
Belgium), penicillin (1000 U/ml) (Biopharma, Rome, Italy) and kanamycin (0.5 
mg/ml) (Gibco). Processing occurred as described below. 
Five birds of each group were randomly selected and were sacrificed at 5 dpbi. The 
remaining ten birds were sacrificed at 15 dpbi. Euthanasia was performed by 
intravenous injection with an overdose (10 mg/kg) of sodium pentobarbital 20% 
(Kela, Hoogstraten, Belgium). The birds were necropsied and examined for gross 
lesions. Samples of the turbinates, trachea and lungs were collected from all 
sacrificed birds for bacteriological examination. A 10% suspension in PBS was made 
from these tissue samples. The sinuses, air sacs, heart, pericardium and liver were 
 148
Experimental studies 
____________________________________________________________________ 
sampled with cotton swabs for bacteriological analysis. These swabs were suspended 
in 1 ml PBS supplemented with Ca2+ and Mg2+. For the animals sacrificed at 18 dpvi, 
the sinuses, turbinates, trachea, lungs, air sacs, heart, pericardium and liver were 
sampled with cotton swabs for bacteriological analysis. All samples for bacterial 
isolation were processed immediately after collection as described below.  
This experiment was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine, Ghent University. 
 
Virological and bacteriological titration of tracheal swabs 
The viral titre in log10CD50 per g mucus and the number of cfu of O. 
rhinotracheale and E. coli per g mucus were determined. This was done using the 
procedures described in Marien et al. (2005), with the following addition to the 
protocol: for the isolation of E. coli, samples were inoculated on MacConkey agar 
and incubated for 24h at 37°C. The isolated E. coli strains were serotyped by a slide-
agglutination test using the antiserum against the E. coli O2:K1 strain (Veterinary 
Laboratories Agency, Surrey, United Kingdom). 
 
Bacteriological titration of tissue suspensions and swabs 
Samples of the turbinates, trachea and lungs were quantified for O. 
rhinotracheale and E. coli from the 25 birds sacrificed at 5 dpbi. The number of cfu 
of O. rhinotracheale or E. coli per g tissue was determined as described in Marien et 
al. (2005) with the following addition to the protocol: for the isolation of E. coli, 
samples were inoculated on MacConkey agar and incubated for 24h at 37°C. The 
swabs taken from the sinuses, air sacs, pericardium, heart and liver were inoculated 
onto 5% sheep blood agar supplemented with 5 µg/ml gentamicin and 5 µg/ml 
polymyxin for O. rhinotracheale isolation and on MacConkey agar for E. coli 
isolation. After 24-48h of incubation at 37°C in a 5% CO2 atmosphere (O. 
rhinotracheale) and after 24h of incubation at 37°C (E. coli), the agar was examined 
for presence of O. rhinotracheale or E. coli.  
The swabs from the turbinates, trachea, lungs, sinuses, air sacs, pericardium, heart 
and liver from the birds sacrificed at 18 dpvi were likewise inoculated and the agars 
were examined for presence of O. rhinotracheale and/or E. coli.  
The isolated E. coli strains were serotyped by a slide-agglutination test using the 
antiserum against the E. coli O2:K1 strain (Veterinary Laboratories Agency). 
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MIC of the parent and re-isolated O. rhinotracheale isolates 
The MIC values of different O. rhinotracheale and E. coli isolates retrieved 
from the tracheal swabs before, during and after antimicrobial treatment were 
determined. More specifically, the enrofloxacin MICs were determined for the 
isolates from enrofloxacin groups E3 and E5, the amoxicillin MICs were determined 
for the isolates from amoxicillin group A, and finally, the florfenicol MICs for the 
isolates from florfenicol group F. 
Determination of the MIC values was performed by sensititre test (Trek 
Diagnostic Systems, West Sussex, UK).  
 
Statistical analyses 
The clinical scores, tracheal swabbing and weight were analysed only from 
animals that were not euthanised at 5 dpbi. Only the time span between 0 and 9 dpbi 
was considered in the analysis as it appears from previous experiments (Marien et al., 
2005; 2006) that after 9 dpbi most of the response variables, including the clinical 
score, return to normal. First, the area under the curve (AUC) of the clinical scores 
and tracheal swabbing between 0 and 9 dpbi was analysed via a fixed-effects model 
with the treatment group as fixed effect. Next, the repeated clinical scores between 0 
and 9 dpbi were analysed using a mixed proportional odds model with the clinical 
score as the response variable, animal as random effect, and treatment group and time 
as categorical fixed effects.  
E. coli and O. rhinotracheale tracheal swabbing values between 0 and 9 dpbi were 
analysed using a mixed model with log10cfu/g mucus as response variable, animal as 
random effect, and treatment group and time as categorical fixed effects.  
Weight was compared at the end of the trial using a fixed-effects model.  
E. coli and O. rhinotracheale titres from the turbinates, trachea and lung of the 
animals euthanised at 5 dpbi were compared between the five treatment groups with 
the Kruskall-Wallis test, whereas the presence of E. coli and O. rhinotracheale in the 
sinus, airsacs, pericardium, liver and heart of the animals euthanised at 5 dpbi were 
compared between the five treatment groups using the Fisher’s exact test (extended 
version for more than two groups).  
All tests were performed at a global 5% significance level, and the seven relevant 
pairwise comparisons (C vs E3, C vs E5, E3 vs E5, E5 vs A, E5 vs F, E3 vs A, E3 vs 
F) were tested at a significance level adjusted using Bonferroni’s multiple 
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comparisons technique. Only these seven comparisons will be considered throughout 
the paper. (Agresti, 2002) 
 
 
Results 
During the experiment, mortalities did not take place in any of the 
experimental groups. 
 
Clinical signs 
The mean clinical score for each group is shown in Figure 1. Respiratory 
signs were seen in all APV-inoculated groups starting from 3 dpvi. From 10 dpbi 
onwards, clinical signs were not detected in any of the animals in the different 
experimental groups.  
Using the AUC from 0 to 9 dpbi, there is a significant difference between the 
five treatments (P<0.0001). Group A has the highest total score, followed by C, F, E3 
and E5. Four of the seven analysed pairwise comparisons, namely C vs E3, C vs E5, 
E3 vs A and E5 vs A, are significant as indicated in Table 1. 
In the proportional odds model, both a significant change in time (P<0.0001) and a 
significant difference (P<0.0001) between the treatments were detected. E5 had the 
lowest odds ratio, followed by E3, F, C and A. All but one (E3 vs E5) analysed 
pairwise comparisons are significant as indicated in Table 1. 
Thus, compared with the untreated control group, clinical signs were significantly 
reduced by the enrofloxacin treatments, irrespective of treatment duration, and by the 
treatment with florfenicol, but not by treatment with amoxicillin. Also, in the 
enrofloxacin-treated groups, clinical signs disappeared completely three days earlier 
compared with the untreated group and the amoxicillin-treated group, and two days 
earlier compared with the florfenicol-treated group.  
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Figure 1. Mean clinical scores in turkeys inoculated with APV, E. coli and O. 
rhinotracheale and subsequently treated with different antimicrobial agents: ■ group 
E3, three days of enrofloxacin (10 mg/kg); ●group E5, five days of enrofloxacin (10 
mg/kg); ▲ group A, five days of amoxicillin (20 mg/kg); ×group F, five days of 
florfenicol (20 mg/kg) or no treatment (     control group). Arrow indicates first day of 
antimicrobial treatment. 
 
Macroscopic findings  
Macroscopic findings were comparable in the different experimental groups, 
with lesions being serous to seromucous exudate in the turbinates and sinuses, and 
hyperaemia of the turbinates and the trachea. These lesions were found in all groups, 
but in the groups receiving enrofloxacin treatment and to a lesser extent in the group 
receiving florfenicol treatment, the observed lesions were less severe.  
 
Viral titrations of tracheal swabs 
APV was recovered from tracheal swabs from every individual bird. The 
mean titres for groups C, E3, E5, A and F were 6.1, 5.9, 6.1, 6.2, and 6.3 log10CD50/g 
mucus, respectively. 
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Bacterial titration of tracheal swabs 
The results of the O. rhinotracheale and E. coli titrations of the tracheal swabs 
of the different groups are shown in Figure 2 for O. rhinotracheale and Figure 3 for 
E. coli. Mean titres for each experimental group are depicted. 
0
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Figure 2. Bacterial O. rhinotracheale titres (log10cfu/g mucus) in tracheal mucus 
collected at different time points after O. rhinotracheale inoculation in triple APV/E. 
coli/O. rhinotracheale infected turkeys, receiving different antimicrobial treatments: 
■ group E3, 3 days of enrofloxacin, (10 mg/kg); ● group E5, 5 days of enrofloxacin 
(10 mg/kg); ▲ group A, 5 days of amoxicillin (20 mg/kg); × group F, 5 days of 
florfenicol (20 mg/kg), or no treatment (     control group). Arrow indicates first day 
of antimicrobial treatment. 
 
O. rhinotracheale titres in tracheal mucus 
Using the AUC in the fixed-effects model, there is a significant difference between 
the five treatments (P<0.0001). The analysis of the repeated counts also reveals a 
significant difference between treatments (P<0.0001) and a significant change in time 
(P<0.0001). All of the seven analysed pairwise comparisons, except E3 vs E5, are 
significant as pointed out in Table 1.  
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Compared with the untreated control group, the number of O. rhinotracheale 
organisms in the tracheal mucus was hence significantly reduced by both 
enrofloxacin treatments (three- and five-day treatment) and by the five-day florfenicol 
treatment, with enrofloxacin treatments showing significantly better reductions than 
florfenicol treatment. Compared with the untreated group, treatment with amoxicillin 
did not cause a significant reduction in the O. rhinotracheale titres in the trachea. 
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Figure 3. Bacterial E. coli titres (log10 cfu/g mucus) in tracheal mucus collected at 
different time points after E. coli inoculation in triple APV/E. coli/O. rhinotracheale 
infected turkeys, receiving different antimicrobial treatments: ■ group E3, three days 
of enrofloxacin, (10 mg/kg); ● group E5, five days of enrofloxacin (10 mg/kg); ▲ 
group A, five days of amoxicillin (20 mg/kg); × group F, five days of florfenicol (20 
mg/kg), or no treatment (      control group). Arrow indicates first day of antimicrobial 
treatment.
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E. coli titres in tracheal mucus 
Using the AUC in the fixed effects model, there is a significant difference between 
the five treatments (P<0.0001), whereas the analysis of the repeated counts based on 
the mixed model reveals a significant difference between treatments (P<0.0001) and a 
significant change in time (P<0.0001). In both analyses, group A has the highest 
score, followed by C, F, E3 and E5. All of the seven analysed pairwise comparisons, 
except E3 vs E5 and E3 vs F for the AUC and E3 vs E5 for the repeated counts, are 
significant as pointed out in Table 2.  
Compared with the untreated control group, the number of E. coli organisms in the 
tracheal mucus was hence significantly reduced by both enrofloxacin treatments 
(three- and five-day treatment) and by the five-day florfenicol treatment, with 
enrofloxacin treatments showing significantly better reductions than florfenicol 
treatment. Compared with the untreated group, treatment with amoxicillin did not 
cause a significant reduction in the E. coli titres in the trachea. 
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Bacterial titration of tissue samples 
O. rhinotracheale and E. coli were never recovered from any of the organs of 
the animals in group E3 and E5 sacrificed at 5 and 15 dpbi. For the other groups 
(group C, A and F), the various O. rhinotracheale and E. coli titres in the sampled 
organs at 5 dpbi are shown in Table 3 and Table 4, respectively.  
 
Table 3. Bacterial titre of O. rhinotracheale (log10 cfu/g tissue) isolated from 
different organs from turkeys inoculated turkeys inoculated with APV, E. coli and O. 
rhinotracheale, and subsequently treated with different antimicrobial agents: group 
A, 5 days of amoxicillin (20 mg/kg); group F, 5 days of florfenicol (20 mg/kg) or no 
treatment, group C. Turkeys were euthanised at 5 dpbi. 
O. rhinotracheale titre (log10 cfu/g tissue) 
Organ 
Group C  Group A  Group F 
 1a 2 3 4 5  1 2 3 4 5  1 2 3 4 5 
Turbinates 8 10.9 10.6 10.2 9.7  9.8 10.2 5 10 10.6  10.6 0 9.5 0 0 
Trachea 6.4 8.1 7.4 7.4 7.5  10.5 7.7 7.3 7.2 7.9  2.7 0 0 0 0 
Lungs 5.3 4.8 6.7 5.9 5.5  6 5.4 4.5 6.9 6.4  0 0 0 0 0 
Sinusb + + + + +  + + + + +  + - - - - 
Air sacsb + + + - +  + - + + +  - - - - - 
Pericardiumb - - - - -  - - - - -  - - - - - 
Heartb - - - - -  - - - - -  - - - - - 
Liverb - - - - -  - - - + +  - - - - - 
a: Number of turkey 
b: These organs were swabbed; no tissue suspensions were made 
c: +: O. rhinotracheale was isolated 
    -: No O. rhinotracheale was isolated 
 
O. rhinotracheale 
Significant differences between treatments were observed for O. 
rhinotracheale titrations from the turbinates (P=0.0019), trachea (P=0.0003), lungs 
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(P=0.0002), sinus (P=0.0003) and air sacs (P=0.002). Pairwise significant differences 
between the treatments are shown in Table 1.  
Compared with the untreated control group, the number of O. rhinotracheale in the 
trachea and lungs was significantly reduced by the enrofloxacin treatments and by the 
florfenicol treatment, as opposed to treatment with amoxicillin. Furthermore, the 
number of O. rhinotracheale isolated from the turbinates was significantly reduced by 
the three- and five-day enrofloxacin treatments. For the pericardium, liver and heart, 
very few positive samples were encountered (in group A), and significant differences 
between the treatments did not occur. 
O. rhinotracheale was not recovered from any of the organs (turbinates, 
trachea, lungs, sinuses, air sacs, pericardium, heart and liver) of the birds in the five 
groups swabbed at 15 dpbi. 
 
Table 4. Bacterial titre of E. coli (log10 cfu/g tissue) isolated from different organs 
from turkeys inoculated with APV, E. coli and O. rhinotracheale, and subsequently 
treated with different antimicrobial agents: group A, 5 days of amoxicillin (20 
mg/kg); group F, 5 days of florfenicol (20 mg/kg) or no treatment, group C. Turkeys 
were euthanised at 5 dpbi. 
E. coli O2:K1 titre (log10 cfu/g tissue) 
Organ 
Group C  Group A  Group F 
 1a 2 3 4 5  1 2 3 4 5  1 2 3 4 5 
Turbinates 8.2 5.1 10.3 10 9.8  10.4 9 5.3 11.4 9.6  10 11.4 0 0 0 
Trachea 5.3 4.4 5.8 4.3 0  6.5 7.4 4.4 4.3 6.9  5.5 6.2 0 0 0 
Lungs 5.1 3.4 3.6 0 0  4.6 0 0 4 4.7  0 0 0 0 0 
Sinusb + + + + +  + + + - +  + - - + - 
Air sacsb - - + - -  - - - - -  - + - - - 
Pericardiumb - - - - -  - - - - -  - - - - - 
Heartb - - - - -  - - - - -  - - - - - 
Liverb - - - - -  - - - - -  - - - - - 
a: Number of turkey 
b: These organs were swabbed; no tissue suspensions were made 
c: +: E. coli was isolated 
    -: No E. coli was isolated 
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E. coli 
Significant differences between treatments were observed for E. coli titrations 
from the turbinates (P=0.0041), trachea (P=0.0047), lungs (P=0.0252) and sinus 
(P=0.0028). Pairwise significant differences between the treatments are shown in 
Table 2. Compared with the untreated control group, none of the treatments caused a 
significant reduction in the number of E. coli isolated from the trachea and lungs. The 
number of E. coli isolated from the turbinates and the sinuses was significantly 
reduced only by both the enrofloxacin treatments, compared with the untreated group. 
For the pericardium, liver and heart, no positive samples were encountered, so 
significant differences between the treatments did not occur. 
From the birds swabbed at 15 dpbi, E. coli was recovered, respectively, from the 
sinuses, turbinates and trachea of 2, 8 and 2 of the 10 birds in group C, 3, 6 and 3 of 
the 10 birds in group A, and 4, 7 and 4 of the 10 birds in group F. E. coli was not 
recovered from any of the organs of the birds in groups E3 and E5 swabbed at 15 
dpbi. 
 
MIC of the parent and re-isolated O. rhinotracheale isolates 
Compared with the challenge strain, no increase was noted in the amoxicillin, 
florfenicol or enrofloxacin MIC values for the re-isolated bacteria from the respective 
groups.  
 
Weight  
Significant differences were not observed between the treatment groups 
(P=0.93) as indicated in Table 2. 
 
Antimicrobial therapy 
The theoretically consumed dose of antimicrobials per group of birds was 
close to the target dose of 10 mg/kg for enrofloxacin and 20 mg/kg for amoxicillin 
and florfenicol. The mean actual daily dose (mg/kg) for the total medication period 
was 10.2 (range: 9.81 – 10.7) for group E3, 9.9 (range: 9.2 – 10.5) for group E5, 22.7 
(range 19.0 – 25.1) for group F, and 21.1 (range 17.3 – 24.4) for group A. 
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Discussion 
This study is the first to investigate experimentally the clinical efficacy of 
different antimicrobial therapies for the treatment of dual E. coli/O. rhinotracheale 
infection after APV challenge in turkeys. Statistical analysis of the obtained results 
revealed that under the circumstances used in this study, recovery from respiratory 
disease caused by APV/E. coli/O. rhinotracheale triple infection in three-week-old 
turkeys was overall most successful after enrofloxacin treatment (three or five days of 
treatment), followed by florfenicol treatment. Compared with the untreated control 
group, clinical signs as well as the O. rhinotracheale and E. coli multiplication in the 
respiratory tract were significantly reduced by both the enrofloxacin treatments and 
the florfenicol treatment, with the enrofloxacin treatments showing significantly 
better reductions than the florfenicol treatment. Five-day treatment with amoxicillin, 
compared with the untreated group, did not cause a significant reduction in any of the 
aforementioned parameters. These results are in accordance with a previously 
executed experiment in which it was proven that enrofloxacin treatment was 
significantly better than florfenicol for a reduction in clinical signs and bacterial 
multiplication in APV/O. rhinotracheale -dually infected turkeys and that amoxicillin 
treatment was not efficacious (Marien et al., 2006). Data presented by Froyman and 
Cooper (2003), also demonstrated that enrofloxacin treatment was most efficacious 
for the treatment of colisepticemia in chickens, followed by florfenicol, and that 
amoxicillin was not effective. Charleston et al. (1998) showed that enrofloxacin was 
effective for treatment of E. coli infection in chickens. 
Possible explanations for the observed differences between the different 
antimicrobial products may be the different pharmacokinetic and pharmacodynamic 
properties of the applied antimicrobials, including the apparent volume of distribution 
at steady state (Vd(ss)), which gives an indication of the diffusion of the antimicrobials 
in the body tissues. Data from different pharmacokinetic studies in turkeys and 
chickens, demonstrate that the Vd(ss) of amoxicillin, compared with that of florfenicol 
and enrofloxacin is lower, which means that amoxicillin is less extensively 
distributed in the extravascular tissues (Carceles et al., 1995; Anadon et al., 1996; 
Rios et al., 1997; Bugyei et al., 1999; Knoll et al., 1999; Shen et al., 2003; Cox et al., 
2004; Switala et al., 2004; Dimitrova et al., 2006). Furthermore, it must be stated that 
enrofloxacin has long half-life values (Brown, 1996; Bugyei et al., 1999; Garcia 
Ovando et al., 1999; Knoll et al., 1999; Dimitrova et al., 2006) and that the values for 
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florfenicol are generally lower (Afifi and El-Sooud, 1997; Shen et al., 2002; Shen et 
al., 2003), with the lowest half-life values noted for amoxicillin (Lashev and Pashov, 
1992; Carceles et al., 1995; Anadon et al., 1996). It is likely that the bactericidal 
effect of amoxicillin is being diminished by its less efficient distribution throughout 
tissues and its relatively fast elimination (Goren et al., 1981). Enrofloxacin, however, 
is rapidly bactericidal at relatively low concentrations (Brown, 1996) and is 
distributed very well throughout tissues (Brown, 1996; McKellar, 1996), which may 
explain its favourable results in the present experiment. 
 
 
Acknowledgements 
This work was supported by a grant from Bayer HealthCare AG, Animal 
Health. The authors would like to express their appreciation to Venessa Eeckhaut, 
Arlette Van de Kerckhove, Carine Boone and Christian Puttevils for their skilled 
technical assistance. Furthermore, we would like to thank Professor H. M. Hafez 
(Institute of Poultry Diseases, Free University of Berlin, Germany) for serotyping the 
O. rhinotracheale strain used and Mr. B. Van Dam (BioChek) for the supply of the 
ELISA. 
 
 
References 
Anadón, A., Martinez-Larrañaga, M.R., Diaz, M.J., Bringas, P., Fernandez, M.C.,  
Martinez, M.A., and Fernandez-Cruz, M.L. (1996). Pharmacokinetics of 
amoxicillin in broiler chickens. Avian Pathology, 25, 449-458. 
Afifi, N.A., and El-Sooud, K.A. (1997). Tissue concentrations and pharmacokinetics  
of florfenicol in broiler chickens. Britisch Poultry Science, 38, 425-428. 
Agresti, A. (2002). Categorical Data Analysis 2nd ed. John Wiley & Sons, Inc.,  
Hoboken, New Jersey. p. 514. 
Brown, S.A. (1996). Fluoroquinolones in animal health. Journal of Veterinary  
Pharmacology and Therapeutics, 19, 1-14. 
Bugyei, K., Black, W.D., and McEwen, S. (1999). Pharmacokinetics of enrofloxacin  
given by the oral, intravenous and intramuscular routes in broiler chickens. 
Canadian Journal of  Veterinary Research, 63, 193-200.  
Carceles, C.M., Vicente, M.S., and Escudero, E. (1995). Pharmacokinetics of  
 162
Experimental studies 
____________________________________________________________________ 
amoxicillin-clavulanic acid combination after intravenous and intramuscular 
administration to turkeys and chickens. Avian Pathology, 24, 643-952. 
Charleston, B., Bate, J.J., Aitken, I.A., Stephan, B., and Froyman, R. (1998).  
Comparison of the efficacies of three fluoroquinolone antimicrobial agents, 
given as continuous or pulsed-water medication, against Escherichia coli 
infection in chickens. Antimicrobial Agents and Chemotherapy, 42 (1), 83-87. 
Cox, S.K., Cottrell, M.B., Smith, L., Papich, M.G., Frazier, D.L., and Bartges, J.  
(2004). Allometric analysis of ciprofloxacin and enrofloxacin 
pharmacokinetics across species. Journal of Veterinary Pharmacology and 
Therapeutics, 27, 139-146. 
Devriese, L.A., De Herdt, P., and Haesebrouck, F. (2001). Antibiotic sensitivity and  
resistance in Ornithobacterium rhinotracheale strains from Belgian broiler 
chickens. Avian Pathology, 30, 197-200. 
Dimitrova, D.J., Lashev, L.D., Janev, St.G., and Pandova, V.D. (2006).  
Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in male and 
female turkeys following intravenous and oral administration. Veterinary 
Research Communications, 30 (4), 415-422. 
Froyman, R., and Cooper, J. (2003). Assessment of the efficacy of fluoroquinolones  
and other antimicrobials against respiratory colibacillosis and septicemia in 
chickens under standardized challenge conditions. In: Proceedings of the XIII 
Congress of the WPVA (pp. 84). Denver, US. 
Garcia Ovando, H., Gorla, N., Luders, C., Poloni, G., Errecalde, C., Prieto, G., and  
Puelles, I. (1999). Comparative pharmacokinetics of enrofloxacin and 
ciprofloxacin in chickens. Journal of Veterinary Pharmacology and 
Therapeutics, 22, 209-212. 
Goren, E., De Jong, W.A., and Van Solkema, A. (1981). Some pharmacokinetical  
aspects of ampicillin trihydrate and its therapeutic efficacy in experimental 
Escherichia coli infection in poultry. Avian Pathology, 10, 43-55. 
Hafez, H.M., and Sting, R. (1999). Investigations on different Ornithobacterium  
rhinotracheale “ORT” isolates. Avian Diseases, 34 (1), 1-7. 
Hafez, H.M. (2005). Current knowledge and prospective risk analysis related to the  
ongoing turkey diseases. In: Proceedings of the 14th Veterinary Poultry 
Congress (pp. 138-149). Istanbul, Turkey. 
Knoll, U., Glünder, G., and Kietzmann, M. (1999). Comparative study of the plasma  
 163
Experimental studies 
____________________________________________________________________ 
pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin 
in broiler chickens. Journal of Veterinary Pharmacology and Therapeutics, 
22, 239-246. 
Lashev, L.D., and Pashov, D.A. (1992). Interspecies variations in plasma half-life of  
ampicillin, amoxicillin, sulphadimidine and sulphacetamide related to 
variations in body mass. Research in Veterinary Science, 53, 160-164. 
Marien, M., Decostere, A., Martel, A., Chiers, K., Froyman, R., and Nauwynck, H.  
(2005). Synergy between avian pneumovirus and Ornithobacterium 
rhinotracheale in turkeys. Avian Pathology, 34 (3), 204-211. 
Marien, M., Nauwynck, H., Duchateau, L., Martel, A., Chiers, K., Devriese, L.,  
Froyman, R., and Decostere, A. (2006). Comparison of the efficacy of four 
antimicrobial treatment schemes against experimental Ornithobacterium 
rhinotracheale infection in turkey poults pre-infected with avian 
pneumovirus. Avian Pathology, 35 (3), 230-237. 
McKellar, Q.A. (1996). Clinical relevance of the pharmacologic properties of  
fluoroquinolones. Compendium of Continuing Education for Practising 
Veterinarians, 18 (2), 492-497. 
Rios, A., Martínez-Larrañaga, M.R., and Anadón, A. (1997). Plasma disposition of  
florfenicol in broiler chickens following intravenous administration. Journal 
of Veterinary Pharmacology and Therapeutics, 20 (Supplement 1), 182. 
Shen, J., Wu, X., Hu, D., and Jizng, H. (2002). Pharmacokinetics of florfenicol in  
healthy and Escherichia coli-infected broiler chickens. Research in Veterinary 
Science, 73, 137-140. 
Shen, J., Hu, D., Wu, X., and Coats, J.R. (2003). Bioavailability and  
pharmacokinetics of florfenicol in broiler chickens. Journal of Veterinary 
Pharmacology and Therapeutics, 26, 337-341. 
Switala, M., Okoniewski, P., Smutkiewicz, A., Jaworski, K., and Hrynyk, R. (2004).  
Pharmacokinetics of florfenicol and thiamphenicol in turkeys. In: Proceedings 
of the Second international conference on antimicrobial agents in veterinary 
medicine (AAVM) (p. 99). Ottawa, Canada.  
Van de Zande, S., Nauwynck, H., Cavanagh, D., and Pensaert, M. (1998). Infections  
and reinfections with avian pneumovirus subtype A and B on Belgian turkey 
farms and relation to respiratory problems. Journal of Veterinary Medicine 
Series B, 45, 621-626.  
 164
Experimental studies 
____________________________________________________________________ 
Van de Zande, S., Nauwynck, H., and Pensaert, M. (2001). The clinical, pathological  
and microbiological outcome of an Escherichia coli O2:K1 infection in avian 
pneumovirus infection in turkeys. Veterinary Microbiology, 81, 353-365. 
van Empel, P.C.M., and Hafez, H.M. (1999). Ornithobacterium rhinotracheale: a  
review. Avian Pathology, 28, 217-227. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 165
 
                                             General Discussion                          
_____________________________________________________________________ 
 
 
 
 
Chapter 4: GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________ 
 167
                                             General Discussion                          
_____________________________________________________________________ 
GENERAL DISCUSSION 
Studying all the possible interactions between the different respiratory 
pathogens of importance to turkeys in one doctoral research, would be an unrealistic 
goal, therefore it was decided to focus on four relevant respiratory pathogens as 
pointed out by scientific literature and personal communications by veterinary 
practitioners. 
Avian metapneumovirus (APV) was the first agent to be included in our research, 
since a prevalence study performed in Belgium by Van de Zande et al. (1997), 
revealed that APV had circulated on 100% of the examined turkey farms. Several 
years later, despite intensive vaccination schemes against APV, antibodies indicative 
for natural APV infections were still frequently detected by Van Loock et al. (2005) 
in Belgian turkey farms. In the field, Escherichia coli and Ornithobacterium 
rhinotracheale are bacterial agents that have frequently been isolated following APV 
infections, alone or in combination with one another (De Rosa et al., 1996; El-Sukhon 
et al., 2002; Vandekerchove et al., 2004). In 2005, Van Loock et al. reported that five 
of the eight examined Belgian turkey farms had experienced an O. rhinotracheale 
infection. Since isolation of O. rhinotracheale is not always straightforward using 
routine diagnostic methods and van Empel and Hafez (1999) reported that O. 
rhinotracheale antibody titres decline quite rapidly after infection, infections with O. 
rhinotracheale may be underestimated. O. rhinotracheale is believed to play an 
important role in the respiratory problems in the Belgian turkey industry, which is 
comparable with the situation in our neighbouring countries (Balloy, 2005; Lister, 
2005). Based on results of routine analyses of clinically healthy, diseased and dead 
birds, Vandemaele et al. (2002) concluded that avian pathogenic E. coli (APEC) is 
circulating intensively in Belgian poultry, and appears to be a major contributor to 
respiratory poultry disease. Finally, an important turkey pathogen able to attribute to 
the respiratory disease complex in turkeys is Mycoplasma gallisepticum (Kleven, 
1998; Levisohn and Kleven, 2000). In spite of national programmes for Mycoplasma 
control, M. gallisepticum remains a threat to the poultry industry (Lister, 2005). 
Albeit at very low frequencies, layer flocks in Belgium are still occasionally found to 
be positive for M. gallisepticum.  
 
From the different experimental studies included, new insights in the 
pathogenesis of O. rhinotracheale and E. coli infections in turkeys were obtained. It 
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became apparent that, although both O. rhinotracheale and E. coli are respiratory 
pathogens that are able to cause similar disease symptoms and lesions, they 
intrinsically have different ways of acting. First of all, O. rhinotracheale has a very 
clear tropism for the intact respiratory system, since it was able to adhere to the 
tracheal epithelium and colonize the turbinates and lungs without previous infection 
with APV. This is in contrast with E. coli, which specifically needs an APV-infected 
respiratory system in order to sustain its presence. Without prior infection with APV, 
E. coli indeed is not able to colonize the respiratory tract (Van de Zande, 2001; Van 
de Zande et al., 2001). The reasoning for this may be two-fold. Firstly, APV directly 
interferes with the mucociliary clearance of bacteria by destroying ciliated cells and 
reducing the number of mucus-secreting goblet cells. Secondly, the degenerative and 
regenerative changes during APV replication may be responsible for the induction of 
surface receptors for E. coli that allow colonisation. The normal mucus and epithelial 
cells may actually lack binding sites for this organism. Destruction of the epithelial 
cells by APV may expose the basement membrane and in this way also uncover 
certain receptors (Ramphal et al., 1980). Ramphal et al. (1980) reported that different 
Pseudomonas aeruginosa strains adhered only to desquamating cells of influenza-
infected tracheas, but not to normal mucosa, the basal cell layer, or the regenerating 
epithelium, and only to injured cells and to areas of exposed basement membrane 
after endotracheal intubation, a phenomenon they call “opportunistic adherence”. Van 
de Zande (2001) was, in APV-primed turkeys, able to demonstrate a large number of 
E. coli in the mucus layer and in the mucus ‘clots’ present in the lumen of the trachea. 
It was impossible to determine whether this was a result of specific adherence and 
colonisation or whether the bacteria were merely retained in a passive way. Most 
bacterial species that have been studied adhere avidly to mucus, by specific (adhesin-
receptor) and non-specific interactions (Dowling and Wilson 1998: Ramphal et al., 
1991; Barsum et al., 1995). Although O. rhinotracheale was able to colonize the 
undamaged trachea, turbinates and lungs, priming with APV still had an exacerbating 
effect, since it facilitated infection of the lungs and was necessary to allow the 
bacterial pathogen to infect the air sacs. Apparently infection with APV allows O. 
rhinotracheale to better reach the lower respiratory tissues.  
In the present thesis, it also became clear that pre-infection with M. 
gallisepticum has an important effect on the duration of the presence of O. 
rhinotracheale and E. coli in the upper respiratory tract (trachea and turbinates). In 
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the experimental studies without M. gallisepticum infection, O. rhinotracheale could 
only be isolated from the trachea until ten to twelve days and E. coli until 
approximately fourteen days post inoculation. When the turkeys were infected first 
with M. gallisepticum, however, O. rhinotracheale and E. coli remained in the 
trachea at rather high levels until at least 20 days post O. rhinotracheale/E. coli 
inoculation (end of experimental period). Apparently M. gallisepticum exerts an 
important impeding effect on the clearance of O. rhinotracheale and E. coli, 
especially from the upper respiratory tract. Indeed, at the end of the experiment (20 
days post E. coli/O. rhinotracheale inoculation), O. rhinotracheale and E. coli were 
cleared from the lungs, air sacs, and non-respiratory organs, but not from the 
turbinates and trachea. This might indicate that the host’s immune response at this 
level was affected. 
Although O. rhinotracheale was able to colonize the healthy respiratory tract, 
actual respiratory symptoms could not be elicited by single infection with this agent. 
Indeed, O. rhinotracheale was not able to cause primary respiratory symptoms, but 
was able to exacerbate the symptoms caused by the APV infection. After dual 
infection, the clinical symptoms in themselves were similar in nature to those caused 
by APV alone, but they were more severe and persisted markedly longer. Since E. 
coli is not able to colonize the respiratory tract without prior damage caused by APV, 
it is of course not surprisingly that single E. coli infection does not cause clinical 
symptoms (Van de Zande et al., 2001). Only after prior APV infection E. coli 
colonizes the respiratory tract of turkeys and subsequently aggravates the disease 
symptoms caused by the viral infection.  
An important focus in our studies was the reproduction of septicemia and 
mortality as seen in the field. Numerous studies have focused on comparing extra-
intestinal E. coli isolates from colibacillosis-affected poultry with faecal isolates from 
clinically healthy birds, but none of the virulence factors examined (adhesins, 
invasivity in cell cultures, serum survival, iron uptake systems, haemolysins, colicin 
production and toxins), was exclusively associated with extra-intestinal isolates even 
though for some characteristics, significant differences were found (Vandekerchove, 
2004). Previously, it has been shown that the lower respiratory tract (lungs and air 
sacs) is an important site of entrance of E. coli into the bloodstream of birds (Cheville 
and Arp, 1978; Ackermann and Cheville, 1991; Pourbakhsh et al., 1997a). Based on 
the results of the APV/E. coli/O. rhinotracheale triple infection model, we concluded 
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that since E. coli was able to invade the lungs and the air sacs of some birds but still 
was not able to cause colisepticemia, the strain was possibly lacking certain 
characteristics necessary for invasion of the bloodstream. However, in the M. 
gallisepticum/APV/E. coli/O. rhinotracheale mixed infection model, the same E. coli 
strain was in contrast able to cause septicemia. This leads us to believe that, besides 
bacterial virulence factors, host susceptibility and resistance factors, the interactions 
with different pathogens are probably at least as important determinants (Barnes et 
al., 2003, Ley, 2003).  
The hypothesis may be forwarded that infection with mycoplasmas is necessary for E. 
coli to cause septicemia. A first possible explanation for the occurrence of 
colisepticemia may be the debilitating effect of mycoplasmas on the efficiency of 
mucociliary apparatus, resulting in the impaired clearance of E. coli. Further, 
mycoplasmas appear to induce transient immunosuppression. This has been shown 
for M. gallisepticum in turkeys concurrently infected with APV and Avibacterium 
(Haemophilus) gallinarum (Matsuo et al., 1978; Naylor et al., 1992). Ganapathy and 
Bradbury (2003) showed that a virulent strain of M. gallisepticum causes temporary T 
cell suppression in infected chickens. Other reports of immunosuppression in turkeys 
were done for Mycoplasma meleagridis (Ortiz et al., 1981) and Mycoplasma iowae 
(Bradbury, 1984). It is also known that mycoplasmas negatively influence a variety of 
immune responses ranging from complement activation to ingestion by macrophages 
(Simecka et al., 1992), and this may influence the immune response against other 
micro-organisms. Another well-known feature of infection with mycoplasmas is the 
massive attraction of inflammatory cells such as macrophages and heterophils to the 
site of infection (Deiters and Mühlradt, 1999), cells designed to destroy different 
pathogens (Dietert et al., 1991). Results from Pourbakhsh et al. (1997b) showed that 
after intrasaccular inoculation of E. coli in chickens, apparently viable bacteria of 
highly pathogenic isolates, but not low pathogenic ones, were often associated with or 
within macrophages in the air sacs and lungs. They also demonstrated a strong 
correlation between the in vivo pathogenicity and the in vitro ability to resist the 
bactericidal effects of macrophages. Mellata et al. (2003) demonstrated that in vitro 
some virulence factors protected E. coli to the bactericidal effect of phagocytes, 
especially heterophils. Since resident macrophages are very scarce in the avian lungs 
and air sacs, heterophils form the first line of cellular defense against invading 
pathogens and their function could be to restrict bacterial multiplication until 
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subsequent host defenses become active (Toth, 2000; Nganpiep and Maina, 2002; 
Mellata et al., 2003). Mellata et al. (2003) reason that some E. coli strains might 
possess virulence factors to combat this heterophil activity and consequently are able 
to invade more easily. It was shown by Miller et al. (1990) that chicken macrophages 
could phagocytose a virulent E. coli phenotype more efficiently in vitro than an 
avirulent phenotype, but the latter was in contrast cleared more efficiently from the 
circulation. 
In order to successfully infect the conducting airway, primary colonising 
bacteria such as O. rhinotracheale, must overcome the inherent innate immunity of 
the respiratory tract. This includes evading the mucociliary escalator and an 
environment of antimicrobial factors. One of the mechanisms to overcome the 
mucociliary escalator is to directly bind to cilia on host epithelium and this is a 
feature which seems important in the pathogenesis of O. rhinotracheale infections. 
Temple et al. (1998) found in a trial comparing in vitro and in vivo data that the 
Bordetella avium strains that were best able to adhere to tracheal cells in culture, were 
also best capable of colonizing turkey poults in vivo. They state that whereas this 
finding may seem reasonable or even expected, it is remarkable from the standpoint 
of the number of factors coming into play in the in vivo situation, e.g. the onset of the 
immune response. We also tested the adherence of different O. rhinotracheale strains 
to tracheal organ cultures (TOC) after one, three, six and ten hours of incubation, and 
found that, although all O. rhinotracheale strains appeared to adhere to some extent 
to the TOCs, there were obvious differences between some of the tested strains (data 
not shown). We observed differences of about 103 cfu/ml between the best adhering 
strains and the least adhering strains. In a small pilot study we inoculated 15 SPF 
turkeys with the least in vitro adhering O. rhinotracheale strain and compared the 
tracheal adhesion with that of the LMG 9086 type strain which exhibited the best 
adhesion in vitro. Strain LMG 9086 was the strain used in the different experimental 
studies of the present PhD research. We came to the same conclusions as Temple et 
al. (1998), namely that the O. rhinotracheale strain less able to adhere in vitro to 
TOCs also was less capable of colonising live birds. One day after inoculation, the 
least in vitro adhering O. rhinotracheale strain could only be isolated from two of the 
15 birds at very low cfu/ml. In these latter two birds, O. rhinotracheale could only be 
isolated until three and four days after inoculation (means of 2.1 and 2.5 log10cfu/g 
mucus). Temple et al. (1998) also noticed that the ability of an O. rhinotracheale 
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strain to cause disease in vivo fully correlated with its in vitro ability to adhere to 
ciliated tracheal cells. We were, however, not able to evaluate whether the difference 
in adherence would also mean a difference in the disease-causing ability, since our 
reference strain was only able to cause obvious clinical symptoms after APV priming.  
It would be very interesting to identify the adhesins and host-receptors important for 
O. rhinotracheale and whether there are toxins which play a role in the adhesion 
process as has been described for the CyaA toxin and dermonecrotic toxin of B. 
bronchiseptica (Edwards et al., 2005; Vojtova et al., 2007). The contributions of the 
individual adhesins and toxins in ciliary attachment should also be evaluated. This 
might be done by comparing ciliary binding by O. rhinotracheale mutant strains 
deficient in single adhesin or toxin expression. If more insights are obtained in these 
features of the O. rhinotracheale pathogenesis, this could possibly lead to the 
development of preventive or therapeutic targets against primary colonizing bacteria 
such as O. rhinotracheale.  
Based upon the results obtained in our studies it can be assumed that both O. 
rhinotracheale and E. coli are secondary pathogens, an issue which in the literature 
has been a subject for debate. This however does not mean that their importance in 
the field should be underestimated, since it was shown in our experiments that both 
are able to exacerbate the clinical picture and especially the duration of the 
respiratory problems. Dust in poultry houses may contain 105-106 E. coli/g and these 
bacteria can persist for long periods, particularly under dry conditions (Harry, 1964; 
Barnes et al., 2003). Also, Lopes et al. (2002) studied the ability of O. rhinotracheale 
to remain viable in poultry litter at different temperatures, and their results indicated 
that this micro-organism survives in poultry litter for some days, especially at lower 
temperatures. These findings implicate that both these secondary bacterial agents 
pose a real threat for the poultry industry, keeping in mind that infections and 
reinfections with APV and M. gallisepticum do occur. If an outbreak of APV or M. 
gallisepticum takes place when E. coli and/or O. rhinotracheale are present in the 
environment, serious respiratory problems may be encountered with serious 
economical consequences. 
 
Bacterial respiratory infections in poultry require a quick, feasible and 
efficacious antimicrobial treatment, preferably via drinking water. Very inconsistent 
and frequently inadequate results have been obtained with antimicrobial treatment of 
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O. rhinotracheale and E. coli infections in the field (van Empel and Hafez 1999; Chin 
et al., 2003). Several explanations may be cited here, including the variable 
susceptibility of the different bacterial strains (Devriese et al., 1995; Dudouyt et al., 
1995; Hafez, 1996; Roger and Léorat, 1997; Devriese et al., 2001; Barnes et al., 
2003; Vandekerchove, 2004). It is indeed a fact that emerging antimicrobial 
resistance is becoming increasingly a problem in most bacterial species. Furthermore, 
as mentioned above, antimicrobials are frequently used on the off-chance, mainly 
because not enough information is available. This inconsistency in antimicrobial 
treatments is to a great extent due to the fact that, at the beginning of this research, no 
good models were available to evaluate the efficacy of different products. Our 
objectives thus were to compare the clinical effectiveness of different antimicrobial 
compounds under identical trial conditions. 
The above described experimental infection models undoubtedly represent a 
number of advantages. In vitro antimicrobial sensitivity measurements, preferably 
minimal inhibitory concentration (MIC) determinations, can be used to predict the 
clinical outcome of antimicrobial therapy. While these measurements are a good 
indication of the potency of an antimicrobial, they do not provide the type of 
information necessary to determine the optimal drug dose or dosing interval. MIC 
tests additionally tell us hardly anything about the effect of varying drug 
concentrations over time. Therefore, besides in vitro studies, animal infection models 
are needed, since they are effective means of examining the relationship between 
pharmacokinetic and pharmacodynamic parameters and in vivo efficacy (Wright et 
al., 2000). By assessing the effect of antimicrobials on the bacteria directly in the 
target organ(s) the overall efficacy of these antimicrobial agents could be evaluated 
with reasonable accuracy. Also from an ethical view-point and with regard to the 3 R 
(reduction, refinement and replacement) principle (Russell and Burch, 1959), the 
optimized models are interesting: because of the daily tracheal swabbing, a lot of data 
could be obtained from each individual bird without having to sacrifice them, 
allowing good statistical analysis using only a limited number of animals. 
Furthermore, the birds apparently did not suffer from the regular tracheal swabbing. 
In the two studies performed to evaluate the clinical efficacy of different 
antimicrobial therapies for the treatment of single O. rhinotracheale and dual E. 
coli/O. rhinotracheale infection, statistical analysis revealed that recovery from 
respiratory disease was overall most successful after enrofloxacin treatment (three or 
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five days of treatment), followed by five-day florfenicol treatment. Five-day 
treatment with amoxicillin, compared with the untreated group under the 
circumstances adopted in this study, did not cause a significant reduction in any of the 
evaluated parameters. Possible explanations for the observed differences between the 
different antimicrobial products are largely straightforward. Some pharmacokinetic 
characteristics, such as the apparent volume of distribution at steady state (Vd(ss)) and 
the half-life values of the various compounds, may be highlighted to explain the 
obtained results. The bactericidal effect of amoxicillin is possibly impaired because of 
its less efficient distribution throughout the tissues (low Vd(ss)) and in addition its 
quick elimination (low half-life values). Indeed, Prescott reported that although 
amoxicillin offers pharmacokinetic advantages over ampicillin, it still retains to some 
degree the difficulty for attaining that concentration in tissues that is necessary to 
control infections with susceptible Gram-negative bacteria (Prescott, 2000). It appears 
that the Vd(ss) of florfenicol and enrofloxacin is generally higher than that of 
amoxicillin, indicating a better distribution throughout the body tissues. Furthermore, 
the long half-life values for especially enrofloxacin and to a lesser degree for 
florfenicol attribute to the observed differences between enrofloxacin and florfenicol. 
Fraatz et al. (2005) performed a pharmacokinetic study in growing turkeys medicated 
in-water with enrofloxacin, florfenicol and amoxicillin. Antimicrobial concentrations 
were measured in serum, muscle, liver and lung using liquid chromatography coupled 
to tandem mass spectrometry (LC-MS/MS), and, for enrofloxacin in nose and trachea 
tissue, with an agar diffusion bioassay. For the amoxicillin product it was shown that 
it was unstable in the drinking water, leading to a loss of 50% over 24h. Furthermore, 
amoxicillin was shown to be unstable during sample processing, invalidating the 
analytical results for this compound. Their results show that in turkeys medicated via 
drinking water with enrofloxacin, mean enrofloxacin concentrations in the upper 
(nasal tissues and trachea) and lower (lungs) respiratory tract exceeded MIC50 values 
(MIC50 = the average MIC of a susceptible population) for E. coli and P. multocida 
by about 5 to 8 log2 steps (× 25 to 28) and for mycoplasma and O. rhinotracheale by 
about 2 to 4 steps (× 22 to 24). In turkeys treated with florfenicol drug penetration in 
the lower (lungs) respiratory tract appeared to be moderate with concentrations lower 
than the MIC50 values for E. coli, mycoplasma and O. rhinotracheale and similar to 
the MIC50 for P. multocida. They concluded that florfenicol does not distribute as 
well as enrofloxacin in the target tissues. Other results by Knoll et al. (1999) showed 
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that enrofloxacin concentrations were three-fold higher in the tracheal tissues than in 
the plasma (Reinhardt et al., 2005). 
In different experimental groups treated with enrofloxacin or florfenicol, first 
bacteria (O. rhinotracheale and E. coli) appeared to be completely eliminated from 
the trachea (or the amounts were below the detection limit), after which a flare-up 
was seen of bacteria without a rise in the MIC value. Whether this temporary rise in 
bacterial titers in the trachea was due to re-excretion or re-infection from the 
environment could not be determined. Re-infection from the environment appears 
possible, since it has been stated that O. rhinotracheale is able to survive in poultry 
litter for a few days (Lopes et al., 2002) and E. coli bacteria may persist for long 
periods, particularly under dry conditions (Harry, 1964; Barnes et al., 2003).  
In one of the experiments, O. rhinotracheale organisms with an eight-fold 
higher MIC value (from ≤ 0.03 µg/ml to 0.25 µg/ml) of enrofloxacin were isolated in 
the group treated with enrofloxacin for five days, starting two days following 
treatment onset, initially from a single turkey and subsequently from the other 
animals. Concurrently with this, O. rhinotracheale could be re-isolated from the 
trachea, and was present in higher numbers in the turbinates and lungs at five days 
post bacterial inoculation, compared with the almost negative O. rhinotracheale 
counts post treatment in the turkeys treated for three days, but without causing a 
clinical relapse. This represents a typical example of selection of a first-step mutant 
by fluoroquinolones, as already reported in the literature. The in vivo emergence of 
diminished susceptibility or even resistance to fluoroquinolones has already been 
described in chickens for, amongst others, Campylobacter jejuni (McDermott et al., 
2002; Luo et al., 2003; Van Boven et al., 2003), Campylobacter coli (Delsol et al., 
2004), and a resident E. coli microbiota (Barrow et al., 1998). Because of the growing 
concern for public health regarding the emergence of fluoroquinolones-resistant 
zoonotic pathogens, such as Salmonella, enterohemorrhagic E. coli, and 
Campylobacter, it is not surprising that most experiments have focused on these 
pathogens (Zhao et al., 2005). Resistance to fluoroquinolones arises almost 
exclusively by de novo mutation, and is characterized by the gradual accumulation of 
mutations that lower intracellular drug concentration and/or sensitivity of the target 
DNA topoisomerases (Lindgren et al., 2003). With some exceptions, the mutations 
reported to date have been chromosomal. As wild-type bacteria replicate, mistakes 
are made in duplicating the DNA. These mistakes are spontaneous mutations that 
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arise at measurable frequencies usually varying from one in 106 (mutation frequency 
= 10-6) to one in 109 (mutation frequency = 10-9) wild-type cells. Because the number 
of bacteria in an active infection readily exceeds 109, it is likely that in addition to the 
wild-type cells, in large populations, there are already mutant cells present at the site 
of the infection (Pourbakhsh et al., 1997; Sanders, 2001; Drlica and Malik, 2003; 
Wetzstein, 2005). Selection pressure exerted by fluoroquinolone treatment will enrich 
the mutant subpopulation (Sanders, 2001; Drlica and Malik, 2003). Studies involving 
well-characterized single-step mutants have shown that each mutation affecting the 
quinolones most often diminishes susceptibility four- to eight-fold (Sanders, 2001). 
Usually, organisms that are highly susceptible to fluoroquinolones remain within the 
susceptible range after single-step mutations and require multiple mutations before 
clinically relevant resistance becomes apparent (Hooper, 2001; Andriole, 2003). This 
in consequence means that when the concentration obtained in the tissues is only 
slightly above the MIC of the wild-type bacteria, there is a reasonable probability that 
any mutant bacteria will be enriched. This knowledge seems rather worrying, but the 
predictable and stepwise evolution of resistance to the quinolones also has a positive 
side, in that it provides an additional basis on which quinolone may provide effective 
therapy and have a lower chance of selecting resistance (Sanders, 2001). One 
approach for restricting resistance is to avoid conditions that enrich resistant bacterial 
subpopulations. Such conditions have been defined in vitro for fluoroquinolones with 
a variety of bacteria. In general, fluoroquinolone-resistant mutants are enriched when 
drug concentrations fall within a range called the mutant selection window (Drlica, 
2003; Drlica and Malik, 2003). The lower boundary of the window is the minimal 
concentration required to block the growth of wild-type bacteria (since below that 
concentration the mutant cells do not have a growth advantage) and is often 
approximated by the MIC99, the minimal concentration that blocks growth of 99% of 
the cells in a culture (Drlica, 2003). The upper boundary, the mutant prevention 
concentration (MPC), which is the MIC of the least susceptible, single-step mutant 
subpopulation, serves as a guide for antimutant dosing strategies, just as the MIC 
functions in strategies to clear infection of susceptible pathogens. The idea with the 
MPC is that above this concentration, two concurrent resistance mutations must be 
acquired so that bacterial growth could occur, so maintaining drug concentrations 
above the MPC throughout therapy is expected to restrict mutant outgrowth. 
Determination of the MPC is done by plating approximately 1010 bacteria (104-105 
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cfu are usually used for MIC testing) into varying concentrations of the quinolone and 
determining the concentration at which no visible re-growth occurs (Sanders, 2001; 
Wetzstein, 2005). In different experiments where both MIC and MPC were measured 
for different isolates, it was shown that there was a poor correlation between the two 
(Marcusson et al., 2005; Hansen et al., 2006). Doses of antimicrobial that are inside 
the window are expected to enrich resistant mutant subpopulations selectively, 
whereas placing concentrations above the window is expected to restrict selective 
enrichment. Growth of mutants at concentrations above the MPC would require the 
concurrent presence of two mutations conferring fluoroquinolone resistance. Such 
clones may be present in populations of about 1014 cfu (Blondeau et al., 2004), which 
are larger than most bacterial populations in diseased chickens (Wetzstein, 2005). 
This concept seems contradictory with traditional medical teaching, in which one 
thinks that resistant mutants are selectively enriched only at concentrations below 
MIC (Drlica, 2003) in stead of also at concentrations above MIC. By attaining MPC 
conditions in vivo, the enrichment of first-step fluoroquinolone-resistant variants 
should be minimized. Hence, a delay or (ideally) prevention of the emergence of 
fluoroquinolone resistant strains in the field may become feasible (Wetzstein, 2005). 
On the negative side however, it should be noted that MPC have been measured for 
only a few drug–pathogen combinations. First experimental results obtained in a 
rabbit mono-infection model with Streptococcus pneumoniae provided direct 
evidence in support of the MPC concept (Etienne et al., 2004; Wetzstein, 2005). This 
concept provides a hopeful perspective for the future of the fluoroquinolones, being 
able to profit from their many benefits and not having to deal with the concerning 
problem of resistance. More research therefore should be invested in finding dosing 
strategies enabling concentrations above the MPC. This however, may appear 
difficult in the poultry industry, since the current method of medicating is by treating 
the entire flock via water, even though relatively few birds may be ill. This practice 
exposes more organisms to the antimicrobial and therefore is more likely to result in 
the emergence of resistant strains. Additionally this may result in suboptimal dosing 
(for instance when diseased birds drink less) increasing the probability of selecting 
for resistant bacterial strains (Barnes et al., 2003; McDermott et al., 2002). Since 
fluoroquinolones are concentration-dependent antimicrobials, perhaps pulse-dosing 
(administration of the daily dose antimicrobial in a two to four hour period) may be 
an interesting option. If enrofloxacin is given in a pulsed manner, the peak levels in 
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serum and lungs are three- and fourfold higher, respectively, than the steady-state 
concentrations observed in birds dosed continuously throughout the day. In spite of 
results from Charleston et al. (1998) and Froyman and Cooper (2003), showing no 
advantage of pulsed dosing compared with continuous dosing, it still might be 
interesting to look again at this option since it could possibly reduce the resistance 
problem associated with fluoroquinolones. Other options may be the use of 
combinations of agents having different targets or of antimicrobial agents that inhibit 
two different targets with equal efficacy (it would require a bacterium to acquire two 
concurrent mutations for growth; only rarely would resistant mutants be recovered). 
A lot of interesting possibilities lie herein for future research. 
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SUMMARY 
Respiratory problems are one of the main disorders leading to economic 
losses on turkey farms world-wide due to reduced growth, an increased mortality rate, 
high medication costs and a higher number of condemnations at slaughter. They may 
be induced by a variety of viral and bacterial agents, either alone or in combination. 
The pathogenesis of infections with these respiratory disease agents and their mutual 
interactions, are very complex matters which are far from fully unraveled. 
Therapeutic measurements against different bacterial infections are virtually 
entirely based on the administration of antimicrobials, although it is frequently 
observed that the clinical effects of the different antimicrobial products are very 
variable in the field. Very few experimental studies have been focusing on the actual 
in vivo efficacy of different antimicrobials for the treatment of respiratory infections 
in poultry, since often no suitable infection models are available. To extend our 
knowledge on the pathogenesis and control of respiratory infections in turkeys, the 
present thesis was initiated. Ornithobacterium rhinotracheale, Escherichia coli, 
Mycoplasma gallisepticum and avian metapneumovirus (APV) were studied, being 
important respiratory pathogens, with a worldwide distribution. 
 
In the first part (part 1.1.) of chapter 1, a review is given on the anatomical 
and physiological properties of the avian respiratory tract and on its defense 
mechanisms. In the second part of chapter 1 (part 1.2.), the most important literature 
data are given on four important turkey respiratory pathogens, i.e. APV, O. 
rhinotracheale, E. coli and M. gallisepticum. Different aspects are reviewed for each 
pathogen, i.e. etiology, epidemiology, pathogenesis, clinical findings and lesions, 
diagnosis, treatment and control measures. Finally, the experimental studies which 
have been performed in turkeys to elucidate the effects of combined action of viruses 
and other micro-organisms are summarized. 
 
Chapter 2 describes the scientific aims of the study. Our main objective was 
to firstly develop experimental infection models using these agents and to, in a second 
stage, use these models to study the pathogenesis and to compare the clinical efficacy 
of different antimicrobial compounds. 
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Chapter 3 describes the performed experimental studies. In a first part (part 
3.1.), the development of different in vivo infection models for the reproduction of 
clinical respiratory disease in turkeys is discussed.  
In a first study (3.1.1.), three-week-old SPF turkeys were inoculated 
oculonasally with either APV, O. rhinotracheale or both agents using two different 
time intervals (three or five days) between infections. The birds were observed 
clinically on a daily basis and swabbed intratracheally at regular intervals for 
bacteriological examination. Birds were euthanised at different time points, examined 
for gross lesions at necropsy and samples of the turbinates, trachea, lungs, air sacs, 
heart, pericardium and liver were taken for bacteriological and/or histological 
examination.  
The results showed that, under the circumstances used in this study, O. 
rhinotracheale on itself was able to adhere to and colonize the upper respiratory tract 
of turkeys, but without viral priming was not capable of inducing respiratory disease. 
Combined APV/O. rhinotracheale infections, regardless of the time interval between 
inoculations, resulted in overt clinical signs and a longer persistence of O. 
rhinotracheale in the respiratory tract and aggravated the macroscopic and 
histological lesions in comparison to the groups given single infections. APV priming 
facilitated infection of the lungs and was necessary to allow O. rhinotracheale to 
infect the air sacs. 
In a second study (3.1.2.), turkeys were inoculated oculonasally with either 
APV, APV/O. rhinotracheale, APV/E. coli O2:K1, APV/E. coli/O. rhinotracheale or 
APV/O. rhinotracheale/E. coli with a three days interval between viral and bacterial 
inoculation and approximately eight hours between the two bacterial inoculations. 
The animals were observed clinically and swabbed intratracheally on a daily basis.  
Five and ten birds were euthanised at five and fifteen days post bacterial inoculation 
(dpbi), respectively, and examined for gross lesions at necropsy. Samples of the 
turbinates, sinuses, trachea, lungs, air sacs, heart, pericardium and liver were taken for 
bacteriological and/or histological examination. 
It was demonstrated that combined APV, E. coli and O. rhinotracheale infections 
resulted in more severe and longer persisting clinical signs and more severe 
macroscopic and microscopic lesions compared to dual APV/O. rhinotracheale and 
APV/E. coli infections, and the latter produced more severe disease than the single 
APV infection. It was shown that both O. rhinotracheale and E. coli were, after APV 
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priming, able to colonize the upper respiratory tract and invade the lower respiratory 
tract of turkeys, although the level of O. rhinotracheale and E. coli multiplication in 
the respiratory organs did not differ greatly between the dual and triple infection 
groups. However, after triple infection, E. coli could be isolated from the trachea two 
days longer in comparison with the dually infected group. Furthermore, it was shown 
that combined action of O. rhinotracheale and E. coli enhanced the invasion of O. 
rhinotracheale but not of E. coli in the non-respiratory internal organs, although it 
should be noted that at necropsy no signs of septicemia were seen. These findings all 
endorsed our conclusions that E. coli and O. rhinotracheale exercise an additive 
pathogenic effect in the reproduction of respiratory disease triggered by APV. 
In a third study (3.1.3.), approximately the same set-up was used, but an 
additional intratracheal priming with M. gallisepticum was performed. The turkeys 
were inoculated with either M. gallisepticum, M. gallisepticum/APV, M. 
gallisepticum/APV/O. rhinotracheale or M. gallisepticum/APV/E. coli/O. 
rhinotracheale with a ten days interval between M. gallisepticum and APV 
inoculations, a three days interval between viral and E. coli and/or O. rhinotracheale 
inoculations, and an eight hour interval between E. coli and O. rhinotracheale 
inoculations. Again, the animals were observed clinically on a daily basis (upper and 
lower respiratory tract symptoms), swabbed intratracheally on a regular basis. Five 
birds of each group were sacrificed 18 days after M. gallisepticum inoculation and the 
remaining birds at the end of the experimental period, i.e. 33 days after M. 
gallisepticum inoculation. The birds were examined for gross lesions at necropsy and 
samples of the turbinates, sinuses, trachea, lungs, air sacs, heart, pericardium and liver 
were taken for bacteriological and/or histological examination.  
The results obtained in this study clearly indicate a marked synergistic connection 
between M. gallisepticum, APV, O. rhinotracheale and E. coli. Evidences for this 
statement were the higher mortality rates and the clinical symptoms which were 
clearly aggravated whenever the birds were infected with an additional pathogen. 
This was also reflected in the more aggravated necropsy findings and microscopical 
lesions. M. gallisepticum exerted an important impeding effect on the clearance of O. 
rhinotracheale and E. coli, especially from the upper respiratory tract. A very 
conspicuous feature was that in the M. gallisepticum/APV/E. coli/O. rhinotracheale 
group, signs of colisepticemia (perihepatitis and/or pericarditis) were seen at 
necropsy. This was a feature not encountered in the previous infection model using E. 
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coli. This finding endorses the statements that compared with bacterial virulence 
factors, pathogenic interactions are probably at least as important determinants of 
colibacillosis occurrence. 
In the second part of chapter 3 (part 3.2.) we evaluated the clinical efficacy of 
different antimicrobials (i.e. enrofloxacin, amoxicillin and florfenicol) for treatment 
of respiratory disease in turkeys. We evaluated this in the APV/O. rhinotracheale and 
APV/O. rhinotracheale/E. coli infection models, based on clinical, bacteriological 
and histopathological examinations using similar techniques and criteria. 
Antimicrobial drinking water treatments (continuous dosing) were initiated at 24 h 
after the last bacterial challenge. 
In the first study (3.2.1.) the efficacy of drinking-water administration of 
enrofloxacin for three and five days, amoxicillin for five days and florfenicol for five 
days for the treatment of respiratory disease induced by an experimental APV/O. 
rhinotracheale infection (three day interval) in turkeys was assessed. After 
inoculation, the birds were scored daily for clinical signs, tracheal swabs were also 
taken on a daily basis and the animals were weighed at different time points. Five 
birds were euthanised and examined for macroscopic lesions at necropsy at five dpbi, 
and the remainder at 15 dpbi. Samples of the turbinates, trachea, lungs, air sacs, heart 
and pericardium were collected for bacteriological and/or histological examination.  
Recovery from respiratory disease caused by an APV/O. rhinotracheale dual 
infection was most successful after enrofloxacin treatment, irrespective of treatment 
duration, followed by florfenicol. Treatment with amoxicillin was not efficacious, 
since compared with the non-treated group, it did not cause a significant reduction of 
any of the evaluated parameters. Although florfenicol treatment significantly 
diminished the O. rhinotracheale multiplication in the trachea and lungs, this did not 
seem to result in a significant reduction of clinical symptoms. Compared with the 
non-treated control group, clinical signs as well as O. rhinotracheale multiplication in 
the respiratory tract were significantly reduced by enrofloxacin treatment for three 
and five days. In the group treated with enrofloxacin for five days, O. rhinotracheale 
organisms with an eight-fold higher MIC value (from ≤ 0.03 to 0.25 µg/ml), were 
isolated starting two days following treatment onset initially from a single turkey and 
subsequently from the other animals. This increase in enrofloxacin MIC value 
concurred with a slight O. rhinotracheale re-excretion in the trachea, also reflected in 
the higher counts in different organs (turbinates and lungs) at five dpbi, compared to 
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the almost negative O. rhinotracheale counts post treatment in the turkeys treated for 
three days.  
In an additional study (3.2.2.) we decided to look further into the genetic 
background of this change in antimicrobial susceptibility. In addition to the O. 
rhinotracheale isolates derived from the experimentally infected animals, other O. 
rhinotracheale field strains with different in vitro sensitivity levels for enrofloxacin, 
were included in this study for comparative purposes. In the isolates showing reduced 
susceptibility following experimental enrofloxacin treatment (increase in MIC from ≤ 
0.03 to 0.25 µg/ml), molecular analysis revealed a constantly recurring point mutation 
(G → T) at nucleic acid position 646 (E. coli numbering) of gyrA resulting in an 
amino acid change from aspartic acid to tyrosine at position 87 of the GyrA subunit, 
which is a known hot spot for fluoroquinolone resistance. The results obtained in the 
study hence indicated that a single course of enrofloxacin treatment may contribute to 
the in vivo selection of the first mutant with reduced fluoroquinolone susceptibility in 
O. rhinotracheale. In the field strains that were either less susceptible or, 
occasionally, resistant to enrofloxacin, point mutations had occurred in amino acids at 
positions 83 (serine) or 87 (aspartic acid) of the GyrA subunit. 
In a final study (3.2.3.) similar techniques and criteria were used in order to 
assess the efficacy of drinking-water administration of enrofloxacin for three and five 
days, amoxicillin for five days and florfenicol for five days for the treatment of 
respiratory disease caused by APV/E. coli/O. rhinotracheale triple infection. The 
enrofloxacin treatments again proved to be most efficacious, regardless of treatment 
duration, followed by the florfenicol treatment. Compared with the non-treated group, 
clinical signs as well as E. coli and O. rhinotracheale multiplication in the respiratory 
tract were significantly reduced by both enrofloxacin treatments and the florfenicol 
treatment, with the enrofloxacin treatments showing significantly better reductions 
than the florfenicol treatment. Five-day treatment with amoxicillin, compared with 
the untreated group, did not cause a significant reduction in any of the evaluated 
parameters. 
 
Chapter 4: Based upon the results obtained in our studies it can be assumed 
that both O. rhinotracheale and E. coli are important respiratory pathogens, since 
they were both able to markedly exacerbate the clinical picture caused by APV and 
M. gallisepticum infections. Both O. rhinotracheale and E. coli are respiratory 
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pathogens that are able to cause similar disease symptoms and lesions, but they 
intrinsically have different ways of acting. O. rhinotracheale has a very clear tropism 
for the healthy respiratory system, in contrast with E. coli which specifically needs an 
APV-infected respiratory system in order to sustain its presence. Furthermore our 
observations support the idea that both O. rhinotracheale and E. coli should be 
considered more as secondary pathogens. It also became clear that M. gallisepticum 
exerted an important impeding effect on the clearance of O. rhinotracheale and E. 
coli, especially from the upper respiratory tract. Also the observation that 
colisepticemia could only be provoked when infection with M. gallisepticum was 
present, emphasises the statement that compared with bacterial virulence factors, 
pathogenic interactions are probably at least as important determinants of 
colibacillosis occurrence. Keeping in mind the triggering effect of APV and M. 
gallisepticum on infection with O. rhinotracheale and E. coli, and keeping in mind 
that infections with APV and M. gallisepticum do occur, both O. rhinotracheale and 
E. coli should remain to be considered as threats to the poultry industry. If an 
outbreak of APV or M. gallisepticum takes place when E. coli and/or O. 
rhinotracheale are present in the environment, serious respiratory problems may be 
encountered. In conclusion, once again the complexity of the respiratory disease 
complex in turkeys has been indicated. 
In the two studies performed to evaluate the clinical efficacy of different 
antimicrobial therapies for the treatment of single O. rhinotracheale and dual E. 
coli/O. rhinotracheale infection, it was shown that recovery from respiratory disease 
was overall most successful after enrofloxacin treatment. Fluoroquinolones, like all 
antimicrobial compounds, should however be used judicious, amongst others in order 
to counteract the spread of antimicrobial resistance. In our research it was established 
that a treatment with enrofloxacin can lead to the selection of an O. rhinotracheale 
mutant with decreased sensitivity to fluoroquinolones. One approach for restricting 
resistance towards fluoroquinolones is to avoid conditions that enrich these mutants. 
In this respect it should be strived for that during a treatment, the fluoroquinolone 
concentrations in the blood and tissues remain sufficiently high, so that also mutants 
with diminished sensitivity will be inhibited and will not be selected. 
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SAMENVATTING 
Ademhalingsproblemen op kalkoenbedrijven leiden wereldwijd tot grote 
economische verliezen, omwille van verminderde groei, verhoogde sterftecijfers, 
hogere medicatiekosten en een hoger aantal afkeuringen bij verwerking. Zij kunnen 
geïnduceerd worden door diverse virale en bacteriële agentia, ofwel afzonderlijk 
ofwel in combinatie met elkaar. De pathogenese van infecties met deze respiratoire 
ziektekiemen en hun onderlinge interacties zijn zeer complex en verre van ontrafeld. 
De behandeling van bacteriële infecties van het ademhalingsstelsel bij 
kalkoenen is bijna volledig gebaseerd op de toediening van antimicrobiële middelen. 
In de praktijk wordt evenwel opgemerkt dat de klinische effecten van antimicrobiële 
therapie zeer variabel zijn. Het aantal experimentele studies waarin de in vivo 
efficaciteit van antimicrobiële middelen voor de behandeling van 
ademhalingsaandoeningen bij pluimvee bestudeerd werd, is zeer beperkt. De 
belangrijkste reden hiervoor is het ontbreken van geschikte infectiemodellen. Om 
onze kennis uit te breiden over de pathogenese en de controle van 
ademhalingsaandoeningen bij pluimvee werd dit thesisonderzoek aangevat. 
Ornithobacterium rhinotracheale, Escherichia coli, Mycoplasma gallisepticum en 
aviair metapneumovirus (APV) werden bestudeerd aangezien zij belangrijke 
respiratoire pathogenen zijn met een wereldwijde verspreiding.  
 
In het eerste deel (deel 1.1.) van hoofdstuk 1 wordt een overzicht gegeven 
van de anatomie en fysiologie van het ademhalingsstelsel bij vogels. Ook de 
afweermechanismen die hier aanwezig zijn, worden besproken. Hierbij wordt eerst 
aandacht besteed aan de aangeboren afweer en daarna wordt ingegaan op verworven 
immuniteit. In het tweede deel van hoofdstuk 1 (deel 1.2.), worden  de belangrijkste 
gegevens uit de literatuur weergegeven betreffende vier belangrijke 
ademhalingspathogenen bij kalkoenen, namelijk APV, O. rhinotracheale, E. coli en 
M. gallisepticum. Verschillende aspecten worden besproken voor elke pathogeen 
agens, namelijk etiologie, epidemiologie, pathogenese, klinische bevindingen, letsels, 
diagnose, behandeling en preventie. Ten slotte wordt besproken welke experimentele 
studies er reeds werden uitgevoerd bij kalkoenen om betere inzichten te bekomen in 
de effecten van gecombineerde actie van virussen en andere micro-organismen.   
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Hoofdstuk 2 beschrijft de wetenschappelijke doelstellingen van de studie. 
Een eerste objectief was het op punt stellen van experimentele infectiemodellen 
waarmee ademhalingsproblemen die veroorzaakt worden door infecties met APV, O. 
rhinotracheale, E. coli en M. gallisepticum, konden gereproduceerd worden. Deze 
modellen werden daarna gebruikt om de klinische efficaciteit van verschillende 
antimicrobiële middelen te vergelijken. 
 
Hoofdstuk 3 beschrijft de uitgevoerde experimentele studies. Hierbij wordt 
vooreerst (deel 3.1.) de ontwikkeling besproken van verschillende in vivo 
infectiemodellen voor het reproduceren van klinische ademhalingsproblemen bij 
kalkoenen.  
In een eerste studie (3.1.1.) werden drie weken oude SPF kalkoenen 
oculonasaal geïnoculeerd met ofwel enkel APV, enkel O. rhinotracheale of eerst met 
APV en drie of vijf dagen later met O. rhinotracheale. De dieren werden dagelijks 
klinisch onderzocht en op regelmatige tijdstippen werden tracheale swabs genomen 
voor bacteriologisch en virologisch onderzoek. Op verschillende tijdstippen werden 
kalkoenen geëuthanaseerd. De aanwezigheid van macroscopische letsels werd 
geëvalueerd en er werden stalen genomen van conchae, trachea, longen, luchtzakken, 
hart, pericard en lever voor bacteriologisch en/of histologisch onderzoek.  
De resultaten toonden aan dat, onder de omstandigheden van deze studie, O. 
rhinotracheale op zichzelf in staat was vast te hechten aan de bovenste 
ademhalingswegen van kalkoenen en deze ook te koloniseren, maar zonder 
voorafgaande infectie met APV, werden geen ademhalingsstoornissen waargenomen. 
Gecombineerde APV/O. rhinotracheale infecties, onafhankelijk van het tijdsinterval 
tussen de inoculaties, resulteerden daarentegen in duidelijke klinische symptomen, 
een langere persistentie van O. rhinotracheale in de ademhalingswegen en in een 
toename van de macroscopische en  histologische letsels in vergelijking met de 
groepen die slechts enkelvoudige infecties hadden gekregen. Een voorafgaande 
infectie met APV vergemakkelijkte ook het aanslaan van O. rhinotracheale ter hoogte 
van de longen en bleek noodzakelijk om O. rhinotracheale toe te laten de luchtzakken 
te infecteren. 
In een tweede studie (3.1.2.) werden kalkoenen oculonasaal geïnoculeerd met 
ofwel APV, APV/O. rhinotracheale, APV/E. coli O2:K1, APV/E. coli/O. 
rhinotracheale of APV/O. rhinotracheale/E. coli met een interval van drie dagen 
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tussen virale en bacteriële inoculatie en ongeveer 8u tussen de inoculaties met de 
twee bacteriën. De dieren werden dagelijks klinisch onderzocht en hun tracheas 
bemonsterd. Op verchillende tijdstippen werden vogels geëuthanaseerd, de 
macroscopische letsels bekeken bij necropsie en verschillende stalen genomen voor 
bacteriologisch en/of histologisch onderzoek. 
Er werd aangetoond dat gecombineerde APV, E. coli en O. rhinotracheale infecties 
resulteerden in ernstigere en langer persisterende klinische symptomen en ernstigere 
macroscopische en microscopische letsels vergeleken met de dubbele APV/O. 
rhinotracheale en APV/E. coli infecties. Deze dubbele infecties veroorzaakten op hun 
beurt ernstigere ziekte dan de enkelvoudige APV infectie. Zowel O. rhinotracheale 
als E. coli waren na een voorafgaande infectie met APV in staat om de bovenste 
ademhalingswegen van kalkoenen te koloniseren en de diepere luchtwegen te 
invaderen, alhoewel het niveau van O. rhinotracheale en E. coli vermeerdering in de 
respiratoire organen niet veel verschilde tussen de dubbele en driedubbele 
infectiegroepen. Na drievoudige infectie, kon E. coli twee dagen langer geïsoleerd 
worden uit de trachea in vergelijking met de dubbel geïnfecteerde groep. Voorts werd 
er aangetoond dat de gecombineerde actie van O. rhinotracheale en E. coli de invasie 
van O. rhinotracheale, maar niet van E. coli, in de niet-respiratoire organen in de 
hand werkte, alhoewel er bij necropsie geen tekenen van septicemie werden gezien. 
Al deze bevindingen ondersteunen onze conclusie dat E. coli en O. rhinotracheale 
een additief pathogeen effect uitoefenen in de ademhalingsziekte uitgelokt door APV.  
In een derde studie (3.1.3.) werd ongeveer dezelfde proefopzet gebruikt, maar 
een additionele intratracheale inoculatie met M. gallisepticum werd uitgevoerd. De 
kalkoenen werden geïnoculeerd met ofwel M. gallisepticum, M. gallisepticum/APV, 
M. gallisepticum/APV/O. rhinotracheale of M. gallisepticum/APV/E. coli/O. 
rhinotracheale met tien dagen interval tussen de M. gallisepticum en APV 
inoculaties, drie dagen interval tussen de virale en E. coli en/of O. rhinotracheale 
inoculaties, en acht uur interval tussen de E. coli en O. rhinotracheale inoculaties. 
Ook nu werden de dieren dagelijks klinisch onderzocht op het voorkomen van 
ademhalingsstoornissen, en op regelmatige tijdstippen intratracheaal bemonsterd. Na 
euthanasie, werden de kalkoenen onderzocht op aanwezigheid van macroscopische 
letsels en verschillende stalen werden genomen voor bacteriologisch en/of 
histologisch onderzoek.  
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De resultaten bekomen in deze studie geven aan dat er een duidelijke synergestische 
werking bestaat tussen M. gallisepticum, APV, O. rhinotracheale en E. coli. Dit werd 
aangetoond door de hogere sterftecijfers en ergere klinische symptomen bij dieren die 
geïnfecteerd werden met een extra pathogeen agens. Dit werd ook gereflecteerd in de 
ergere bevindingen bij necropsie en ergere microscopische letsels. M. gallisepticum 
oefende een belangrijk belemmerend effect uit op de verwijdering van O. 
rhinotracheale en E. coli, voornamelijk uit de bovenste ademhalingswegen. Een zeer 
opvallende bevinding was dat in de M. gallisepticum/APV/E. coli/O. rhinotracheale 
groep tekenen van E. coli septicemie (perihepatitis en/of pericarditis) gezien werden 
bij necropsie. Dit werd niet vastgesteld in het vorige infectiemodel met E. coli. Deze 
bevinding ondersteunt de hypothese dat het al dan niet tot uiting komen van 
colibacillose niet enkel afhankelijk is van de virulentiefactoren van de E. coli stam 
waarmee dieren geïnfecteerd worden, maar dat interacties met andere pathogene 
agentia op zijn minst even belangrijk zijn.  
 
In het tweede deel van hoofdstuk 3 (deel 3.2.) werd de klinische efficaciteit 
van drinkwatermedicatie met verschillende antimicrobiële middelen (enrofloxacine, 
amoxicilline en florfenicol) voor de behandeling van ademhalingsziekten bij 
kalkoenen onderzocht. Hierbij werd gebruik gemaakt van de APV/O. rhinotracheale 
en APV/O. rhinotracheale/E. coli infectiemodellen. Voor het beoordelen van de 
efficaciteit werden zowel klinische, bacteriologische en histopathologische 
parameters gebruikt. De antimicrobiële drinkwaterbehandelingen (continue dosering) 
werden gestart 24u na de laatste bacteriële inoculatie. 
In een eerste studie (3.2.1.) werd de efficaciteit beoordeeld van 
drinkwatertoediening van enrofloxacine gedurende drie en vijf dagen, amoxicilline 
gedurende vijf dagen en florfenicol gedurende vijf dagen voor de behandeling van 
ademhalingsproblemen bij kalkoenen veroorzaakt door een experimentele APV/O. 
rhinotracheale infectie (drie dagen interval). Na de infectie werden van de vogels 
dagelijks tracheaal swabs verzameld voor bacteriologisch (en virologisch) onderzoek. 
De dieren werden ook dagelijks gescoord voor de ergheid van de klinische tekenen en 
op verschillende tijdstippen werden ze gewogen. Vijf dieren werden geëuthanaseerd 
en onderzocht voor macroscopische letsels op vijf dagen na inoculatie met O. 
rhinotracheale en de overblijvende dieren op vijftien dagen na deze inoculatie. Stalen 
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van conchae, trachea, longen, luchtzakken, hart en pericard werden verzameld voor 
bacteriologisch en/of histologisch onderzoek.  
Herstel van de respiratoire ziekte veroorzaakt door de APV/O. rhinotracheale 
dubbele infectie was het meest succesvol na behandeling met enrofloxacine, 
onafhankelijk van de behandelingsduur, gevolgd door behandeling met florfenicol. 
Behandeling met amoxicilline bleek niet doeltreffend, aangezien vergeleken met de 
niet-behandelde controle groep, er geen significante reductie werd gezien van de 
geëvalueerde parameters. Alhoewel behandeling met florfenicol de O. rhinotracheale 
vermeerdering in de trachea en longen significant verminderde, bleek dit toch niet te 
resulteren in een significante vermindering van de klinische symptomen. Vergeleken 
met de niet-behandelde controlegroep, werden zowel de klinische symptomen als de 
O. rhinotracheale vermeerdering in de ademhalingswegen significant gereduceerd 
door behandeling met enrofloxacine gedurende drie en vijf dagen. In de groep 
behandeld met enrofloxacine gedurende vijf dagen, werd O. rhinotracheale terug 
uitgescheiden in de trachea vanaf twee dagen na de aanvang van de behandeling, eerst 
bij een enkele kalkoen maar vervolgens ook bij de andere dieren. In deze groep was 
het aantal kolonie vormende eenheden  O. rhinotracheale per gram conchae- en 
longweefsel ook hoger op vijf dagen na bacteriële infectie, vergeleken met de bijna 
negatieve O. rhinotracheale tellingen na behandeling van de kalkoenen met 
enrofloxacine gedurende drie dagen. Voor de O. rhinotracheale organismen die 
geïsoleerd werden in de groep die gedurende vijf dagen behandeld werd,  was de 
minimum inhibitorische concentratie (MIC) van enrofloxacine achtmaal hoger 
(0.25µg/ml) dan voor de andere O. rhinotracheale isolaten (≤ 0.03µg/ml). Deze 
toename in enrofloxacine MIC waarde lag welliswaar nog steeds onder het resistentie 
breekpunt (2 µg/ml), maar duidt toch op opbouw van verworven resistentie.  
In een additionele studie (3.2.2.) werd dieper ingegaan op de genetische 
achtergrond van deze verandering in antimicrobiële gevoeligheid. Naast de O. 
rhinotracheale isolaten verzameld van de experimenteel geïnfecteerde dieren, 
werden, ter vergelijking, ook andere O. rhinotracheale veldstammen ingesloten met 
verschillende in vitro gevoeligheidsniveaus voor enrofloxacine. In deze veldstammen 
die ofwel veminderd gevoelig ofwel resistent aan enrofloxacine waren, hadden 
puntmutaties plaatsgevonden in de aminozuren op posities 83 (serine) of 87 
(aspargine zuur) van de GyrA subunit. Bij de isolaten met verminderde gevoeligheid 
na experimentele enrofloxacine behandeling (toename in MIC van ≤0.03 tot 0.25 
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µg/ml), toonde moleculaire analyse een punt mutatie (G → T) aan op nucleïnezuur 
positie 646 (E. coli nummering) van gyrA resulterend in een aminozuur verandering 
van aspargine zuur naar tyrosine op positie 87 van de GyrA subunit. Dit is een 
gekende “hot spot” voor fluoroquinolone resistentie. De resultaten bekomen in deze 
studies tonen dus duidelijk aan dat een enkele enrofloxacine behandeling kan 
bijdragen tot de in vivo selectie van een mutant met verminderde fluoroquinolone 
gevoeligheid in O. rhinotracheale. 
In een laatste studie (3.2.3.) werden dezelfde technieken en criteria gebruikt 
om de efficaciteit te beoordelen van drinkwatertoediening van enrofloxacine 
gedurende drie en vijf dagen, amoxicilline gedurende vijf dagen en florfenicol 
gedurende vijf dagen voor de behandeling van ademhalingsproblemen veroorzaakt 
door APV/E. coli/O. rhinotracheale infecties. De enrofloxacine behandelingen, 
onafhankelijk van de behandelingsduur, bleken opnieuw het meest doeltreffend, 
gevolgd door de florfenicol behandeling. Vergeleken met de niet-behandelde groep, 
werden klinische symptomen, alsook de E. coli en O. rhinotracheale vermeerdering 
in de ademhalingswegen significant gereduceerd door beide enrofloxacine 
behandelingen en de florfenicol behandeling, met bij de enrofloxacine behandelingen 
significant betere reducties dan bij de florfenicol behandeling. Behandeling met 
amoxicilline gedurende vijf dagen bleek, in vergelijking met de niet-behandelde 
controlegroep, geen significante reductie te geven van de geëvalueerde parameters. 
 
In hoofdstuk 4 worden de resultaten van de verschillende studies globaal 
bediscussieerd. Uit deze studies blijkt dat zowel O. rhinotracheale als E. coli 
belangrijke respiratoire pathogenen zijn bij kalkoenen, aangezien beide in staat waren 
om zeer duidelijk het klinisch beeld veroorzaakt door APV en M. gallisepticum 
infecties te verergeren. Alhoewel O. rhinotracheale en E. coli hierbij gelijkaardige 
ziektesymptomen en lesies veroorzaken, zijn er toch ook duidelijke verschillen. O. 
rhinotracheale heeft klaarblijkelijk een tropisme voor de gezonde ademhalingswegen, 
in tegenstelling tot E. coli die een APV-geïnfecteerd ademhalingsstelsel nodig heeft 
om aanwezig te kunnen blijven. Voorts ondersteunen onze observaties het idee dat 
zowel O. rhinotracheale als E. coli eerder moeten beschouwd worden als secundaire 
pathogenen. Verder werd het ook duidelijk dat M. gallisepticum een belangrijk 
belemmerend effect uitoefende op de verwijdering van O. rhinotracheale en E. coli, 
vooral uit de bovenste ademhalingswegen. De observatie dat een E. coli septicemie 
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enkel kon worden uitgelokt wanneer de dieren ook geïnfecteerd waren met M. 
gallisepticum, duidt er op dat menginfecties met verschillende pathogene agentia een 
heel belangrijke rol spelen bij het tot uiting komen van  colibacillose bij pluimvee. 
Zowel  O. rhinotracheale als E. coli dienen beschouwd te worden als bedreigingen 
voor de pluimvee-industrie. Indien deze agentia aanwezig zijn wanneer kalkoenen 
geïnfecteerd worden met APV of M. gallisepticum, kunnen ernstige 
ademhalingsproblemen worden verwacht. Als algemene conclusie kan gesteld 
worden dat ademhalingsproblemen bij kalkoenen bijzonder complex zijn.  
In de twee studies uitgevoerd om de efficaciteit van verschillende antimicrobiële 
middelen te evalueren voor de behandeling van O. rhinotracheale en E. coli/O. 
rhinotracheale infecties, werden de beste resultaten bekomen met enrofloxacine. 
Fluoroquinolones, zoals trouwens alle antimicrobiële middelen, moeten evenwel 
oordeelkundig gebruikt worden, onder andere om verspreiding van antimicrobiële 
resistentie tegen te gaan. In ons onderzoek werd trouwens vastgesteld dat een 
behandeling met enrofloxacine kan leiden tot het uitselecteren van een O. 
rhinotracheale mutant met verminderde gevoeligheid voor fluoroquinolones. Een 
benadering voor het beperken van resistentie tegenover fluoroquinolones is het 
vermijden van omstandigheden die dergelijke mutanten aanrijken. Hierbij moet er 
naar gestreefd worden dat gedurende een behandeling, de fluoroquinolone 
concentraties in het bloed en de weefsels voldoende hoog blijven, zodat ook mutanten 
met verminderde gevoeligheid toch geïnhibeerd worden en niet geselecteerd worden.  
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aan iedereen die mij heeft geholpen met platen gieten, kalkoenen opensnijden, 
vasthouden en euthanaseren, bloed nemen, stalen nemen, epjes vullen, ... een 
 208
Dankwoord 
____________________________________________________________________ 
eindeloze lijst weliswaar... Bedankt Arlette, Sofie, Serge, Venessa, Gunter, Jurgen, 
Dieter, Koen, Marleen, Karolien, Nathalie, Christian, Johan, Delphine, Julien, Paul, 
Anneke, Rosalie, Renzo, Veerle, Jules, Isabel, ... niet alleen voor jullie hulp, maar 
ook voor de leuke tijd en toffe babbels.  
Hetzelfde ook voor de andere collega’s, ook vanuit deze hoek heb ik veel hulp, steun 
en vriendschap gekregen: Kathleen, Ellen, Margo, Lotte, Leen, Inne, Venessa, Emma, 
Anouk, Evelyne, Dries, Lies, Jana, Els, Kim, Katleen, Lieve, Koen, Frank, Filip, 
Manuelle, Ann, Eef, Bram, Griet, Eef, Ingrid, Anja, Linn, nen dikke merci en nog 
veel succes allemaal.  
Hilde en Liesbeth, jullie verdienen een apart woordje. ‘k Vind jullie allebei 
toffe meiden, ik ben blij dat we samen op de bureau zaten, een perfecte combinatie 
van werk en op tijd en stond een ontspannende babbel. Hilde, natuurlijk vooral 
proficiat met je komende spruit. Je gaat dat goed doen, geniet ervan. Liesbeth, ik heb 
ongelooflijke bewondering voor jouw inzet en karakter, veel succes in je nieuwe 
avontuur. Ik heb veel aan jullie beiden gehad en veel van jullie geleerd, we blijven in 
contact. An, je hebt de fakkel van mij overgenomen. Veel succes, ik zie en hoor wel 
dat je het goed doet.  
Ik mag natuurlijk ook de mensen van de dienst virologie niet vergeten, 
Fernand, Geert, Chris, Lieve, Chantal, Mieke, Gert, Dirk, bedankt. Alhoewel ik maar 
met perioden bij jullie op ’t labo zat, stonden jullie toch altijd voor mij klaar. Carine, 
een speciaal bedankje voor jou, om mij de beginselen bij te brengen van 
trachearingetjes enzo, maar vooral voor je luisterend oor. Ik vind je een super madam. 
Filip, Els, Nick, Kalina, Hannah, Konstantinos, Sarah, An, Annelies, Annick, Karen, 
... ik ken niet iedereen van jullie zo goed als ik zou willen, maar ’t was toch tof.  
Magda, ik zou je niet kunnen vergeten. Ik ken weinig mensen met zo veel 
inzet, moed en kracht. Het was een leuke ervaring om met jou samen te werken en het 
was een geruststelling te weten dat jij mee een oogje in het zeil hield voor mijn 
kalkoentjes. 
Al deze mensen hebben gezorgd voor het allerbelangrijkste, een toffe, 
gezonde werksfeer. Ik ben er als geen ander van overtuigd dat je goed voelen op je 
werk van ongelooflijk belang is. ’t Was altijd leuk om ’s middags eventjes gas terug 
te nemen en gezellig samen te eten in de resto of in de keuken. Serge, je staat 
waarschijnlijk zo in elke doctoraatsthesis, maar bedankt voor je toffe animatie en 
voor je verfstripper (onze trap had er anders nooit zo goed uitgezien).  
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Dankwoord 
____________________________________________________________________ 
Natuurlijk mag ik ook de mensen van mijn nieuwe avontuur niet vergeten. 
Aan alle nieuwe collega’s bij Alpharma, we zijn goed gestart, en ik hoop dat we nog 
vele leuke en (zo hoort dat nu eenmaal in de industrie) succesvolle jaren mogen 
beleven.  Karl, bedankt om “een onervaren, jonge snotneus als ik” deze kans te geven. 
Maarten, je weet wat je betekent voor mij, bedankt voor alles wat je me hebt geleerd 
en de deuren die je voor me hebt geopend. Dré, bedankt om er te zijn en voor je 
goede raad en babbels. Ge zijt nen toffe. Dieter, onze nieuwste aanwinst, ik ben blij 
dat je ons “technical clubje” bent komen vervoegen, het feit dat ik je al kende van de 
bacteriologie is alleen maar meegenomen. We gaan met z’n allen nog veel lol hebben 
en ook veel mooie dingen realiseren. Ook mijn andere “dichte” collega’s, Stéphane, 
Sarah, Erik, Frederika, Katelijne, Joost, Davy, Bob, Jean-François, en de rest, bedankt 
voor de leuke werksfeer. 
 
Tenslotte nog het laatste woordje voor het thuisfront. Mama, papa, zonder 
jullie was ik hier nooit geraakt. Ik hoop dat jullie dat ook beseffen. Bedankt om er 
steeds te zijn voor mij, voor jullie steun, inzet, goede raad, maar vooral voor jullie 
liefde. Ik zie jullie graag!!! Liefste zusje, je weet hoeveel ik van je hou en hoeveel ik 
aan je heb. Tom, ook jou heb ik graag, bedankt om er te zijn voor Tess. Nisse, wij 
lijken erg op mekaar. Vergeet niet dat ik er altijd ben voor jou, zorg gewoon dat je 
mijn hulp vraagt wanneer je ze nodig hebt! Bonneke, je bent de liefste. Jij weet als 
geen ander hoe fier bompa zou geweest zijn, spijtig dat hij er niet bij kan zijn. 
Bomma en bompa, dit hadden we nog niet in de familie, het is eens wat anders dan 
uitblinken in het bespelen van een instrument, dansen, zingen of toneelspelen, maar ik 
weet dat jullie ook trots zijn op mij. Chris en Michel, Inneke en Sven, nog niet 
helemaal familie, maar toch zo goed als, bedankt ook voor jullie tijd, hulp, geduld en 
liefde.  
De belangrijkste persoon komt altijd op het laatste. Dimi, ik ben geen 
gemakkelijke, ik ben de eerste om dat toe te geven. Omdat je het dichtste bij mij staat, 
krijg je het ook het meeste te verduren. Bedankt om er al die jaren te zijn voor mij, je 
geduld, je inzet, je steun, je liefde, ... ze zijn eindeloos. Dankzij jou heb ik de tijd 
gekregen die ik nodig had om te staan waar ik nu sta. Bedankt voor je 
onvoorwaardelijke steun, ik had het nodig!!! 
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